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ABSTRACT
A study was undertaken on the metabolism of a series of 14 aminotetralins displaying 
activity at the 5-HT,a receptor. All of the compounds possessed a 
2-(yV,/V-di-/7-propylamino)tetralin (DPAT) nucleus and varying substituents at either the 
5- or 8- positions (or both). The objectives of the study were (i) to investigate the 
effects of the substituents on routes and rates of metabolism in rat isolated 
hepatocytes (ii) to investigate the enzymology of the metabolism and whether it was 
affected by the various substitutions and (iii) to see whether information obtained from 
hepatocytes was predictive of in vivo metabolism. For 13 of the compounds, the 
major route of metabolism in hepatocytes was /V-dealkylation as determined by LC/MS 
and LC/MS/MS. For 5-F-B-OH-DPAT, direct glucuronide conjugation was the major 
metabolic route although A/-dealkylation (followed by glucuronidation) was again 
important. Minor routes of metabolism were hydroxylation in the aromatic ring, 
saturated ring or on the propyl side-chains. The presence of electron withdrawing 
substituents on the aromatic ring tended to protect against aromatic hydroxylation. 
The rate of metabolism (intrinsic clearance relative to that of DPAT) varied 
approximately 10-fold across the series. This 'relative metabolic stability' correlated 
with experimentally determined values of log D indicating that lipophilicity was a major 
determinant of the rate of metabolism. The metabolism of 5-F-B-OH-DPAT was much 
faster than was predicted by the correlation as a result of rapid glucuronidation. P450 
2B1 was the major isoform responsible for metabolism of the aminotetralins in hepatic 
microsomes from phénobarbital pretreated rats, with a smaller contribution from P450 
3A. Inhibition studies in hepatocytes from control animals indicated the involvement 
of 2C6 and 3A. Hepatocytes were generally predictive of the urinary metabolites of 
the aminotetralins following single oral administration to rats.
(c) lain Martin 1996
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CHAPTER 1 
INTRODUCTION
Aminotetralins and 5-HT
1.1 Medicinal Chemistry of 8-OH-DPAT
Twenty years ago, the synthesis and potent dopamine receptor-stimulating 
properties of 5-, 6- and 7-OH-DPAT were reported (McDermed et at. 1976). This 
provoked interest in the pharmacological properties of 8-OH-DPAT which was 
subsequently synthesised (Feenstra et al. 1980) and tested in reserpinised rats 
(Arvidsson etal. 1981) using an in vivo biochemical test (Wikstrom et ai. 1978). This 
method utilises the ability of 5-HT and dopamine agonists to inhibit the synthesis of 
5-HT and dopamine via regulatory feedback mechanisms. Accumulation of DOPA, 
following inhibition of I-aromatic amino acid decarboxylase, was used as an indicator 
of the rate of dopamine synthesis. Similarly, 5-HTP accumulation was used as an 
indicator of 5-HT synthesis rate. Surprisingly, 8-OH-DPAT was found to be a potent 
inhibitor of the formation of brain 5-HTP in vivo whilst it was much less effective in 
reducing DOPA. The 5-, 6- and 7-hydroxy analogues did not affect 5-HTP 
accumulation even at high doses, it was subsequently shown that 8-OH-DPAT has 
high affinity for 5-HT,a binding sites and is selective for these sites over 5-HT,b and 
5 -HT2 (Middlemiss and Fozard 1983). The contrast in pharmacological profile between 
8-OH-DPAT and its isomers may be in part rationalised by considering their structural 
similarities to either dopamine or 5-HT (see Figure 1.1).
Following the discovery that 8-OH-DPAT was a potent 5-HT,a agonist, the SAR of 
8-hydroxy-2-aminotetralins was investigated with respect to variations in the amine 
substituents (Arvidsson et ai. 1984, see Table 1.1). Of the secondary amines studied.
NH
HO
OH
Dopamine
HO
5/6/7-OH-DPAT
HO
.NH
HN 5-HT
8-OH-DPAT
Figure 1.1 Structural similarities between dopamine, 5-HT and hydroxy-DPAT 
isomers (* denotes chiral centre of 8-OH-DPAT).
Table 1.1 Effects of A/-alkyl-substituted 8-hydroxy-2- 
aminotetralins on rat brain 5-HTP accumulation. 
From Arvidsson et aL (1984).
RO Ri .
EDçg (/[/mol kg‘^  subcutaneously)
B2 Umbic Striatum Hemispheres
(cortex)
OH H CH3 1.5 1 . 6 1 . 8
OH H C2 H5 0.27 0 . 2 0 0 . 2 2
OH H /7-C3 H7 0.14 0.15 0.18
OH H /^ -C^ Hg 4.3 4.5 6.3
OH H /7-CgHi7 >56.2 >56.2 >56.2
OH H CH(CH3 ) 2 2 . 6 2.9 4.1
OH CH3 CH3 0.38 0.43 0.36
OH C.Hs C2 H5 0.054 0.068 0.070
OH /7-C3H; /7-C3 H7 0.052 0.052 0.063
OH r^ 'C^ Hg 5.0 6 . 6 5.7
OH -(CHz)^ 1 . 6 1 . 1 1.4
OH A7-C3 H7 CzHg 0.057 0.059 0.066
OH /7-C3 H7 /7-QHg 0.27 0.26 0.34
OH r?-C3 H7 CHz-Ph 2.7 2.9 2.3
OCH3 /7-C3 H7 /7-C3 H7 0.34 0.29 0.23
highest activity was observed with an ethyl or n-propyl group and there was a marked 
decrease in activity (approximately 30-fold) on moving to the /7-butyl group. The 
A/,/V-diethyl and /V,A/-di-/7-propyl compounds displayed approximately the same potency 
but the /V,/V-di-/7-dibutyl analogue was 100-fold less potent. These data would seem 
to suggest that alkyl groups not larger than /7-propyl are required for optimal potency 
and that activity at the B-HT^  ^receptor is not purely a distribution-related phenomenon. 
There was no significant difference in the 5-HT,a activity of the resolved enantiomers 
of 8 -OH-DPAT (Arvidsson et aL 1984).
1.2 Historical Aspects of Serotonin Research
Serotonin (5-HT) was discovered in the 1930s by Vialli and Erpsamer who 
identified a pharmacologically active vasoconstrictive substance which they named 
enteramine (Vialli and Erpsamer 1933). 5-HT was first isolated and structurally 
characterised some years later (Rapport et at. 1948) and it was subsequently realised 
that this was the same substance discovered by Vialli and Erpsamer (Erpsamer and 
Asero 1952). Serotonin receptor subtypes were soon discovered (Gaddum and Picarelli 
1957) and termed "D" (located on smooth muscle and blocked by phenoxybenzamine) 
and "M" (located on ganglia and parasympathetic fibres and blocked by morphine). 
This classification has since been abandoned as phenoxybenzamine is not specific for 
the D subtype and morphine antagonises the release of acetylcholine, not 5-HT. 5-HT 
receptors are currently classified according to the system of Bradley et al. (1986) 
which is based on the use of high-affinity agonists and antagonists (where available) 
to obtain functional correlates. The properties of seven distinct 5-HT receptor classes 
have recently been described (Breier 1995).
1.3 Functional and Clinical Aspects of 5-HT: the Cardiovascular System and the 
CNS
Endogenous 5-HT effects positive inotropic and chronotropic responses in 
mammalian hearts through modulation of norepinephrine release (Fozard and 
Mobarok Ali 1978, Thandroyen et a i 1985) although it is thought that this effect may 
only be important in cases of impaired ventricular function. 5-HT acts on vascular 
endothelial cells mediating the release of endothelium-derived relaxing factor resulting 
in smooth muscle relaxation (Angus 1989) leading to hypotension. The 5-HT-,a 
receptor has subsequently been implicated in this effect. Generally, the effects of 
5-HT on vascular muscle are tissue-dependent, however it has been noted that 
intracranial vascular smooth muscle is more sensitive to 5-HT than extracranial vessels 
(Peroutka 1984). Peripheral vasoconstriction and release of platelet 5-HT is known to 
be mediated by b-HTg receptors but in small coronary beds 5-HT is generally a 
vasodilator.
The majority of the 5-HT receptor subtypes have been identified in the brain 
(Breier 1995). These receptors have been implicated in a wide range of effects 
associated with the CNS of which many of the mechanisms are still unknown. Food 
intake is decreased by the action of 5-HT but thermogenesis and locomotion are 
increased (Leibowitz 1980, Coscina 1981, Merely 1989). It is still unclear whether 
5-HT has a major causal role in depression but it is thought that 5-HT abnormalities are 
present in this condition (Curzon 1988) and that the b-HTg receptor is involved (Cowen 
1990). Benzodiazepines, a widely used class of compounds in the treatment of 
anxiety, are known to reduce 5-HT turnover and decrease 5-HT neuronal activity 
(Chopin and Briley 1987). 5-HT neurotransmission can also be reduced by antagonism
ain
and thus buspirone (a partial agonist which acts via antagonism of
endogenous 5-HT) and ritanserin (a 5-HTg antagonist) have anxiolytic effects. It is not 
yet clear whether migraines are caused by excessive vasodilation of extracerebral 
cranial arteries or whether they are due to other changes in the brain of which 
vasodilation is a consequence (Saxena and Ferrari 1989). Migraines are associated 
with a rapid release of platelet 5-HT and excretion into the urine and it is thought that 
5-HT release is mediated intracranially by 5 -HT3 receptors. Consequently MDL-72222, 
5 -HT3 receptor antagonist is useful in the treatment of migraine. The role of 5-HT 
sleep is another area of intensive research; the neuropharmacology of sleep involves 
both the 5-HT and the norepinephrine/dopamine systems and antagonism of the 5-HT 
system leads to insomnia (Adams 1985).
1.4 Aminotetralins Studied In this Thesis
The discovery that 8 -OH-DPAT is a potent and selective 5-HT,a agonist 
(Arvidsson etal. 1981 ) sparked interest in 5-HT^^ ligands as therapeutic agents. Many 
compounds from different structural classes are now known to bind to the 5-HT,a 
receptor; apart from aminotetralins, these include the indolethylamines, 
tetrahydropyridylindoles, arylpiperazines and tricyclic partial ergolines (see Figure 1.2). 
All of the compounds studied in this thesis are DPAT analogues and were synthesised 
as part of The Upjohn Company's CNS discovery program. One of the aims of this 
program was to evaluate the therapeutic potential of compounds which bind to the 
5-HTiA receptor as anxiolytics. The structures of the compounds are given in 
Figure 1.3 with their abbreviated names which will be used hereafter. The majority of 
the compounds were obtained as racemic mixtures, however in some cases, only a 
single enantiomer was available.
N80H-DPAT
OH
NH
H
OCH
LY197206
H
OCH
NH
H CF,
5-HT RU 24969 Trifluoromethylpîperazîne
Figure 1.2 Examples of receptor ligands.
■N.
-enon t ione r
DPAT
OH
8-OH-DPAT
8-OTi-DPAT
R -en an f  i omer
5 -F-DPAT
R -en on f  iomer
5-F-8 -O H -D P A T
CF,
S-CFj-DPAT 8-CONHo-DPAT
NH
0=0
C=N
8 -ON-DPAT
8-Br-DPAT
NH,  
I ^ SOo
8-SONHo-DPAT
8 - ( p y r r o l e - 2 - c a r b o n y l ) -DPAT
R -enan t i ome r 
5 - F - 8 - CONH2 - DPAT
HO.
8-CO.H-DPAT
•N.
5 -OTf-DPAT
0<—S— >0 I
C F ,
Figure 1.3 Aminotetralin compounds studied in this thesis.
1.4.1 Pharmacology
The data presented in Table 1.2 were obtained from The Upjohn Company 
XOUSIN' database which contains various information on more than 100,000 
compounds. The aminotetralins studied here were screened for their ability to displace 
[®H]8-0H-DPAT from calf hippocampus S-HT,^ receptors in vitro. The JC50 values 
represent the concentration of compound required to displace 50% of the radioligand 
from the receptors, therefore the lower the value, the higher the affinity of the 
aminotetralin for the receptor. The ICgo value for a given compound may vary between 
different experiments and corrections may be made for the receptor preparation, the 
concentration of the radioligand and its specific activity, to obtain a value for the 
affinity of the receptor site for the test compound, K, . Whilst it can be seen in 
Table 1.2 that none of the compounds being studied bind to the BHT^  ^ receptor as 
strongly as 8 -OH-DPAT, the variation in structure and binding are valuable to medicinal 
chemists and pharmacologists in their attempts to build an SAR for the receptor.
1.4.2 Chemical Synthesis
The compounds studied in this thesis were synthesised by colleagues in the 
Medicinal Chemistry Research unit of Upjohn Laboratories, Kalamazoo, Ml, USA. There 
are several reports of the synthesis of 2 -aminotetralins in the literature and many of 
these workers have used j9-tetralone derivatives as starting points (e.g. Cannon at ai. 
1977, Arvidsson at ai. 1984). Tetralones and methoxytetralones are now 
commercially available and Figure 1.4 illustrates how they have been be used to 
prepare DPAT and 8 -OH-DPAT. Figure 1.5 gives an example of how some of the other 
substituted aminotetralins have been obtained (Liu at ai. 1993).
Table 1.2 Affinity of aminotetralins for the rat hippocampal 5-HT,a receptor.
Compound IC50 (nM) K,(nM)
8 -OH-DPAT 0.3 0.13
DPAT 138.0 46.0
5-F-DPAT 5.4 2 .1
5-F-8-OH-DPAT 1 0 .2 4.1
5-OTf-DPAT 42.0 15.0
8 -OTf-DPAT 5.7 2.9
8 -CN-DPAT 6 8 .2 28.9
8 -Br-DPAT 17.0 9.6
8 -CF3-DPAT 34.2 16.6
8 -CONH2-DPAT 21.7 14.6
8 -SONH2-DPAT 89.7 55.7
8-(pyrrole-2-carbonyl)-DPAT 9.3 3.6
5 -F-8 -CONH2-DPAT 59.0 32.2
8 -CO2H-DPAT 240.8 131.5
10
PfjNH
NoCNBH; 
HOAc '
PrgNH
NaCNBH, 
HOAc '
C H ,0
A8% HBr
heat
Figure 1.4 Synthetic scheme for the preparation of DPAT and 8 -OH-DPAT.
Triflic anhydride
K2 CO3
NaOH HoO
OSO2CF3
Pd(OAc)
COCH
{i)S0Cl2 
(ii) NH^OH
POCI.
Figure 1.5 Synthetic scheme for the preparation of some of the substituted 
aminotetralins studied in this thesis (adapted from Liu et at. 1993).
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1.5 The Metabolism of Aminotetralins
The pharmacological properties and SARs of aminotetralin derivatives have been 
extensively studied over the past 20 or so years (McDermed et al. 1975, Cannon et 
ai. 1977, Hacksell et ai. 1979, Arvidsson état. 1984, Naiman et ai. 1989, Lin et ai.
1993, Liu et ai. 1993). Through these studies it has become evident that substantial 
variation in the structure (e.g. substitution in the benzene ring, amine substituent 
modification and benzylic substitution) often results in retention of biological activity. 
Thus, metabolic modification of these compounds may be pharmacologically activating 
as well as deactivating and it is therefore surprising that there are relatively few reports 
of aminotetralin metabolism in the literature.
Rollema et ai. (1980) studied the brain and serum levels of 2-amino-5,6- 
dihydroxytetralin and 2-amino-6,7-dihydroxytetralin following administration of the 
dibenzoyl ester prodrugs to rats. They found that the comparatively lower levels of 
2-amino-6,7-dihydroxytetralin were due to its greater susceptibility to catechol- 
0-methyltransferase. Wikstrom et ai. (1988) concluded that aromatic ortho- 
hydroxylation was probably not the reason for the low oral bioavailabilities of 5- and 
8 -OH-DPAT. Brain levels of the catechol metabolites represented an estimated 0.3%  
of the administered dose following subcutaneous administration of 8 -OH-DPAT to rats. 
The authors also reported 5,6-dihydroxy-DPAT to be a poor substrate for catechol- 
0 -methyltransferase.
The major metabolites of 5-hydroxy-6-methyl-DPAT in the rat were identified as the 
products of /V-dealkylation, oxidation of the methyl carbon (to yield the carboxylic acid) 
and sulphation of the hydroxy group (Koble et at. 1985). Gerding and co-workers
12
studied the metabolism of 2-(/V-propyl-A/-thienylethylamino)-5-hydroxytetralin in rats
stumptailed macaque 
(Gerding et aL 1990a, 1990b) ahdjfmonkeys (Gerding et a i  1990c) following oral,
intravenous and ocular (monkey only) administration. In the rat, glucuronidation of the
phenolic group was the major metabolic route accounting for 50% (intravenous) or
65% (oral) of the administered dose. The corresponding sulphate conjugate accounted
for less than 0.2% of the dose. Hydroxylation at the 6 - (ortho) position was also
observed and the resulting catechol was excreted as both the 5- and 6 -glucuronide in
approximately equal amounts. The same metabolic routes were observed for the
monkey but in addition to the phenolic glucuronide, a sulphate conjugate was found
in urine which accounted for 15% of dose following intravenous or ocular
administration; the sulphate conjugate was virtually absent following oral
administration. The authors proposed that intrarenal sulphation of the parent drug
could explain these results, however the capacity of sulphation may have been a factor
as the dose to rats was 40-fold greater than that given to monkeys. The monkey also
exhibited a regioselective preference for glucuronidation of the catechol at the 6 -
position.
Following oral administration of R-(4-)-8 -(2 ,2 -dimethyl-1 -propanone)-DPAT to rats, the 
metabolites detected in plasma were the products of /V-dealkylation and déméthylation 
of the t-butyl terminal carbon (Swanson et al. 1994). /V-Dealkylation was the major 
metabolic route following either oral or intravenous administration of 
8 -(5 -isoxazole)-DPAT to rats (Catlow et al. 1994). First pass metabolism by this 
pathway appeared to be the major reason for the low oral bioavailability of this 
compound. Recently, the in vivo metabolism of 8 -OH-DPAT was elucidated using 
methods developed during the current study (see acknowledgements in Mason et at. 
1995a); the majority of the radioactivity following oral, intravenous or subcutaneous
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administration of I^H]-8-0H-DPAT to rats, was recovered in the urine with the major 
metabolites being the giucuronide conjugates of 8 -OH-DPAT and its monopropyl 
metabolite.
Isolated Hepatocytes as a Model for Drug Metabolism
The main technique used for the investigation of aminotetralin metabolism in this study 
is that of isolated hepatocytes. The routine use of viable preparations of isolated 
hepatocytes for the study of drug metabolism is relatively new compared to subcellular 
fractions such as microsomes.
1 .6  Hepatocyte Isolation Methodology
The key event in the preparation of isolated hepatocytes is the irreversible 
cleavage of desmosomes, the fibrous structures which literally hold cells together. It 
is now well established that Ca^  ^ is required for desmosome integrity and that 
perfusion with Ca^^-free medium will result in desmosome cleavage (Berry eta/. 1983, 
Wang et at. 1985). However, collagenase, the enzyme used to digest the connective 
tissue, requires Ca^  ^ for activity. The 'one-step' method (Berry and Friend 1969, 
modified by Berry 1974) takes advantage of the fact that the Ca^+ concentration 
required for collagenase activity is very much lower than that required for desmosomal 
integrity. The only significant modification to this method has been the development 
of the 'two-step' perfusion (Seglen 1972, 1976). In the first step, desmosomal 
cleavage is initiated by perfusion with a Ca^^-free medium which may also contain a 
calcium chelating agent such as EGTA. This is followed by perfusion with a medium 
containing collagenase and supplemented with Ca^^.
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Not long after the publication of the one-step method, it was found that incubation of 
cells isolated by this method, in the absence of Ca^^, resulted in their inability to 
maintain normal intracellular levels of Na'  ^ and with implications for normal 
metabolic behaviour (Barnabei etal. 1974, Baur etal. 1975). Such problems were not 
encountered by users of the two-step procedure and Berry eta/. (1991) suggested that 
this may have resulted in the two-step procedure becoming generally more popular. 
The one-step method was subsequently modified (Berry 1974) to include replacement 
of Ca^  ^ immediately after the perfusion and Berry and coworkers have indicated that, 
in their experience, there is no difference in the yield of viable cells between the two 
procedures.
The standard method for assessing cellular integrity in a preparation of isolated 
hepatocytes is the trypan blue exclusion test (Phillips 1973). It has been proposed that 
the negatively charged dye is excluded from intact cells as a result of the plasma 
membrane potential (Claret and Mazet 1972, Berry et ai. 1988). Injury resulting in loss 
of this membrane potential leads to staining of the cell, but trypan blue exclusion 
remains a reasonably crude method of assessing cellular integrity.
Succinate oxidation, carried out by the mitochondria, was shown to decrease as the 
degree of cell damage, as assessed by trypan blue exclusion, increased (Mapes and 
Harris 1975). However, it is necessary to assay the amount of succinate oxidation 
that takes place when all the cells are damaged to provide a reference point. This 
requires the addition of digitonin to a sample of cells in order to lyse the plasma 
membrane. Insufficient digitonin will not lyse all of the cells whereas too much 
digitonin may damage the mitochondrial membrane, in both cases, there will be an 
underestimation of the rate of succinate oxidation occurring when all the cells are
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damaged resulting in an overestimation of the metabolic capability of the 'intact' 
preparation. There does not seem to be any evidence that succinate oxidation is a 
better measure of the integrity of a preparation than trypan blue exclusion.
The measurement of LDH leakage from hepatocytes as an assessment of cell integrity 
has some advantages over trypan blue exclusion. LDH can still be measured if a cell 
has disintegrated whereas in the trypan blue method it could not be counted as a 
stained cell. Furthermore, LDH measurement avoids the statistical problems of the 
trypan blue method associated with the sample size. However it has been proposed 
that LDH released from cells damaged during the isolation will be lost during the 
resuspension and washing steps (Jauregui etaL 1981). On the basis of this. Berry et 
al. (1991) suggested that the LDH leakage method is more suited to the assessment 
of cell damage over the course of an incubation. Nonetheless, the level of LDH leakage 
appears to correlate with the degree of trypan blue staining (Jauregui et ai. 1981).
1.7 The Use of Isolated Hepatocytes to Study Drug Metabolism
Since the development of techniques to isolate large numbers of intact 
hepatocytes, the use of such preparations has become commonplace. Isolated 
hepatocyte suspensions have become an important part of the battery of in vitro 
methods available to study the metabolism of drugs and xenobiotics which also 
includes purified enzymes, enzymes expressed in host cells, subcellular fractions, cell 
cultures, tissue slices and perfused organs. Isolated hepatocytes are now routinely 
used to study both routes and rates of metabolism, species differences and the effects 
of inducing agents or inhibitors on metabolism.
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For the study of drug metabolism, each model system can be used to provide valuable 
information according to the nature of the study to be undertaken. The main 
advantage of using isolated hepatocytes is their ability to carry out both phase I and 
phase II metabolic reactions in an environment which is physiologically and 
enzymatically akin to the in vivo situation; this ability has been demonstrated for a 
range of drugs (Moldéus et ai. 1974, Billings et ai. 1977, 1978, Moldéus 1978, 
Abraham et ai. 1983, deBethizy and Rickert 1984). In particular, isolated hepatocytes 
have proved useful in investigations into the factors affecting phase II conjugation 
reactions. The sulphation of model compounds such as 1-naphthol (Schwarz 1980) 
and harmol (Sundheimer and Brendel 1984) has been shown to be dependent on levels 
of inorganic sulphate. The importance of cofactor supply to giucuronide conjugation 
was demonstrated by Sundheimer and Brendel (1984) who showed that 
glucuronidation was decreased by fasting of animals prior to hepatocyte isolation. 
Glucuronidation was also decreased when cofactors were depleted by preincubation 
of hepatocytes with galactosamine (Moldéus et ai. 1979, Schwarz 1980). The phase 
II metabolism of a range of phenolic substrates in isolated hepatocytes was shown to 
be concentration-dependent (Andersson et ai. 1978, Koster et ai. 1981). At low 
substrate concentrations, sulphation predominated but glucuronidation became 
quantitatively more important with increasing concentration. The shift from sulphation 
to glucuronidation of harmol and phenol in hepatocytes was also shown to occur with 
increasing dose in vivo (Koster et ai. 1981).
c
Whilst isolation of hepatocytes results in loss of the physical structure of the liver, 
rates of xenobiotic metabolism in hepatocytes have often been found to be comparable 
to the isolated perfused liver (Billings et al. 1977) or indeed predictive of the in vivo 
rate of metabolism (Houston 1994, Ashforth etal. 1995, Zomorodi etal. 1995). From
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a qualitative standpoint, the profiles of metabolites found in hepatocytes are often 
similar to those in urine (Green et al. 1986, Salonen and Suolinna 1988) and plasma 
(Seddon et al. 1989). Whilst the majority of studies with isolated hepatocytes have 
used the rat, the utility of hepatocytes for the study of species differences in drug 
metabolism has also been demonstrated. Gee etal. (1984) studied the metabolism of 
tolbutamide in hepatocytes from a range of species; by comparison with human in vivo 
data, they were able to conclude that rabbit hepatocytes were a better model for the 
human metabolism of tolbutamide than those from squirrel monkey. Information on 
the species differences in metabolism by isolated hepatocytes can be very useful in 
determining the most appropriate species for the safety assessment of drug candidates.
Hepatocytes have also proved useful in studying the influence of inducing agents and 
inhibitors on drug metabolism. Treatment of animals with known inducers of drug 
metabolising enzymes prior to hepatocyte isolation has been shown to result in 
preparations with increased metabolising activity (Loft and Poulsen 1989, Martin et 
al. 1993a, Richards et al. 1993). The enzymes responsible for the metabolism of 
various drugs and the potential for drug interactions have been probed by the use of 
known inhibitors (Bodd et al. 1986, Loft and Poulsen 1989, Cross et al. 1990). The 
majority of studies on the hepatic drug metabolising enzymes have been carried out 
using microsomal fractions due to their ease of preparation and storage. However the 
activities of various enzymes have also been demonstrated in isolated hepatocytes. 
Examples include total P450 in rat hepatocytes (Diener et a i 1995); P450 1 A l (probed 
by ethoxyresorufin 0-deethylase) in both rat (Schrenk et al. 1991) and human 
(Coundouris et al. 1993) and P450 2C11 (probed by testosterone 2a-hydroxylase) in 
rat (Diener et al. 1995). These groups of workers have also demonstrated the 
presence of sulphotransferases, glucuronyltransferases and glutathione S-transferases.
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There are also limitations to the use of isolated hepatocytes. Preparations only remain 
viable for a few hours after the isolation procedure thus ruling out longer term studies. 
In addition, current supplies of suitable human liver are erratic. This can result in much 
of a preparation being wasted unless the laboratory concerned is in a constant state 
of readiness with their experimental set-up. The use of cryopreservation techniques 
may overcome the issue of erratic supply. However more work is needed to define 
conditions under which human hepatocytes can be stored with no appreciable loss of 
viability or metabolic competence (Coundouris et al. 1993).
Many groups have investigated hepatocyte culture techniques. The major problem 
associated with hepatocyte culture is the loss of liver-specific functions, one of which 
is the high-level expression of P450 (Paine 1990). Although levels of total P450 can 
be maintained by use of a metyrapone-supplemented medium or a cysteine-free 
medium supplemented with aminolaevulinic acid (Paine 1990), the relative levels of the 
different isoforms of P450 are not maintained (Steward et al. 1984, Turner et a i 
1988). Other workers have concentrated on the physical environment of the cells in 
culture. Koebe etal. (1994) have demonstrated maintenance of P450 1A1-dependent 
activity (p-nitroanisole 0-demethylation) for 3 weeks and the sulphation and 
glucuronidation of paracetamol for 16 days in hepatocytes cultured in a collagen gel 
sandwich. Clearly, if cultured human hepatocytes are to be used as a reliable model 
of in vivo metabolism, then a system in which the various drug metabolising enzymes 
are expressed at the appropriate levels is required.
The choice of isolated hepatocytes for the study of aminotetralin metabolism was 
based on a number of factors. A balance had to be struck between the ease of 
preparation, reproducibility and versatility of the test system and its possible relevance
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to the in vivo case. For the study of the metabolism of a series of compounds and the 
effects of enzyme inducers and inhibitors on that metabolism, the choice appeared to 
lie between hepatic microsomes and isolated hepatocytes. Liver slices were excluded 
on the basis that, at the time, we did not possess a tissue slicer. There were also 
concerns regarding drug penetration into the centre of the slice as the slices would be 
bathed in drug-containing media rather than perfused as would be the case in vivo. 
The advantages of microsomes with regard to their ease of preparation, storage and 
characterisation were outweighed, in our view, by the ability of hepatocytes to carry 
out coupled phase I and phase II drug metabolism in a physiologically intact 
environment. In addition, the cell membrane barrier was deemed relevant to the in vivo 
situation as each cell would be in contact with the incubation medium. This was 
thought to be particularly important for the quantitative study of aminotetralin 
metabolism where the rate of metabolism may be affected by drug penetration into the 
hepatocyte.
1.8 Objectives
The main objective of this study was to increase existing knowledge of the 
metabolism of aminotetralin compounds by studying a series of fourteen 
A/,A/-dipropylaminotetralins with various substituents in the aromatic ring. The 
/V,A/-dipropyl function was chosen for its relevance to BHT^  ^pharmacology (see 1.1). 
By studying the in vitro metabolism of aminotetralins in the rat isolated hepatocyte 
system it was intended to address the following questions:
•  How does variation in the substituent on the aromatic ring affect the 
routes and rates of aminotetralin metabolism?
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•  Can these effects be rationalised in terms of (a) the physicochemical 
properties of the compounds? or (b) changes in the enzymology of 
metabolism? (or indeed both).
Lastly, by studying aminotetralin metabolism in the intact animal, it was intended to 
assess the utility of the rat isolated hepatocyte system as a model for the in vivo 
metabolism of aminotetralins.
The broader aims of this work were to investigate a possible structure-metabolism 
relationship for the aminotetralins and to establish the utility of hepatocytes in this type 
of study. From an industrial point of view, the ability to predict routes and rate of 
metabolism within a particular structural class is invaluable in assisting medicinal 
chemists to design pharmacologically active agents with appropriate metabolic and 
pharmacokinetic characteristics. Furthermore, investigation of the metabolism 
enzymology for a series of related compounds may help in our understanding of the 
structural requirements for metabolism by a particular enzyme.
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CHAPTER 2 
MATERIALS AND METHODS
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ISOLATION OF RAT HEPATOCYTES BY //V S/H/COLLAGENASE PERFUSION
Hepatocytes were isolated from male Sprague Dawley rats by two-step in situ 
collagenase perfusion of the liver. The method was based on the procedure of Seglen 
(1972, 1976) which itself was developed from the one step procedure of Berry and 
Friend (1969).
2.1 Chemicals and Reagents
All reagents were obtained from Sigma Chemical Co. Ltd. unless otherwise stated.
Milli-Q water:
5% Hydrogen peroxide:
Pre-perfusion solution (lOx):
Pre-perfusion solution (1x):
Digestion medium (lOx):
Digestion medium (1x):
Milli-Q water purification system (Millipore)
60% (w/v) hydrogen peroxide (Fisons) diluted with 
Milli-Q water.
87.0 g NaCI (Fisons), 24.0 g Na HEPES, 30.0 g D- 
fructose, 1.9 g EGTA, 6.0 ml 0.5%  (w/v) phenol 
red (Fisons), made up to 1 L with Milli-Q water, pH 
to 7.5 with 1 M HCI, stored at 0 -4 °C for up to 3 
months.
50 ml pre-perfusion solution (lOx, prepared as 
above), 445 ml Milli-Q water, 5 ml heparin 
(5,000 units ml \  National Veterinary Supplies), pH 
to 7.5 with 1 M NaOH. Used on day of 
preparation.
5.0 g KCI (Fisons), 83.0 g NaCI, 24.0 g Na HEPES, 
7.4 g CaCl2.2H20,30.0 g D-fructose, 6.0 ml 0.5%  
(w/v) phenol red, made up to 1 L with Milli-Q 
water, pH to 7.5 with 1 M HCI, stored at 0 -4 °C 
for up to 3 months.
50 ml digestion medium (lOx, prepared as above), 
450 ml Milli-Q water, 46,500 units hyaluronidase 
(type l-S, Boehringer Mannheim Ltd.) 500 units 
collagenase (type H, Boehringer Mannheim Ltd.), 
33 mg trypsin inhibitor, 1.0 g BSA fraction V, Ph 
to 7.5 with 1 M NaOH. Used on day of 
preparation.
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Dulbecco's Modified Eagle 
Medium (DMEM):
Insulin solution:
Suspension Buffer:
Hypnorm/Hypnovel:
11.0 g NaHCOa (Fisons), 11.7 g Na HEPES,
10.0 g BSA fraction V, 2.0 g D-fructose, 500 ml 
DMEM (Gibco - Life Technologies; w / 1 g L‘  ^
glucose, w / Na pyruvate, w/o NaHCOg), made up 
to 5 L with Milli-Q water, pH to 7.4 with 1 M HCI, 
filtered into 500 ml sterile bottles (0.22 fjm 
cellulose acetate filter. Costar UK Ltd.), stored at 
0-4°C for up to 1 month.
5 mg fatty acid-free BSA, 3.27 mg bovine 
pancreatic insulin, 15 //I 10 M HCI, made up to 
5 ml with Milli-Q water, stored as 50 fj\ aliquots at 
-20°C for up to 12 months.
1.0 g BSA fraction V, 4.5 //I insulin solution,
25.0 ml PCS (Gibco - Life Technologies), 500 ml 
DMEM, pH to 7.2 with 1 M HCI. Used on day of 
preparation.
2 ml Hypnorm (National Veterinary Supplies; 
0.079 mg mM fentanyl citrate, 2.5 mg ml'^  
fluanisone) 2 ml Hypnovel (National Veterinary 
supplies; 1.25 mg mM midazolam) 4 ml Milli-Q 
water, stored at room temperature for 1 month.
2.2 isolation of Rat Hepatocytes
2.2.1 In Situ Collagenase Perfusion
The perfusion apparatus was set up as shown in Figure 2.1. The system was 
washed through with approximately 200 ml hydrogen peroxide (5% w/v) and then 
rinsed with 3 litres of distilled water followed by 1 litre of Milli-Q water. Reservoir 1 
contained pre-perfusion solution (1 x ) and reservoir 2 digestion medium (1 x ). The 
system was primed with pre-perfusion solution to exclude air bubbles and fill the 
bubble trap.
An adult male Sprague-Dawley rat weighing between 200 and 250 g was 
anaesthetized by intraperitoneal injection of Hypnorm/Hypnovel at a dose of 3.0 ml kg*’
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Reservoir 1 Reservoir 2
Clomp Clomp
Connector
Heat exctionger
Peristaltic pump
Bubble trap
LIVER
Waste
Figure 2.1 Sctiematic diagram of apparatus for tlie in situ perfusion of rat liver.
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body weight. The rat was placed dorsal side down on the perfusion plate and 
maintained in a 'spread-eagle' position by means of masking tape applied to the fore- 
and hind-legs. The skin was cut along the mid-ventral line from the pelvis to the throat 
to expose the abdominal wall. The abdominal wall was then cut along the mid-ventral 
line from the pelvis to the sternum, taking care not to damage the liver capsule. Two 
further incisions were made from the central point of the vertical incision round to the 
dorsal side of the rat. The intestines were then displaced to the right to expose the 
hepatic portal vein. Two lengths of black suture thread (approximately 10 cm each) 
were drawn under the vein just below the junction of the hepatic portal vein with the 
splenic and pyloric veins. A third length of thread was drawn under the vein 
approximately 1.5 cm further down. This last thread was tied around the vein to cut 
off the portal blood supply to the liver.
A cannula (IV catheter, 22 gauge, Sherwood Medical Industries) was introduced into 
the vein between the ligature and the top two threads and gently inserted along the 
vein towards the liver. The cannula needle was removed, leaving the cannula in place, 
and a flow of blood back along the cannula indicated correct insertion. The top two 
threads were then tied around the vein, holding the cannula in place. The perfusion 
tubing was connected to the cannula and perfusion from reservoir 1 (pre-perfusion 1 x) 
commenced at 10 ml min'\ Upon commencing perfusion, the inferior vena cava was 
cut to allow drainage of blood and perfusate from the system and the liver cleared to 
an even tan colour. After 1 min, the flow rate was increased to 20 ml min'\ After a 
further 5 min, reservoir 1 was clamped shut and perfusion from reservoir 2 (digestion 
1 x ) commenced at 30 ml min'\ Perfusion was continued until the liver tissue 
displayed evidence of extensive dissociation (usually a further 6-8 min).
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2.2.2 Hepatocyte Isolation
The liver was deemed to be sufficiently digested when it took on a speckled 
appearance and an impression could be made in the surface with a cotton bud soaked 
in saline. The flow rate was reduced to 10 ml min*’ to maintain back pressure, and the 
liver dissected out into a weighing boat containing cool digestion medium. The liver 
capsule was cut with a razor blade and the cells gently teased out into the medium 
with a spatula. The cells were then passed through a 250 //m mesh into a plastic 
beaker containing 50 ml suspension buffer. The mesh was rinsed through into the 
beaker with further suspension buffer to a final volume of 200 ml. The suspension 
was divided between four plastic 50 ml centrifuge tubes (pre-cooled on ice) and 
centrifuged at 50xg for 2 min at 4°C . The supernatants were decanted and the pellets 
resuspended in suspension buffer to the original volume. The centrifugation step was 
repeated and each pellet resuspended in 10 ml suspension buffer. The suspensions 
were combined and the volume made up to 50 ml with suspension buffer.
2.2.3 Estimation of Hepatocyte Yield and Viability
An aliquot of cell suspension (0.25 ml) was diluted with 0.25 ml suspension 
buffer. An aliquot of this dilution (0.25 ml) was added to 0.1 ml trypan blue solution 
(0.4% w/v) and the contents of the vial gently mixed. After 2 min a pasteur pipette 
was used to withdraw a sample and fill an Improved Neubauer Counting Chamber by 
capillary action. The cells were then counted (central square only) using an inverted 
microscope, viable cells being able to exclude the dye and non-viable cells being 
stained. The percentage of viable cells in the preparation was calculated thus:
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Viable cell count ^ JOO  ^
Total cell œunt 1
The total yield of cells was calculated from the volume of the counting chamber square 
(10"  ^ml) and the appropriate dilution factors:
Total cell yield = Total cell count x 10^  x x 2 x 60 
0.25
Similarly, the concentration of viable cells was calculated:
Viable cells mT^  -  Viable cell count x  10^  x -2 ^  x  2 
0.25
The cell suspension was diluted with an appropriate volume of suspension buffer to 
give a suspension of 5 x 10® viable cells ml ’ which was stored on ice for up to 1 h 
prior to use.
QUALITATIVE METABOLISM STUDIES WITH HEPATOCYTES
In order to elucidate the in vitro metabolic pathways, each aminotetralin was 
incubated with a suspension of rat isolated hepatocytes and the incubates analysed by 
HPLC linked via a TSP interface to a mass spectrometer. In this way, drug and 
metabolites were separated from the components of the biological matrix and mass 
spectra obtained on-line. One of the main advantages of this "soft" ionisation 
technique is that molecular ions, indicative of molecular weight, are readily obtained. 
Subsequent tandem MS/MS analysis was used to yield structural information from
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fragmentation patterns. The application of this technique to the study of drug 
metabolism is well established (Straub 1988, Baillie 1992) and some studies of 
aminotetralin metabolism using this method have also been reported (Martin et al. 
1993b, 1993c; Sonesson etal. 1993, 1995; Mason etal. 1995a).
2.3 Chemicals and Reagents
All reagents were obtained from Sigma Chemical Co. Ltd. and all solvents 
were obtained from Fisons (HPLC grade) unless otherwise stated.
Aminotetralins:
(Details of chemical and 
optical purity may be found 
in the back pocket).
0.1 M Sodium acetate buffer:
jff-Glucuronidase:
Aminotetralins were obtained from The Upjohn 
Company and were supplied as solid in either free 
base or salt form. The compounds were dissolved 
in either Milli-Q water, dilute HCI, 50% (v/v) 
DMSG or DMSG as appropriate, to a concentration 
of 1 mg ml ’ free base equivalents.
Sodium acetate (anhydrous) was dissolved in 
Milli-Q water and the volume made up to give a 
0.1 M solution. Following warming to 3 7 °C, the 
pH was adjusted to 5.0 with glacial acetic acid 
(Fisons).
Type H-3 from H. pomatia (with sulphatase 
activity).
2.4 Investigation of the Metabolism of Aminotetralins by Rat isolated Hepatocytes
2.4.1 Incubation of Aminotetralins with Rat Isolated Hepatocytes
Into a 25 ml plastic conical flask was dispensed 5 ml of hepatocyte suspension 
(prepared as in 2.2). The flask was incubated at 3 7 °C in a shaking water bath 
(120 strokes min’ ) for 2 min prior to the addition of an appropriate volume of 
aminotetralin solution (final drug concentration: 40 //M). The incubation was continued
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for a further 120 min with samples (2 ml) being withdrawn after 30 and 120 min into 
2 ml 0.1 M sodium acetate buffer (pH 5.0 at 37 °C) and ultrasonicated for 5 min. An 
aliquot of hepatocytes without aminotetralin was processed as above to act as a blank. 
The samples were stored at -2 0 °C overnight. Following thawing, each sample was 
divided into two aliquots which were incubated with or without /ff-glucuronidase (50 //I) 
for 4 h. The incubations were terminated by the addition of 2 ml acetonitrile (Fisons) 
and the precipitated protein was pelleted by centrifugation at 12,000xp for 5 min at 
ambient temperature. Acetonitrile was removed from the supernatants in vacuo to 
yield aqueous residues of approximately 2 ml.
2.4.2 Analysis of incubates by TSP/LC/MS and TSP/LC/MS/MS
An aliquot (100 //I) of each sample was injected onto a reversed-phase HPLC 
system coupled to a TSQ 70 mass spectrometer via a TSP II interface (both Finnigan 
MAT Ltd.). The proportion of organic modifier (acetonitrile) was varied for each 
compound such that the retention time of the parent drug was of the order of 
25-30 min. In LC/MS mode, 0 3  was scanned over a mass range chosen to detect 
predicted metabolites for each compound. In LC/MS/MS mode, Q1 was used to select 
the mass of the analyte to be fragmented, collision (with Argon) took place in 02 , and 
the daughter fragments were detected in 03. The following conditions were common 
to all the compounds analysed; conditions which varied are listed in Table 2.1.
HPLC Pump: Waters 600MS (Millipore).
Guard column: Brownlee RP8 15 x 3.2 mm (Anachem Ltd.).
Column: Zorbax Rx C8, 250 x 4.6 mm (Hichrom Ltd.).
Mobile Phase: acetonitrile (see Table 2.1) and 0.1 % (v/v) TFA in Milli-Q water. 
Flow rate: 1.5 ml min ’ .
Injector: manual U6K (Millipore). Injection volume: 100 //I.
30
Table 2.1 Variable parameters for LC/MS and LC/MS/MS analysis of incubations 
of aminotetralins with rat isolated hepatocytes.
Compound Acetonitrile in 
mobile phase 
(% v/v)
LC/MS scan 
range (amu)
LC/MS/MS 
scan range 
(amu)
Collision
offset
(eV)
5-OTf-DPAT 33 180-500 20-400 -25
8 -OTf-DPAT 33 175-610 10-400 -25
8 -CF3 -DPAT 29 190-610 20-350 -30
8 -Br-DPAT 27.5 165-610 20-350 -30
5-F-DPAT 23 165-610 20-300 -25
8 -(pyrrole-2 -
carbonyD-DPAT
25 185-610 20-350 -35
8 -CN-DPAT 18 165-610 20-310 -30
DPAT 19.5 145-450 20-300 -30
5-F-8-OH-DPAT 25 180-500 20-300 -35
8 -OH-DPAT 17 162-450 20-300 -30
8 -SO2 NH2-DPAT 14 200-610 20-350 -30
5 -F-8 -CONH2 -DPAT 13 190-610 20-325 -30
8 -CONH2 -DPAT 1 1 185-505 20-300 -30
8 -CO2 H-DPAT 17 180-610 *
No MS/MS analysis was performed as no metabolites were detected.
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LC/MS Full scan mode: Q3 scanned in 2 seconds (see Table 2.1).
TSP vaporiser temperature: 9 0 °C.
TSP source temperature: 2 0 0 °C. TSP repeller voltage: + 5  V. 
Electrometer gain: 10*®. Electron multiplier: 1,800 V.
LC/MS/MS
As per LC/MS except for the following:
Scan time: 2 seconds (see Table 2.1 for range).
Electrometer gain: 10 ®. Electron multiplier: 2,000 V.
CID: Argon at 1 mTorr; collision offset: see Table 2.1.
MS/MS correction factor: 0.
QUANTITATIVE METABOLISM STUDIES WITH HEPATOCYTES
In order to quantify the rate of metabolism of the aminotetralins, their intrinsic 
clearances (CLj )^ were estimated following incubation with rat isolated hepatocytes. 
The term CL;  ^was first used to describe the rate of metabolism of a drug under in vivo 
conditions (Gillette 1971, Rane et ai. 1977). Intrinsic clearance does not take into 
account blood flow to the organ of metabolism or binding of drug to plasma proteins 
and as such, is a measure of the metabolising enzyme's activity towards a drug 
(Houston 1994). The rate of metabolism of a drug may be expressed in terms of its 
CLjnt and the concentration of the drug at the enzyme site (Cg, assumed to be 
equivalent to free drug concentration in the liver):
Rate of Metabolism = CL,„^ . 1
According to the fundamental relationship of enzyme kinetics (the Michaelis-Menten 
equation), the rate of metabolism (or velocity of reaction) is defined thus:
V C
Rate of Metabolism = -  ^  2
/(n + Gg
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When Cg <  <  equation 2 can be written as:
K n a v  .  OcRate of Metabolism = max * 
«m
Equations 1 and 3 are analogous and hence:
C L ^ - ^
In the case of hepatocytes, is measured in terms of nmoles min ’ (10® cells)*’ and 
as nmoles ml ’ . Therefore, dividing by yields units of clearance i.e. 
ml min*’ (10® cells)*’ .
2.5 Chemicals and Reagents
All solvents were obtained from Fisons and were of HPLC grade.
2.6 Estimation of CLj  ^of Aminotetralins in Rat Isolated Hepatocytes
2.6.1 Incubation of Aminotetralins with Rat Isolated Hepatocytes
Into each of three 25 ml plastic conical flasks was dispensed 5 ml of 
hepatocyte suspension (prepared as in 2.2). The flasks were incubated at 3 7 °C in a 
shaking water bath (120 strokes min*’) for 2 min prior to the addition of an appropriate 
volume of aminotetralin solution (prepared as in 2.3) to give a final concentration of 
either 10, 20 or 60 //M. Samples (0.5 ml) were withdrawn into 0.5 ml acetonitrile at 
0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 5.0, and 10.0 min. Following centrifugation (5,000xgr,
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5 min, ambient temperature) the supernatant was removed and stored at -20°C prior 
to analysis.
The experiment was repeated, using DPAT alone, to investigate the difference between 
incubates that were continuously shaken (as above) or incubated static. A further 
incubation (continuous shaking) was performed to see whether the number of cells 
removed during sampling was consistent with the cell concentration (5 x 10® viable 
cells ml ’ ) and whether this remained constant throughout the incubation. Accordingly, 
triplicate incubations were set up and 0.5 ml samples removed at 0, 5 and 10 min. 
The cell content of each sample was assessed as in 2.2.3.
2.6.2 Analysis of incubates by HPLC
Incubates from 2.6.1 were analysed quantitatively for parent drug by HPLC 
with UV detection. HPLC conditions were similar to those used for LC/MS in 2.4.2 and 
the mobile phase compositions and detection wavelengths are given in Table 2.2. 
Mobile phase conditions for some compounds were modified from those used in 2.4.2  
to resolve drug-related material from endogenous material. In some cases the 
resolution enabled the appearance of a metabolite to be monitored.
HPLC Pump: Waters 600E (Millipore).
Guard column: Brownlee RP8 15 x 3.2 mm (Anachem Ltd.).
Column: Zorbax Rx C8, 250 x 4.6 mm (Hichrom Ltd.).
Mobile Phase: acetonitrile (see Table 2.2) and 0.1 % (v/v) TFA in Milli-Q water. 
Flow rate: 1.5 ml min ’ .
Injector: Waters WISP 712 (Millipore). Injection volume: 50 p\.
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Table 2.2 Variable parameters for HPLC analysis of aminotetralins following either 
incubation with rat isolated hepatocytes (see 2.6.2) or partitioning in 
/7-octanol/buffer (see 2.8).
Compound Acetonitrile in mobile phase 
(% v/v)
UV
detection
wavelength
(nm)Section 2.6.2 Section 2.8
5-OTf-DPAT 33 41 215
8 -OTf-DPAT 33 41 215
8 -CF3 -DPAT 29 37 2 2 0
8 -Br-DPAT 27 37 230
5-F-DPAT 23 29 2 1 0
8 -{pyrrole-2 -
carbonyD-DPAT
20.75 33 305
8 -CN-DPAT 19 25 235
DPAT 19.5 29 2 1 0
5-F-8-OH-DPAT 19 29 2 1 0
8 -OH-DPAT 17 25 225
8 -SO2 NH2 -DPAT 1 2 2 1 225
5 -F-8 -CONH2 -DPAT 11.75 19 2 1 0
8 -CONH2 -DPAT 1 1 17 2 2 0
8 -CO2 H-DPAT 17 25 235
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2.6.3 Graphical Analysis of HPLC Data
The peak area of the unchanged drug (determined by integration) was plotted 
against time and the slope of the linear portion calculated for each drug concentration. 
The slopes (peak area/min) were converted to units of nmoles min ’ 10® cells ’ by 
reference to the peak area of a standard of known concentration. These values of 
reaction velocity (v) were then used to construct a direct linear plot according to the 
method of Eisenthal and Cornish-Bowden (1974). From the Michaelis-Menten equation 
(where s = substrate concentration):
V = ^
Km* s
simple algebraic manipulation yields the equation for a straight line.
Abscissa (K )^ and ordinate (V^^) axes are constructed and simple substitution shows 
that values of -s are plotted on the {i.e. = 0) axis and values of v are plotted
on the Vmax {i.e. = 0) axis. The corresponding points for -s and v are joined to yield
three lines with a family of intercepts in the first quadrant (see Figure 2.2 for an 
example). The median intercept, when extrapolated to the axes, yields values of 
and that satisfy all three incubation concentrations. CL^ is then calculated from 
Vm«/Km
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Vmax (nmoles/min/10® cells) 0.7 -
0.6 -
0.5 -
•  60 uM
■ 20 uM
^  10 uM
70 - 6 0  - 5 0  - 4 0  - 3 0  - 2 0  - 1 0  0 10 20 30
Km (nmoles/ml, i.e. uM)
Figure 2.2 Example of direct linear plot for obtaining and K .^
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DETERMINATION OF DISTRIBUTION COEFFICIENTS
The distribution coefficients of the aminotetralins were determined using the 
method of Stopher and McClean (1990). This method requires only small amounts 
(0.5 mg) of each compound per determination, and relies on a simple HPLC 
determination of the compound in the two phases.
2.7 Chemicals and Reagents
0.5 M Phosphate buffer: Solutions (0.5 M) of potassium dihydrogen
phosphate and disodium hydrogen phosphate (both 
Sigma Chemical Co. Ltd.) were mixed in the ratio 
20:80 and the pH of the resulting buffer adjusted 
to 7.4 with dilute orthophosphoric acid.
2.8 Determination of Distribution Coefficients
Aminotetralin (0.5 mg) was dissolved in 1 ml /7-octanol (HPLC grade, Aldrich) 
or 1 ml phosphate buffer (if more soluble in aqueous media) in a 4  ml glass vial. To 
this was added 1 ml phosphate buffer (or /7-octanol) and the vial was capped, shaken 
and left on a roller mixer for 1 h at ambient temperature (20-22°C ). The vial was 
centrifuged at 3 ,000xgr for 5 min at ambient temperature and samples taken of the 
octanol and buffer phase. The aminotetralin content of these samples was determined 
by HPLC using the same methodology as in 2.6 .2 . Mobile phase compositions are 
given in Table 2.2. The peak areas of the aminotetralin in each phase were used to 
determine the distribution coefficients:
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P - |P@84rawea]*a», - 14»%. 
[P eakare4^„.
where 'V  is the volume analysed by HPLC.
Log P values {clog P) were calculated using the program developed by Leo (Leo, A. 
Pomona College Medicinal Chemistry Project, Pomona College, Claremont, CA 91711, 
USA).
METABOLISM STUDIES WITH RAT HEPATIC MICROSOMES
In order to gain information on the enzymes responsible for aminotetralin 
metabolism in rat liver, the compounds were incubated with hepatic microsomal 
preparations from rats which had been pretreated with known enzyme-inducing agents. 
Such studies are generally carried out with microsomes due to their relative ease of 
preparation, storage and characterisation when compared to isolated hepatocytes. 
Four inducing agents were used to elevate a range of P450 enzymes. A list of these 
inducing agents, the mechanism of induction and the probe substrates used to assay 
the isoform activities is given in Table 2.3. Fentem and Fry (1991) used these inducing 
agents and probe substrate assays in a comparative study of P450 in the rat and 
Mongolian gerbil. They reported induction of the various P450 activities as 24-fold 
(P450 1A1), 64-fold (P450 2B1/2), 3.5-fold (P450 2E1) and 3.8-fold (P450 3A1/2).
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2.9 Chemicals and Reagents
All reagents were obtained from Sigma Chemical Co. unless otherwise stated.
Saline: Sodium chloride intravenous infusion BP (0.9%
w/v) was obtained from National Veterinary 
Supplies.
BNF: BNF (16 mg mM) was dissolved in peanut oil with
the aid of gentle warming and ultrasonication.
FS: Phénobarbital sodium (16 mg mM) was dissolved
in saline.
II^H' INH (100 mg ml' )^ was dissolved in saline.
FCN: PCN (U-14975, The Upjohn Company) was
dissolved in peanut oil (10 mg ml ’ ) with the aid of 
gentle warming and ultrasonication.
FBS: PBS tablets were dissolved in water to provide
0.01 M PBS (5 tablets in 1 litre) or 0.025 M PBS 
(25 tablets in 2 litres). Following cooling to 4°C , 
the buffers were adjusted to pH 7.4 with dilute 
orthophosphoric acid.
0.05 M Phosphate buffer: Solutions of potassium dihydrogen phosphate and
disodium hydrogen phosphate (both 0.05 M) were 
mixed in the ratio 20:80. The resulting buffer was 
cooled to 4°C  and the pH adjusted to 7.4 with 
dilute orthophosphoric acid.
0.25 M Phosphate buffer: Solutions of potassium dihydrogen phosphate and
disodium hydrogen phosphate (both 0.25 M) were 
mixed in the ratio 20:80. The resulting buffer was 
warmed to 37°C  and the pH adjusted to 7.5 with 
dilute orthophosphoric acid.
0.1 M Tris buffer: Trizma crystals (pH 7.4 pre-set crystals) were
dissolved in distilled water and the volume made 
up to give a 0.1 M solution. The buffer was 
warmed to 37 °C and the pH adjusted to 7.8 with 
dilute hydrochloric acid.
0.1 M Tris buffer containing: To 800 ml of a 0.1 M solution of Trizma (pH 7.4
20% w/v glycerol pre-set crystals) was added 200 g of glycerol
(Fisons Analytical Reagent). Following cooling to 
4°C  the pH was adjusted to 7.4 with dilute 
hydrochloric acid.
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Coomassie reagent and BSA:
Magnesium chloride solution:
Cofactor solution A:
Cofactor solution B:
Coomassie reagent and BSA standard (2 mg ml ’ ) 
were supplied ready to use (Pierce and Warriner).
Magnesium chloride was dissolved in an 
appropriate volume of distilled water to give a
5.06 mg ml ’ solution.
60 mg Nicotinamide, 38 mg glucose 6-phosphate, 
5 mg NADP^, 20 units glucose 6-phosphate 
dehydrogenase, 3 ml MgClg (5.06 g I ’ ), 30 ml Tris 
buffer (0.1 M, pH 7.8 at 3 7 °C).
As cofactor solution A except Tris buffer was 
replaced by phosphate buffer (0.25 M, pH 7.5 at 
37°C).
Cofactor solution C:
Ethoxyresorufin:
Pentoxyresorufin:
Resorufin standards:
Ascorbate:
As cofactor solution B with the addition of 50 mg 
semicarbazide.
Ethoxyresorufin was dissolved in DMSO to give a 
final concentration of 5 mM (prepared on day of 
assay and stored in the dark).
Pentoxyresorufin was dissolved in DMSO to give 
a final concentration of 5 mM (prepared on day of 
assay and stored in the dark).
Resorufin (1.18 mg of sodium salt) was dissolved 
in methanol and the volume made up to 100 ml to 
give solution A (50 //M). A 1 in 10 dilution of 
solution A with methanol yielded solution B 
(5 //M).
L-ascorbic acid (88 mg) was dissolved in distilled 
water and the volume made up to 100 ml to give 
5 mM ascorbate.
p-Nitrophenol: p-Nitrophenol (69.5 mg) was dissolved in distilled 
water and the volume made up to 100 ml to give 
a 0.5 mM solution.
Perchloric acid:
Sodium hydroxide:
Aniline hydrochloride solution:
Perchloric acid was supplied as a 70% (w/v) 
solution (Fisons). A 1.5 M solution was prepared 
by dispensing 21.75 ml into a 100 ml volumetric 
flask and making up to volume with distilled water.
Sodium hydroxide pellets (40 g) were dissolved in 
distilled water and the volume made up to 1 L.
Aniline hydrochloride was dissolved in an 
appropriate volume of distilled water to give a 
10 mM solution.
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Trichloroacetic acid solutions:
Phenol solution:
Sodium carbonate solution:
p-Aminophenol solution:
Erythromycin solution:
Zinc sulphate solution:
Saturated barium hydroxide: 
solution
Nash reagent:
Formaldehyde solution:
Trichloroacetic acid was dissolved in an 
appropriate volume of distilled water to give a 
20% (w/v) solution. An aliquot of this solution 
was further diluted to give a 6% (w/v) solution.
Phenol was dissolved in an appropriate volume of 
distilled water to give a 1 % (w/v) solution.
Sodium carbonate was dissolved in an appropriate 
volume of distilled water to give a 1 M solution.
p-Aminophenol was dissolved in an appropriate 
volume of ethanol to give a 10 pM solution. The 
solution was prepared just prior to use and was 
discarded after use.
Erythromycin was dissolved in an appropriate 
volume of DMSO to give a 20 mg ml ’ solution.
Zinc sulphate was dissolved in an appropriate 
volume of distilled water to give a 20% (w/v) 
solution.
Distilled water was warmed to approximately 
6 0 °C and barium hydroxide added with stirring 
until saturation was achieved. The solution was 
allowed to cool to room temperature prior to use.
Ammonium acetate (60 g) was dissolved in 200 ml 
distilled water to which was added 0.8 ml 
acetylacetone. The reagent was prepared fresh on 
a daily basis in a brown glass bottle.
Formaldehyde solution (1.018 ml of a 37% w/v 
solution as supplied) was dispensed into a 100 ml 
volumetric flask and the volume made up with 
distilled water. A 1 ml aliquot of this solution was 
dispensed into a 1 litre volumetric flask and the 
volume made up with distilled water to give a 
4 pg ml*’ solution.
2.10 Administration of Inducing Agents
Five groups of male Sprague Dawley rats (n = 3 per group; Charles River UK 
Ltd.) of approximately 225 g bodyweight were used in this study. Each group received 
single daily administrations of an inducing agent (or saline as control) for four
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consecutive days. The doses were: Group A; saline, 1 ml kg ’ day ’ : Group B; BNF, 
80 mg kg ’ day ’ : Group C; PB, 80 mg kg ’ day ’ : Group D; INH, 100 mg kg ’ day ’ and 
Group E; PCN, 50 mg kg ’ day ’ . All doses were given intraperitoneally except for 
Group D where INH was administered orally by gavage.
2.11 Preparation of Hepatic Microsomal Fractions
Buffers for the preparation of microsomes were used ice-cold. The centrifuge 
rotor and homogenising vessels were cooled to 4°C  prior to use.
Twenty-four hours after the last administration of inducing agent, rats were killed by 
cervical dislocation and the livers removed into 0.01 M PBS. The livers were flushed 
with 0.01 M PBS via the hepatic portal vein, blotted dry and weighed. The livers were 
roughly chopped (razor blade) and homogenised in 3 volumes of 0 .025 M PBS using 
an Ultra Turrax homogeniser (Janke & Kunkel GmbH & Co. KG). The homogenising 
vessel was encased in ice to dissipate local heat generated by the homogenizer. The 
homogenate from each liver was split between two centrifuge tubes (25 x 89 mm 
polyallomer, Beckman Instruments UK Ltd.) and 0.025 M PBS added to bring the 
volume of the homogenate to about 20 mm below the top of each tube. The tubes 
were capped and centrifuged in a Beckman L8-60M ultracentrifuge at 10,500 rpm 
(9,000 xp) for 20 min at 4°C . The supernatants, representing the S9 fraction, were 
decanted into clean centrifuge tubes to which was added sufficient 0.05 M phosphate 
buffer to fill the tubes; the tubes were then capped and centrifuged at 35,000 rpm 
(100,000xgr) for 1 hour at 4°C . This centrifugation step was repeated after discarding 
the supernatant and resuspending the pellet in 0.05 M phosphate buffer using a 
hand-held homogeniser (Fisons). The supernatants were again discarded and the
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pellets, representing the microsomal fraction, resuspended in 0.1 M Tris buffer 
containing 20% (w/v) glycerol (10 ml per pellet). The resuspended microsomes were 
divided into 1 ml aliquots and frozen at -2 0 °C prior to storage at -80°C.
2.12 Characterisation of Hepatic Microsomal f^ractions
2.12.1 Protein Content
The protein content of microsomes was assayed using the Coomassie reagent 
kit supplied by Pierce and Warriner. This method is based on that of Bradford (1976) 
and utilises the absorbance shift from 465 nm to 595 nm when Coomassie Brilliant 
Blue G-250 binds to protein in acidic solution.
Microsomes (100 //I, prepared as in 2.11) were dispensed into a 100 ml volumetric 
flask and the volume made up with distilled water. To 1 ml of this dilution was added 
1 ml of Coomassie reagent. Following mixing, the absorbance was read at 595 nm 
against distilled water using a ShimadzU UV-160A spectrophotometer (VA Howe Ltd.). 
A blank sample (1 ml of distilled water instead of diluted microsomes) was also 
assayed. A calibration curve was prepared by dilution of a stock solution of BSA 
(2 mg ml ’) with distilled water to give standards of 1 , 2 ,  5, 10, 15 and 25 //g ml ’; 
these were assayed as above (1 ml standard added to 1 ml reagent).
2.12.2 Total Cytochrome P450 Content
The total P450 content of microsomal preparations was determined using the 
method of Omura and Sato (1964). The basis of this method is the reduction of the
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haem iron which is subsequently complexed with carbon monoxide to produce a 
characteristic absorbance spectrum with at around 450 nm. The extinction 
coefficient for the wavelength couple 450-490 nm has been accurately determined to 
be 91 mM ’ cm ’ thus allowing quantitative determination of the haemoprotein in 
microsomes.
To 1 ml of microsomes (prepared as in 2.11) was added 3.3 ml ice-cold 0.1 M Tris 
buffer/20% v/v glycerol. A few grains of sodium dithionite were added to this sample 
which was then mixed and divided equally between reference and sample cuvettes 
(10 mm pathlength, acrylic cuvettes; Sarstedt Ltd). A baseline was recorded between 
400 and 500nm using a Shimadzu UV-160A spectrophotometer. Carbon monoxide 
(BDH Laboratory Supplies) was gently bubbled through the sample cuvette for 
approximately 60 seconds and the spectrum immediately rescanned between 400 and 
500 nm. The absorbance difference between 450 nm and 490 nm was determined 
and used to calculate the P450 concentration by substitution into Beer's law:
A = E.c.l
Where 'A' is the absorbance difference (450 nm - 490 nm), 'V is the cuvette path 
length (1cm), 'c' is the P450 concentration (mM) and E' is the extinction coefficient 
for the 450-490 nm wavelength couple (91 mM ’ cm ’). By rearranging this equation, 
the cytochrome P450 content of the original, undiluted microsomes is given by:
^  ^ nmol mf-^
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2.12.3 Alkoxyresorufin O-Dealkylase Activities
The 0-dealkylations of ethoxy- and pentoxyresorufin have been demonstrated 
to be highly sensitive and selective measures of the induction of P450 1A1 and 2B1 
respectively in rat liver (Burke and Mayer 1975, Burke etal. 1985, 1994). The basis 
of the alkoxyresorufin 0-dealkylase assays is the production of resorufin which can be 
measured fluorimetrically with high sensitivity (Burke and Mayer 1974).
Cofactor solution A (9 ml) and microsomes (0.9 ml, prepared as in 2.11) were 
dispensed into 25 ml conical flasks (in duplicate for each microsomal preparation). A 
blank was prepared containing 18 ml cofactor solution A and 1.8 ml of pooled 
microsomes (obtained by combining the remaining 0.1 ml of each microsomal aliquot). 
The flasks were preincubated at 3 7 °C for 2 min in a shaking waterbath 
(100 strokes min ’). The appropriate alkoxyresorufin solution (1 0 0 //I, to give a 
concentration of 50 //M) was added to the flasks (except the blank) and the incubation 
continued for 8 min. During the incubation, 3 ml ice cold acetone was added to each 
of three glass tubes (on ice) for each sample being incubated. At the end of the 
incubation, triplicate 1 ml aliquots were removed from each incubation into the tubes 
which were centrifuged at 2,000xgr for 5 min at room temperature (N.B. during 
centrifugation, the calibration standards were prepared as described below). The 
fluorescence of each supernatant was read at 522 and 588 nm excitation and emission 
wavelengths respectively, after zeroing with the blank, using a Perkin Elmer LS-5B 
luminescence spectrometer (Perkin Elmer Ltd.). The calibration standards were 
prepared in glass tubes in duplicate according to Table 2.4 using the remaining 
contents of the blank incubation flask. To each tube was added 3 ml ice-cold acetone 
followed by 10 //I of the appropriate alkoxyresorufin solution. The tubes were capped
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Table 2.4 Components of resorufin incubation standards.
Standard
no.
Volume of 
blank 
incubate (a/I)
Volume of 
resorufin 
standard*
Resorufin
content
(nmol)
1 1000 0 0
2 950 50 fj\ of A 2.500
3 980 20 //I of A 1.000
4 900 100 A/I of B 0.500
5 925 75 //I of B 0.375
6 950 50 A/I of B 0.250
7 975 25 A/I of B 0.125
Refer to 2.9 (p42) for components of resorufin standards.
48
and incubated at 3 7 °C for 8 min followed by centrifugation at 2,Q00xg for 5 min. The 
fluorescence was read as above after zeroing the instrument with standard no. 1.
The blank-corrected fluorescence was used to determine the amount of resorufin 
liberated in 1 ml of the 10 ml supernatant in 8 minutes. The specific activity of 
alkoxyresorufin 0-dealkylase was given by:
%  X  10  , ________  ! -J _-(
y  X 0.9 X 8
nmol resorufin min"’ mg~^  protein
where the amount of resorufin liberated = x nmol and the protein concentration of the 
microsomes = y mg ml ’ .
2.12.4 p-Nitrophenol Hydroxylase Activity
The activity of P450 2E1 was estimated using a 4-nitrophenol hydroxylase 
assay based on the method of Koop (1990). Ascorbate was used to stabilise the
4-nitrocatechol product allowing its spectrophotometric determination following 
basification.
Cofactor solution A (1 ml), microsomes (0.2 ml, prepared as in 2.11) and ascorbate 
(0.4 ml) were dispensed into a 20 ml glass vial and incubated at 3 7 °C for 2 min. 
p-nitrophenol (0.4 ml) was added and the incubation continued for a further 10 min. 
The incubation was terminated by the addition of 0.4 ml perchloric acid followed by 
centrifugation at 12,000xp for 5 min at ambient temperature. To 1 ml of the 
supernatant was added 1 ml of sodium hydroxide and the absorbance was read at 
510 nm. The concentration of 4-nitrocatechol was determined using an extinction
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coefficient of 15.4 mM ’ cm ’ :
X X 2.4 4-pj{rocatechol min"’ mg'^protein
y  X 0.2 X 8
where the concentration of 4-nitrocatechol = x nmol ml ’ and the protein concentration 
of the microsomes = y mg ml ’ .
2.12.5 Aniline Hydroxylase Activity
Many workers have demonstrated increased activity of aniline p-hydroxylase in 
liver preparations from rats pretreated with inducers of P450 2E1 such as ethanol and 
isoniazid (Rubin etal. 1968, Liu etal. 1975, Ryan etal. 1986). The assay used in this 
study was based on the method published by Reinke et a i (1978) which measures the 
coloured product, p-aminophenol.
Incubations were carried out in 20 ml glass vials and consisted of 0.35 ml phosphate 
buffer (0.25 M), 0.15 ml magnesium chloride (5.06 g L*’), 1.5 ml cofactor solution B 
and 0.25 ml microsomes (prepared as in 2.11). The vials were pre-incubated at 3 7 °C 
for 1 min and the reaction was initiated by the addition of 0.25 ml aniline hydrochloride 
(final concentration 1 mM). A blank incubation was prepared in the same manner and 
substituting distilled water for aniline hydrochloride. After 30 min incubation the 
reaction was terminated by the addition of 0.5 ml trichloroacetic acid (20% w/v). The 
vials were allowed to stand on ice for 5 min after which time the contents were 
centrifuged at 2,000xp for 10 min at room temperature. Duplicate 1 ml aliquots were 
removed from each sample into glass test tubes containing 1 ml phenol. Following 
addition of 1 ml sodium carbonate the tubes were left in the dark at room temperature
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for 30 min to allow the colour to develop. The absorbance at 630 nm of each sample 
was read against the blank. Calibration standards (1 ml volume) were prepared by 
diluting 1 0 //M p-aminophenol with 6% (w/v) trichloroacetic acid to give a range of 
p-aminophenol content of 0-10 nmol. The standards were treated as per the duplicate 
1 ml aliquots (see above).
The aniline p-hydroxylase activity was given by:
X X 2.5
y  X 0.25 X 30
nmol p-amlnophenol min ’ mg''^protein
where the amount of p-aminophenol liberated = x nmol and the protein concentration 
of the microsomes = y mg ml ’ .
2.12.6 Erythromycin /V-Demethylase Activity
The /V-demethylation of erythromycin is known to be carried out by P450 3A1 
in the rat (Guengerich 1989). In common with many other déméthylation reactions, 
it can be monitored by measuring the by-product, formaldehyde. The assay relies on 
the Hantzsch reaction between acetylacetone, ammonia and formaldehyde to form 
3,5-diacetyI-1,4-dihydrolutidine. The colorimetric determination of this compound was 
described by Nash (1953) but a more sensitive fluorimetric assay was subsequently 
developed (Belman 1963) and was employed in this study.
Incubations were carried out in duplicate in 20 ml glass vials. Each incubation consisted 
of 1.5 ml cofactor solution C, 0.5 ml magnesium chloride (5.06 g L*’) and 0.25 ml 
microsomes (prepared as in 2.11). Following 1 min preincubation at 3 7 °C, the
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reaction was initiated by the addition of 33 pi erythromycin (final concentration 
400 pM). A blank was prepared in the same manner with the substitution of 
erythromycin solution by DMSO. The incubation was continued for a further 20 min 
and was terminated by the addition of 1 ml zinc sulphate followed 5 min later by 1 ml 
barium hydroxide. The incubates were centrifuged at 2,000xp for 10 min at room 
temperature. Samples (2.5 ml) of the supernatants were dispensed into glass tubes 
to which were added 1 ml Nash reagent. The tubes were capped and incubated at 
37 °C for 60 min. Following further centrifugation as above, the fluorescence of the 
supernatants was read at 410 nm (excitation) and 510 nm (emission). Calibration 
standards (of 2.5 ml volume) were prepared from dilutions of a 4 pg ml ’ solution of 
formaldehyde to give a range of 0 - 0.8 pg ml ’ (0 - 2 pg total). The calibration 
standards were treated as the first supernatant above.
The erythromycin A -^demethylase activity was given by:
V X, I  V
formaldehyde rcm~^  mg'^protein
y  X 0.25 X 20
where the amount of formaldehyde liberated = xpg and the protein concentration of 
the microsomes = y mg ml ’ .
2.12.7 Statistical Methods
One way analysis of variance was used to compare group means from the 
assays in 2.12.3-6 (SAS/Windows, version 6.08; SAS Institute Inc). Pairwise 
contrasts were carried out for each induction group versus control. This test is 
appropriate for obtaining p values from the comparison of a small number of groups 
where the possibility of obtaining significance by chance alone is low.
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2.13 Investigation of the Metabolism of Aminotetralins by Rat Hepatic Microsomes
2.13.1 Incubation of Aminotetralins with Hepatic Microsomes
Incubations were carried out in 20 ml glass vials and contained 3 ml cofactor 
solution B, 0.5 ml microsomes (prepared as in 2.11) and 1.5 ml phosphate buffer 
(0.05 M). The vials were preincubated for 1 min at 3 7 °C and the reaction was 
initiated by the addition of aminotetralin solution (prepared as in 2.3) to give a drug 
concentration of 60 pM. Samples of the incubate (0.5 ml) were removed into 0.5 ml 
acetonitrile at the following timepoints; 0.5, 1.0, 2.0, 5.0, 10.0 and 20.0 min. The 
samples were centrifuged at 12,000xp for 5 min at ambient temperature and the 
supernatant removed for HPLC analysis.
2.13.2 Analysis of Microsomal Incubates by HPLC
Microsomal incubates were analysed by HPLC using the same conditions as 
described in 2.6.2. Where possible, the appearance of metabolites as well as 
disappearance of parent drug was monitored.
METABOLISM STUDIES WITH INHIBITORS OF DRUG METABOLISM ENZYMES
Studies of the metabolism of aminotetralins by rat hepatocytes and induced rat 
hepatic microsomes have been described. To complement these studies, the effect of 
inhibitors of drug metabolising enzymes on aminotetralin metabolism by rat 
hepatocytes has been investigated. These experiments help to build up a picture of the 
enzymology of aminotetralin metabolism. Two P450 inhibitors were chosen on the
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basis of findings from studies with induced microsomes. Orphenadrine and 
erythromycin have been shown to inhibit P450 2B (Reidy etal. 1989) and 3A (Murray 
1987, Murray and Reidy 1990) respectively. DPAT bears structural similarity to 
amphetamine derivatives known to be metabolised by the polymorphically-expressed 
P450 2D6 (Alvan et al. 1984, Hawes et al. 1987). Therefore the effects of quinine, 
a potent inhibitor of the rat orthologue, 2D1 (Kobayashi et al. 1989), on the 
metabolism of DPAT were studied. Galactosamine was used as an inhibitor of 
glucuronidation (Schwarz 1980) to investigate the metabolism of 8-OH-DPAT and
5-F-8-OH-DPAT.
2.14 Chemicals and Reagents
All reagents were obtained from Sigma Chemical Co. Ltd. and all solvents 
were obtained from Fisons (HPLC grade) unless otherwise stated.
Erythromycin solutions:
Orphenadrine solutions:
Galactosamine solution:
p-Nitrophenol solution:
Sodium hydroxide solutions:
A stock solution was prepared by dissolving 
erythromycin in 0.01 M HCI to a concentration of 
20 mg ml ’ . A range of working solutions of 
0-20 mg ml ’ was prepared by further dilution of 
the stock solution with 0.01 M HCI.
Orphenadrine hydrochloride was dissolved in water 
to give a stock solution of 20 mg ml ’ . A range of 
working solutions of 0-20 mg ml ’ was prepared by 
further dilution of the stock solution with water.
( -F )-Galactosamine hydrochloride was dissolved in 
water to give a solution of 360 mM free base.
p-Nitrophenol was dissolved in ethanol to give a 
200 mM solution.
Sodium hydroxide pellets were dissolved in water 
to give a 10 M solution. A portion of this solution 
was diluted 100-fold with water to give a 0.1 M 
solution.
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Resorufin solution: Resorufin (sodium sait) was dissolved in 50% (v/v)
DMSO to give a 2 mg ml ’ solution.
Dicumarol solution: D i c u m a r o l  [ 3 , 3 ' - m e t h y l e n e - b i s ( 4 -
hydroxycoumarin)] was dissolved in 0.1 M sodium 
hydroxide to give a 2 mM solution.
Pentoxyresorufin solution: Pentoxyresorufin was dissolved in DMSO to give
a 5.18 mM solution.
Quinine solutions: Quinine hemisulphate was dissolved in distilled
water to give a 7.47 mg ml ’ solution. Subsequent 
dilutions in water gave solutions of 0, 0.00747, 
0.0747 and 0.747 mg ml. ’
2.15 Investigation of the Effect of P450 Inhibitors on the In Vitro Metabolism of 
Aminotetralins
2.15.1 Metabolism of Aminotetralins in Rat Isolated Hepatocytes following 
Preincubation of Cells with Erythromycin or Orphenadrine
Hepatocyte suspension was prepared as in 2.2 to a concentration of 
6x10® cells ml ’ . Into each of five 25 ml plastic conical flasks was dispensed 5 ml of 
hepatocyte suspension and 0.7 ml of suspension buffer (prepared as in 2.1). The 
flasks were placed in a shaking water bath at 37 °C for 2 min after which 220 pi of the 
appropriate erythromycin or 92 pi of the appropriate orphenadrine solution was added 
such that the final concentrations of inhibitor were 0, 50, 100, 500 and 1000 pM. 
After a further 10 min, aminotetralin solution (prepared as in 2.3) was added to each 
flask to give a final concentration of 60 pM. The incubation was continued and 0.5 ml 
samples were taken into 0.5 ml acetonitrile at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 5.0, 10.0,
20.0, 30.0 min (timed from the addition of aminotetralin). Following centrifugation 
(5,000xp, 5 min, ambient temperature) the supernatant was removed and stored at 
-20 °C prior to analysis.
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2.15.2 Effect of Quinine on the Metabolism of DPAT in Rat Hepatic Microsomes
Incubations were carried out in 20 ml glass vials and contained 1.5 ml cofactor 
solution B (prepared as in 2.9), 0.4 ml microsomes (prepared as in 2.11) and 0.1 ml 
of the appropriate quinine solution to give incubations at 0, 0.1, 1, 10 and 100 pM 
quinine. The vials were preincubated for 5 min followed by addition of DPAT (prepared 
as in 2.3) to give a concentration of 60 pM. Samples of the incubate (0.25 ml) were 
removed into 0.25 ml acetonitrile at the following timepoints (from the addition of 
DPAT); 0.5, 2, 5, 10.0 and 20.0 min. The samples were centrifuged at 12,000xp for 
5 min at ambient temperature and the supernatant removed for HPLC analysis.
2.15.3 Analysis of incubates by HPLC
Samples were analysed for parent drug by HPLC with UV detection. HPLC 
conditions were as described in 2.6.2 and the mobile phase compositions and detection 
wavelengths are given in Table 2.2.
2.16 Investigation of the Effect of Inhibiting Glucuronide Formation on the 
Metabolism of 8-OH-DPAT and 5-F-8-OH-DPAT by Rat Isolated Hepatocytes
2.16.1 Metabolism of 8-OH-DPAT and 5-F-8-0H-DPAT with Rat Hepatocytes 
following Preincubation of Cells with Galactosamine
Into a 25 ml plastic conical flask was dispensed 6 ml hepatocyte suspension 
(prepared as in 2.2). The flask was placed in a shaking water bath at 3 7 °C for 2 min 
after which 50 //I of galactosamine solution was added giving a final concentration of
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3 mM. A control flask was prepared in similar manner, substituting water for 
galactosamine. After a further 20 min in the water bath, solutions of either 
8-OH-DPAT or 5-F-8-OH-DPAT (prepared as in 2.3) were added to give a final 
aminotetralin concentration of 60 //M. The incubation was continued and 0,5 ml 
samples were taken into 0.5 ml acetonitrile at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 5.0, 10.0,
20.0, 30.0 min (timed from the addition of aminotetralin). Following centrifugation 
(5,000xp, 5 min, ambient temperature) the supernatant was removed and stored at 
-20°C prior to analysis.
2.16.2 Analysis of Incubates by HPLC
Samples were analysed for parent drug by HPLC with UV detection. HPLC 
conditions were as described in 2.6.2 and the mobile phase compositions and detection 
wavelengths are given in Table 2.2. Mobile phase conditions for some compounds 
were modified to resolve drug-related material from endogenous material and inhibitor.
2.17 Investigation of the Effects of Drug Metabolism Inhibitors on Cell Viability 
during Incubation with Rat Isolated Hepatocytes.
The purpose of this experiment was to see whether inhibition of aminotetralin 
metabolism was due to toxicity of the inhibitor resulting in decreased cell viability. In 
the case of orphenadrine and erythromycin, the incubations were carried out as 
described in 2.15.1 up to the addition of inhibitor. At this stage the cell viability was 
determined as described in 2.2.3 after which the inhibitor was added. The incubation 
was continued for 30 min after which a further viability determination was made. For 
galactosamine, the incubation was carried out as described in 2.16.1 with viability
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determinations made before and 30, 60 and 90 min after addition of galactosamine.
2.18 Investigation of the Effects of Orphenadrine and Erythromycin on the Activity 
of Pentoxyresorufin O-Depentylase in Rat Isolated Hepatocytes
Orphenadrine and erythromycin have been used as inhibitors of P450 2B and 
3A respectively in section 2.15.1. Studies with inhibitors have traditionally been 
carried out in microsomes and it was therefore felt necessary to establish the ability 
of orphenadrine to inhibit P450 2B in hepatocytes. Pentoxyresorufin O-depentylase 
was used in section 2.12.3 as a marker activity for P450 2B with the reaction product, 
resorufin, being measured fluorimetrically. However, it was felt that in hepatocytes, 
the hydroxy group of resorufin would be vulnerable to phase II conjugation. Having 
confirmed this, it was decided to follow the disappearance of pentoxyresorufin using 
a colorimetric method. This method, whilst less sensitive than the fluorimetric assay 
for resorufin, would not be affected by the further metabolism of resorufin.
To investigate the metabolism of resorufin, 5.85 ml of hepatocyte suspension 
(prepared as in 2.2; 5x10® viable cells ml*’) was dispensed into each of four 25 ml 
plastic conical flasks. The flasks were incubated at 37 °C for 2 min in a shaking water 
bath prior to the addition of 50 //I of water to two flasks (control) and 50 //I of 
galactosamine (final concentration 3 mM) to the remaining two flasks (test). This was 
immediately followed by the addition of 60 p\ of dicumarol (final concentration: 20 //M) 
to all flasks to inhibit DT-diaphorase. This cytosolic enzyme interferes with the assay 
by reducing resorufin to a non-fluorescent product (Lubet et al. 1985b). Further 
incubation (10 min) was followed by addition of 35 p\ of resorufin (final concentration 
5 0 //M) to all flasks (t= 0  min). The incubation was continued and 1 ml samples
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removed into glass tubes containing 3 ml of ice-cold acetone at 5, 15, 30, 60 and 
90 min. The tubes were capped and centrifuged at 2,000xg for 5 min. The 
fluorescence of each supernatant was read at 522 and 588 nm excitation and emission 
wavelengths respectively, using a Perkin Elmer LS-5B luminescence spectrometer 
(Perkin-Elmer Ltd.).
The effects of orphenadrine and erythromycin on pentoxyresorufin O-depentylase in rat 
isolated hepatocytes were subsequently studied using a colorimetric method. 
Hepatocyte suspension (2.5 ml, prepared as in 2.2; 5 x 10® viable cells ml*’ ) was 
dispensed into each of twenty 25 ml plastic conical flasks representing duplicate 
incubations at five concentrations of each inhibitor. The flasks were incubated at 
37 °C for 2 min followed by addition of the appropriate inhibitor solution to give 
inhibitor concentrations of 0, 50, 100, 500 and 1000 //M. At this time, 2b p\ of 
dicumarol was added to the incubation (final concentration 20 //M). After a further 
10 min incubation, 25 p\ of pentoxyresorufin was added (final concentration 
approximately 50 //M) and the incubation continued for another 20 min. A 0.5 ml 
sample was removed from each flask into tubes containing 3 ml ice-cold acetone. The 
tubes were capped and centrifuged at 2,000xgr for 5 min and the absorbance of the 
supernatant read at 466 nm. This wavelength was determined as the for 
pentoxyresorufin and was not affected by resorufin, orphenadrine, erythromycin or 
dicumarol. A blank sample was obtained from a flask set up as described above except 
that the pentoxyresorufin was added immediately prior to removal of the sample.
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2.19 Investigation of the Effect of Galactosamine on the Metabolism of 
p-Nitrophenoi by Rat Isolated Hepatocytes
In order to confirm that galactosamine was inhibiting glucuronidation in the rat 
hepatocyte system, a probe substrate was used. p-Nitrophenol is commonly used to 
monitor glucuronidation activity {e.g. Bock et a!. 1983, Franklin et a!. 1993) using 
standard colorimetric techniques. The following incubations were prepared in plastic 
25 ml conical flasks:
Incubation Hepatocyte 
Suspension* (ml)
Suspension 
Buffer  ^ (ml)
Galactosamine 
solution (ml)
p-Nitrophenol 
solution (pi)
A 12.0 0.1 - 6
B - 12.1 - 6
C 12.0 - 0.1 6
D - 12.0 0.1 6
Prepared as in 2.2;  ^ Prepared as in 2.1
The flasks were incubated at 37 °C for 20 min prior to the addition of p-nitrophenol. 
Samples (1.0 ml) were taken 0, 5, 10, 30, 60 and 90 min after the addition of 
p-nitrophenol into tubes containing 1 ml acetonitrile and 5 pi sodium hydroxide (0.1 M). 
Following centrifugation (5,000xp, 5 min, ambient temperature) the absorbance of the 
supernatant was read at 400 nm. The absorbance values of incubates B and D were 
used to correct the values of A and C respectively to take account of any p-nitrophenol 
breakdown not caused by the action of the hepatocytes.
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STUDIES ON THE IN  VIVO METABOLISM OF THE AMINOTETRALINS
Information on the metabolism of aminotetralins in rat isolated hepatocytes has 
been obtained. The aim of this study was to investigate the in vivo metabolism of 
some of these compounds and thereby assess the utility of the hepatocyte model in 
predicting the in vivo metabolites. The compounds studied were DPAT itself and 
8 -CO2H-, 8-{pyrrole-2-carbonyl)-, 8 -CF3- and 5-F-8-OH-DPAT.
2.20 Chemicals and Reagents
All reagents were obtained from Sigma Chemical Co. Ltd. and all solvents were 
obtained from Fisons (HPLC grade) unless otherwise stated.
Aminotetralins Aminotetralins (see 2.3) were dissolved in 1 mM
HCI at a concentration of 1.5 mg ml ’ in the case 
of DPAT and 8-(pyrrole-2-carbonyl)-DPAT and 
2 mg ml ’ for the remaining compounds.
Reference compounds 7 ,8 -d ih yd ro xy-D P A T  and 7 -hydroxy-8 -
methoxy-DPAT were obtained from Research 
Biochemicals International (UK distributors: 
Semat).
2.21 Investigation into the In Vivo Metabolism of the Aminotetralins
2.21.1 Animals
Male Sprague Dawley rats (Charles River) were used in this study. The animals 
were held in a quarantine area for 5 days prior to the study with free access to food
(Special Diet Services, Porton Combined Diet, Special Quality Control, %" cubed diet 
for rats and mice. Special Diet Services, Wm Lillico and Sons) and water (tap). From 
24 h prior to until 48 h after dose administration, the
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animals were housed in glass Metabowls (Jencons Scientific Ltd.). Predose urine 
samples were collected during the 24 h period prior to dosing. Water was available ad 
libitum throughout the study; food was withheld from 16 h prior to until 4  h after dose 
administration and was available ad libitum at all other times. The weight range of the 
animals just prior to dose administration was 204-219 g.
2.21.2 Administration of Compounds and Sample Collection
The aminotetralins were administered as a single oral dose to one animal per 
compound. The compounds were administered as a solution by oral gavage at a dose 
of 25 pmol kg ’ . Urine was collected into preweighed vessels encased in dry ice over 
the following time periods; 0-6, 6-24 and 24-48 h postdose. Following collection, the 
vessels were weighed to ascertain the amount collected. Urine samples were stored 
at -20°C prior to analysis.
2.21.3 Analysis of Samples by ESI/LC/MS and ESI/LC/MS/MS
As described in 2.4.2, hepatocyte incubates were analysed by LG/MS utilising 
a TSP interface. Just prior to initiating the in vivo study, the mass spectrometer was 
modified including the replacement of the TSP interface with an ESI interface. 
Electrospray ionisation requires the dispersion of charged droplets at atmospheric 
pressure and the subsequent evaporation of the droplets. The LC effluent is split to 
allow a small flow (typically 1 0 //I min*’) through a capillary tube. Application of an 
electric field between the end of the capillary and an electrode results in the production 
of a spray. Charge is accumulated at the surface of the droplets until the repulsive 
forces are sufficient to overcome surface tension and ions are expelled. The
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production of electrosprays from liquids of high aqueous content may be assisted by 
heating of the capillary tube. Detection sensitivity is high due to efficient ion 
production. As will be seen in chapter 8, intact glucuronide conjugates of the 
aminotetralins were detected using electrospray ionisation whereas they were labile in 
the TSP interface.
HPLC Pump: Waters 600MS (Millipore).
Guard column: Brownlee RP8 15 x 3.2 mm (Anachem Ltd.).
Column: Zorbax Rx C8, 250 x 4.6 mm (Hichrom Ltd.).
Mobile Phase: acetonitrile (see Table 2.1) and 0.1 % (v/v) TFA in Milli-Q water. 
Flow rate: 1.5 ml min’ .
Injector: Rheodyne (Millipore). Injection volume: 50 //I.
LC/MS Full scan mode: Q3 scanned 142 - 600 amu in 2 seconds.
Capillary temperature: 250°C  
ESI spray voltage: + 4 .5  V.
Electrometer gain: 10 ®. Electron multiplier: 1000 V.
LC/MS/MS
As per LC/MS except for the following:
Scan time: 0 - ([M +  H]^ +  10) in 2 seconds.
Electrometer gain: 10 ®. Electron multiplier: 1500 V.
CID; Argon at 1 mTorr; collision offset: -30 eV.
2.22 Suppliers
The names and addresses of suppliers are listed below (UK unless stated):
Aldrich The Old Brickyard, New Road, Gillingham, Dorset,
SP8 4JL.
Anachem Ltd. Anachem House, 20 Charles Street, Luton,
Bedfordshire, LU2 OEB.
BDH Laboratory Supplies Merck Ltd., Hunter Boulevard, Lutterworth,
Leicestershire, LEI 7 4XN.
Beckman Instruments UK Ltd. Progress Road, Sands Industrial Estate, High
Wycombe, Buckinghamshire, HP12 4JL.
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Boehringer Mannheim Ltd. 
Charles River UK Ltd.
Costar UK Ltd.
Finnigan MAT Ltd.
Fisons
Gibco - Life Technologies
Hichrom Ltd.
Jencons Scientific Ltd.
Janke & Kunkel GmbH & Co. KG 
Millipore
National Veterinary Supplies
Perkin-Elmer Ltd.
Pierce and Warriner 
Sarstedt Ltd.
SAS Institute Inc.
Semat.
Sherwood Medical Industries 
The Upjohn Company 
Sigma Chemical Co. Ltd.
VA Howe Ltd.
Wm Lillico and Sons
Bell Lane, Lewes, E. Sussex, BN7 1LG.
Mansion Road, Margate, Kent, CT9 4LT.
10 The Valley Centre, Gordon Road, High 
Wycombe, Buckinghamshire, HP13 6EQ.
Paradise, Hemel Hempstead, Hertfordshire, HP2 
4TG.
Bishop M eadow Road, Loughborough, 
Leicestershire, LE11 ORG.
Trident House, PO Box 35, Washington Road, 
Paisley, PA3 4EF.
1 The Markham Centre, Station Road, Theale, 
Reading, Berkshire, RG7 4PE.
Cherrycourt Way Industrial Estate, Stanbridge 
Road, Leighton Buzzard, Bedfordshire, LU7 8BR.
IKA-Werk, D-7813, Staufen-i-Breisgau, Germany.
The Boulevard, Blackmoor Lane, Watford, 
Hertfordshire, WD1 8YW.
Govan Road, Fenton Industrial Estate, Fenton, 
Stoke-on-Trent, ST4 2SZ.
Beaconsfield, Buckinghamshire, HP9 1QA.
44 Upper Northgate Street, Chester, CHI 4EF.
Sarstedt Ltd., 68 Boston Road, Beaumont Leys, 
Leicester, LE4 1 AW.
SAS Circle, Box 6000, Cary, North Carolina, USA.
One Executive Park, Hatfield Road, St Albans, 
Hertfordshire, AL1 4TA.
County Oak Way, Crawley, W.Sussex, RH11 7YQ.
Kalamazoo, Michigan, USA.
Fancy Road, Poole, Dorset, BH17 7NH.
Beaumont Close, Banbury, Oxfordshire, 0X16  
7RG.
Wonham Mill, Betchworth, Surrey, RH3 7AD.
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CHAPTER 3
THE METABOLISM OF THE AMINOTETRALIN SERIES BY 
SUSPENSIONS OF FRESHLY ISOLATED RAT HEPATOCYTES:
QUALITATIVE STUDIES
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3.1 Introduction
In order to investigate the effects of various substituents on the metabolism of 
the aminotetralins, it was first necessary to elucidate the various metabolic pathways 
in the chosen model system i.e. rat hepatocytes. A sensitive and highly flexible 
TSP/LC/MS method was developed, incorporating tandem MS/MS (Martin et a!. 1993b) 
which allowed analysis of all of the compounds under study resulting in a metabolic 
pathway being proposed for each compound.
The technique of TSP/LC/MS has gained in popularity over the last decade for the 
analysis of drugs and their metabolites in complex biological matrices. Using suitable 
HPLC conditions, the various drug-related species can be separated from each other 
and from endogenous components. The HPLC eluate enters the TSP interface and is 
volatilised in a heated capillary to produce a supersonic jet of fine droplets, a proportion 
of which are charged. Further heating during passage through the source reduces 
droplet size and increases the electrical field at the droplet surface resulting in ions in 
the liquid phase being expelled from the droplet. This so-called "soft" ionisation 
technique typically yields abundant [M-FH]^ or [M + H]‘ ions which are indicative of 
molecular weight. Tandem MS/MS may then be used to fragment the components and 
provide a mass spectrum from which structural information can be derived.
An alternative technique is that of "metabolic mapping" utilising tandem MS/MS 
(Straub et at. 1987). Briefly, the sample is scanned for those components which, upon 
fragmentation, give rise to a daughter ion which is common to all drug-related 
components. The sample may also be scanned for components which eliminate a 
particular fragment which is again characteristic of the drug in question (constant
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neutral loss scanning). Having detected the parent ions of putative metabolites, full 
daughter ion spectra can be obtained to confirm their molecular structures. Such 
techniques can be extremely powerful in identifying drug metabolites in complex 
biological matrices but rely heavily on the choice of a suitable characteristic daughter 
ion or fragmental mass loss.
In the present study, it was felt that the wide range of substituents on the tetralin 
moiety would lead to difficulties in selecting suitable daughter ions and/or fragments 
for metabolic mapping techniques. A simple, yet flexible HPLC/MS method was 
developed which required only alteration of the proportion of organic modifier in the 
mobile phase (acetonitrile) to permit analysis of any of the compounds under study. 
Under the acidic mobile phase conditions, the amine nitrogen of the aminotetralin is 
fully protonated leading to high sensitivity of detection in positive ion mode. Having 
obtained [M +  H]"^  ions for suspected metabolites, CID daughter ion spectra were 
obtained in MS/MS mode. The method developed for the analysis of aminotetralin 
metabolites has also been adapted in this laboratory for use with other compounds 
containing basic nitrogens (Martin and Duncan 1994, Speed etaL 1994, Williams et 
a!. 1994, Coleman et ah 1996), thus demonstrating its flexibility.
One disadvantage of this method is that, despite the "soft" ionisation technique, some 
phase II conjugates appear to undergo degradation in the TSP interface (Martin et a!. 
1993c) and this is thought to be due to a combination of heat in the TSP interface and 
the strongly acidic mobile phase. Other workers have successfully employed 
ammonium acetate buffer (typically 0.01 M, pH 5.5) in the mobile phase to obtain 
molecular ions of intact glucuronides (Mattamal et al. 1990, Patanella et al. 1990, 
Wong et al. 1990, Doig and Clare 1991). However, many sulphate and glucuronide
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conjugates are not well retained on reversed-phase HPLC systems and co-elute with 
polar endogenous material making detection difficult. In such cases, samples are often 
treated with preparations of ^ -^glucuronidase and/or sulphatase to liberate the 
unconjugated compound and a comparison between enzyme-treated and control 
samples yields information on the nature and extent of conjugation. This last approach 
has been adopted in the current study and the methodology is detailed in 2.4.
3.2 Results
A vast amount of mass spectroscopic data was generated during the study of 
aminotetralin metabolism. The data for two of the compounds are given here to 
illustrate the interpretation of spectra and proposal of metabolic pathways. Proposed 
metabolic pathways for the remaining compounds are presented at the end of this 
results section and the mass spectroscopic data are given in the appendix.
3.2.1 8-(Pyrrole-2-carbonyl)-DPAT
For 8-{pyrrole-2-carbonyl)-DPAT, the main opportunities for metabolism 
appeared to be /V-dealkylation, A/-oxidation and C-hydroxylation at a variety of 
positions. The molecular weights of these putative metabolites were used to produce 
single ion traces from the LC/MS chromatograms (Figure 3.1). Peaks were present in 
the 30 min incubate which corresponded to the retention time and molecular weight 
of the parent drug and its /V-dealkylated metabolite standard. The m/z 341 trace 
showed one major peak and two minor peaks which could correspond to addition of 
oxygen to the parent drug (m/z 325 +  16). Although the major m/z 341 peak
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Figure 3.1 Top panel: mass chromatogram of 8-(pyrrole-2-carbonyl)-DPAT (m/z 325) 
and authentic standard of its monopropyl metabolite (m/z 283). Bottom panel: mass 
chromatogram of hepatocyte incubate (30 min) of 8-(pyrrole-2-carbonyl)-DPAT 
following treatment with ^9-glucuronidase. Horizontal axis is time (min); right-hand 
vertical axis indicates intensity of ion current (exponential notation). RIC is ion current 
summed over complete scan range.
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co eluted with the proposed /V-dealkylated metabolite, the mass-selective detection
resolved the two components. Smaller peaks were observed which could result from
oxidation of the /V-dealkylated metabolite (m/z 299) or further /V-dealkylation to the
primary amine (m/z 241). Both of the proposed oxidised metabolites appeared to be
conjugated to some extent as judged by comparison of mass chromatograms from
(data not shown)
y9-glucuronidase/sulphatase-treated and control incubate^ The magnitude of the 
instrument response to the parent drug and its monopropyl metabolite was 
approximately equal. It is therefore reasonable to suggest that the /V-dealkylated 
metabolite was the major metabolite of 8-(pyrrole-2-carbonyl)-DPAT after 30 min 
incubation. Analysis of the 120 min incubate revealed that the proposed oxidised 
metabolite (m/z 341 ) was more abundant than the /V-dealkylated metabolite (m/z 283). 
The LC/MS spectra averaged across each peak demonstrated the presence of a 
molecular ion ([M + H]^) often accompanied by an acetonitrile adduct, 
[M + H-t-CHaCN]^, 41 amu higher. None of the peaks attributed to metabolites of 
8-(pyrrole-2-carbonyl)-DPAT were observed in the blank sample.
Confirmation of these assignments was provided by the MS/MS data. The MS/MS 
spectrum of 8-(pyrrole-2-carbonyl)-DPAT (Figure 3.2) showed a protonated species at 
m/z 224 resulting from the loss of the dipropylamine moiety (101 amu) which itself 
was detected as a protonated fragment at m/z 102. The pyrrole ring then either 
fragmented (losing ethene to yield m/z 196), or was lost entirely to give m/z 157. 
Alternatively, the pyrrole-2-carbonyl moiety was lost as m/z 94. The spectrum of the 
proposed /V-dealkylated metabolite was virtually identical to that of the authentic 
standard thus confirming the identity of the metabolite by retention time, molecular 
weight and CID spectrum. The m/z 102 ion of the parent compound has been replaced
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Figure 3.2 CID MS/MS spectra of 8-(pyrroie-2-carbonyl)-DPAT (top; daughters of 
m/z 325) and its monopropyl metabolite (bottom; daughters of m/z 283) following 
incubation with rat isolated hepatocytes. Horizontal axis is amu and right-hand vertical 
axis indicates intensity of ion current (exponential notation). The scheme in the middle 
panel illustrates the proposed fragmentation of 8-(pyrrole-2-carbonyl) DPAT.
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by an ion at m/z 60 in the A/-deaIkyiated metabolite (indicating loss of propylamine 
rather than dipropylamine) thus confirming the structure.
Figure 3.3 shows the MS/MS spectrum (daughters of m/z 341) of the proposed 
oxidised metabolite of 8-(pyrrole-2-carbonyl)-DPAT (largest m/z 341 peak in 
Figure 3.1). There was no observed IM+H]'^ ion at m/z 341 and the spectrum has 
been expanded to highlight other ions. Ions at m/z 224, 196 and 157 were present 
(compare Figure 3.2) suggesting that the tetrahydronaphthalene nucleus was intact 
{i.e. not oxidised). The presence of an ion at m/z 118 and not at m/z 102 suggested 
that oxidation had taken place in the dipropylamine moiety. It was considered that 
/V-oxidation would result in marked changes in the fragmentation pattern and that the 
strong m/z 118 ion was therefore indicative of aliphatic hydroxylation. Furthermore, 
it was thought that an aliphatic alcohol (but not an /V-oxide) could lose water (18 amu) 
during MS/MS and indeed there is an ion at m/z 100. Thus there was good evidence 
that the metabolite was the product of aliphatic hydroxylation in one of the propyl 
chains. The spectra of the two minor peaks at m/z 341 were very weak although that 
of the later-eluting was not inconsistent with hydroxylation in one of the propyl chains. 
Figure 3.4 gives the proposed metabolic pathway of 8-(pyrrole-2-carbonyl)-DPAT based 
on the mass spectroscopic evidence obtained.
3.2.2 8 -OH-DPAT
In addition to possible /V-dealkylation and hydroxylation, 8 -OH-DPAT has a 
hydroxy group available for conjugation. The mass chromatogram of the 30 min 
incubate of 8 -OH-DPAT is given in Figure 3.5 (top panel). The largest two
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Figure 3.3 CID MS/MS spectrum (daughters of 341) of proposed oxidised metabolite 
of 8-(pyrrole-2-carbonyi)-DPAT following incubation with rat isolated hepatocytes. 
Horizontal axis is amu and right-hand vertical axis indicates intensity of ion current 
(exponential notation). There was no observed [M +  H]"*^  ion at m/z 341 and the 
spectrum has been expanded to highlight other ions. The scheme illustrates the 
proposed fragmentation.
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CONJUGATION
Figure 3 .4  Proposed metabolic pathway of 8-(pyrrole-2-carbonyl)-DPAT in rat isolated 
hepatocytes. Numbers refer to major metabolites detected after 30 or 120 min 
incubation.
74
100 -
50-
m / z : 164
ata:
m / z : 206
1
m /z :  248 1li . K .... .
m / z : 264
. . _
RIC
L.. , . , t T - ]  1 ,
5 : 0 0  1 0 : 0 0
1 1 1 '1 ' 1 1 -1 ' 1 i""i
1 5 : 0 0  2 0 : 0 0 2 5 : 0 0
100-1
8 0 -
60-
4 0 -
20 -
2 48
156
225
183
197
lilllill
200
233
1
41
*2-1-06 
3 . 7 0 5
* 2  + 06  
4 . 7 2 4
* 2 + 0 5
1 . 9 8 7
* 2 + 0 4
4 . 4 5 5
* 2 + 0 7
5 . 4 1 1
t
250
272 287
2G9_i r
300 350
355 375
I I
++-I+-
4 00
' * 2 + 0 4
433
-4
-2
4 50
188 212 236
m
* 2  + 04
200 250 300 350 400 450
Figure 3.5 Top panel: mass chromatogram of rat isolated hepatocyte incubate (30 min) 
of 8 -OH-DPAT. Horizontal axis is time (min); right-hand vertical axis indicates intensity 
of ion current (exponential notation). RIC is ion current summed over complete scan 
range. Middle and bottom panels are LC/MS spectra of mz 248 peaks eluting at 
approximately 10 and 25 min respectively. Horizontal axis is amu.
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responses corresponded to the products of /V-dealkylation initially to the secondary 
amine (m/z 206) and subsequently to the primary amine (m/z 164). In the m/z 248 
trace there were two peaks of roughly equal intensity, the later-eluting of which 
corresponded to the retention time of the parent drug. The LC/MS spectra of both 
peaks exhibited m/z 248 as the predominant ion. In line with earlier work (see 
introduction to this chapter), it was thought that the earlier-eluting peak could arise 
from thermal degradation of a conjugate of 8 -OH-DPAT in the TSP interface. There 
were two very weak responses in the m/z 264 trace which were thought to be 
hydroxylated metabolites of 8 -OH-DPAT.
MS/MS analysis of the proposed metabolites provided good evidence for their 
assignments as above with the exception of the m/z 264 metabolites where the 
responses were too weak to obtain MS/MS data. Figure 3.6 gives the CID MS/MS 
spectra of the proposed /V-dealkylated metabolite (m/z 206), the proposed degraded 
conjugate (m/z 248) and the parent drug (m/z 248). The MS/MS spectra of these 
compounds were essentially analogous, with loss of the amine moiety to give the 
common m/z 147 ion. Fragmentation then proceeded via breakdown of the saturated 
ring to give m/z 132, m/z 119 and the tropyllium ions m/z 107 and m/z 91. Although 
no molecular ion was observed in either daughters of 248 spectrum, the spectra were 
very similar and featured characteristic ions at m/z 147, m/z 119, m/z 107 and 
m/z 102. This similarity was good evidence that the earlier-eluting m/z 248 peak was 
indeed the product of degradation of a conjugate of 8 -OH-DPAT. Data from incubates 
treated with ^ -glucuronidase/sulphatase were consistent with this assignment (data not 
shown). The proposed metabolic pathway for 8 -OH-DPAT is given in Figure 3.7.
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Figure 3.6 CID/MS/MS spectra of proposed A/-dealkylated metabolite (top panel, 
daughters of 206), proposed conjugate of 8 -OH-DPAT (left middle panel, daughters 
of 248) and parent drug (right middle panel, daughters of 248) following incubation of 
8 -OH-DPAT with rat isolated hepatocytes. Horizontal axis is amu and right-hand 
vertical axis indicates intensity of ion current (exponential notation). The scheme in 
the bottom panel illustrates the proposed fragmentation.
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Figure 3.7 Proposed metabolic pathway of 8 -OH-DPAT in rat isolated hepatocytes. 
Numbers refer to major metabolites detected after 30 or 120 min incubation.
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3.2.3 Remaining Compounds
Proposed metabolic pathways in rat isolated hepatocytes for remaining
compounds (numbers on Figures refer to major metabolites detected after 30 or 
1 2 0  min incubation):
DPAT, 8 -CO2 H-DPAT - Figure 3.8
5-F-DPAT, 5-F-8-0H-DPAT - Figure 3.9
8 -OTF-DPAT, 5-OTF-DPAT - Figure 3.10
8 -CF3 -DPAT, 8 -Br-DPAT - Figure 3.11
8 -CONH2 -DPAT, 5 -F-8 -CONH2 -DPAT - Figure 3.12
8 -SO2 NH2 -DPAT, 8 -CN-DPAT - Figure 3.13
The mass spectroscopic data from which the above metabolic pathways were derived 
are summarised in tabular form in the appendix (except for 8 -CO2 H-DPAT for which no 
MS/MS data were obtained).
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Figure 3.8 Proposed metabolic pathways for DPAT (top) and S-COgH-DPAT 
(bottom) in rat isolated hepatocytes.
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Figure 3.9 Proposed metabolic pathways for 5-F-DPAT (top) and 5-F-8-OH-DPAT
(bottom) in rat isolated hepatocytes.
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et at. 1993) and 5-OTf-DPAT (bottom) in rat isolated hepatocytes.
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Figure 3.11 Proposed metabolic pathways for 8 -CF3-DPAT (top) and 8 -Br-DPAT
(bottom) in rat isolated hepatocytes.
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Figure 3.12 Proposed metabolic pathway of S-CONHg-DPAT (top) and
5-F-8-CONH2-DPAT (bottom) in rat isolated hepatocytes.
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(bottom) in rat isolated hepatocytes.
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3.3 Discussion
A/-dealkyIation was shown to be a major metabolic route in rat isolated 
hepatocytes for all of the compounds studied. In all cases, the respective 
A^-dealkylated metabolite was the major drug-related species present in the 30 min 
incubate as judged by peak heights in the single ion traces. Whilst this is only a semi- 
quantitative assessment, authentic /V-dealkylated metabolite standards (where 
available) were shown to have a similar LC/MS response factor to their respective 
parent drugs.
The unsubstituted dipropylaminotetralin, DPAT, was extensively metabolised by
/V-dealkylation and hydroxylation in both the propyl side-chain and the aromatic ring
(Martin et a!. 1993b). There appeared to be some preference for the position of
aromatic hydroxylation and subsequent synthesis of phenolic standards provided
evidence for the 6 - and 7-hydroxy metabolites being more abundant than the other 
(data not shown)
isomers  ^ There was no evidence for further hydroxylation of these phenolic 
metabolites at any position nor for subsequent méthylation of potential catechol 
metabolites. With 8 -OH-DPAT there was some evidence for a dihydroxy metabolite 
which was not seen following incubation of DPAT, however there was insufficient 
material to determine the position of hydroxylation. Consistent with these data, 
Wikstrom etaL  (1988) found that ortho-hydroxylation was a very minor pathway 
following administration of 5- or 8 -OH-DPAT to rats.
As well as extensive /V-dealkylation, 8 -OH-DPAT was also shown to undergo direct 
conjugation to form either a sulphate or glucuronide metabolite. Another phenolic 
aminotetralin, 2-(/V-propyl-/V-2-thienylethylamino)-5-hydroxytetralin, underwent
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0 -gIucuronidation as the major metabolic route following oral or intravenous 
administration to rats (Gerding et al. 1990a, 1990b). More recently, 8 -OH-DPAT was 
shown to be metabolised to the 0-glucuronide in the rat (Mason et al. 1995a). 
Another possibility is that 8 -OH-DPAT could undergo conjugation to form a quaternary 
ammonium-linked A/-glucuronide, a well documented biotransformation of tertiary 
aliphatic amines. Such a conjugate would be expected to yield a similar mass 
spectrum to the unconjugated species following thermal decomposition in the TSP 
interface (Martin et al. 1993c). This pathway has been reported for cyclobenzaprine 
(Hucker et al. 1978), cyproheptadine (Fischer et al. 1980), ketotifen (Le Bigot et al. 
1983), amitriptyline, imipramine, chlorpromazine (Lehman etaL 1983) and a range of 
H,-antihistamines (Luo etal. 1991). A clear trend that emerges from these studies is 
that whilst man and other primates can form quaternary ammonium-linked 
/V-glucuronides in vivo, rats and mice are virtually lacking in this capability both in vitro 
and in vivo. Despite the lack of a molecular ion, it was therefore thought that the 
conjugate of 8 -OH-DPAT formed by rat isolated hepatocytes was the phenolic 
0 -glucuronide.
Glucuronic acid conjugation, to form an ester with the C-1 hydroxyl of glucuronic acid, 
is an important metabolic route of carboxylic acids (Caldwell 1980). This reaction has 
been shown to occur for aryl carboxylic acids (of which 8 -CO2H-DPAT is an example) 
in a variety of species (Christensen et ai. 1990, Tanaka et ai. 1990). The only 
metabolite of 8 -COgH-DPAT detected was the /V-dealkylated product which was only 
seen after 120 min incubation. It was thought that 8 -CO2H-DPAT was too polar to 
extensively penetrate either the cell membrane or subsequently the endoplasmic 
reticulum membrane and was hence extremely slowly metabolised.
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A/-oxidation of tertiary aliphatic amines to /V-oxides has long been established as a 
common metabolic pathway (Bickel 1969) and it is therefore perhaps surprising that 
no evidence for /V-oxide formation was obtained in the current study. However, 
/V-oxides are known to be susceptible to reduction and imipramine oxide (Bickel et al.
1966), morphine oxide (Heimans etal. 1971) and dimethylamphetamine oxide (Jenner 
1971) are all reduced back to the tertiary amine in vivo. Although non-enzymic and 
extra-hepatic mechanisms are often responsible (Bickel 1969, Jenner ef a/. 1973), the 
major site of enzymic /V-oxide reduction is thought to be the liver (Dajani et ai. 1975, 
Sugiura et ai. 1976). In some cases, detection of /V-oxides is hindered by their 
chemical decomposition. Cashman (1989) found that the rate of verapamil /V-oxide 
formation in pig and rat microsomes was variable due to its decomposition via a Cope 
elimination. A similar reaction was observed by Swanson et ai. (1994) who studied 
the metabolism of R-( + )-8-(2,2-dimethyl-1-propanone)-DPAT in rats. The /V-oxide of 
this compound was synthesised but spontaneously decomposed yielding the 
corresponding dihydronaphthalene. This decomposition product was detected in rat 
urine by GC/MS from which it may be inferred that the /V-oxide was a metabolite. In 
the current study, it is unlikely that such decomposition products would have been 
detected using positive ion TSP/LC/MS due to the elimination of the basic nitrogen and 
lack of an alternative site for protonation.
The substitution of fluorine, the most electronegative element, for hydrogen in a given
drug results in a change in electron distribution which can affect its pKa, dipole
moments and the reactivity of its functional groups. In addition, fluorine substitution
(Park and Kitteringham 1994). 
also results in increased lipophilicit^ It is therefore not surprising that such
substitutions can have profound effects on the routes and rates of drug metabolism.
The metabolism of 5-F-DPAT appeared to occur at a similar rate to that of DPAT itself
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and whilst /V-deaikylation appeared to be more predominant, aromatic hydroxylation 
was still evident. In contrast, there was no aromatic hydroxylation observed for 
8 -CF3-DPAT. Thus, despite better access to the drug metabolising enzymes afforded 
by increased lipophilicity, the electron withdrawing trifluoromethyl group appeared to 
deactivate the aromatic ring with respect to hydroxylation by cytochrome P450, a 
process which is thought to involve attack by an electrophilic species (Poulos 1988, 
Lewis 1990, Ackland 1993). Glucuronide formation is thought to proceed via an 8^2 
mechanism with nucleophilic displacement of the UDP moiety and subsequent inversion 
(Kasper and Henton 1980). The substitution of fluorine into phenol reduces its pKa 
and would therefore be expected to increase its reactivity as a nucleophile in 
glucuronidation reactions (Park and Kitteringham 1994). However, whilst ortho 
substitution decreases the pKa by approximately 1.2 units, para substitution has very 
little effect (Park and Kitteringham 1994). Consistent with this, the extent of 
glucuronidation of 5-F-8-OH-DPAT did not appear to be significantly different to that 
of 8 -OH-DPAT.
There did not appear to be any marked differences in metabolism between 
8 -CONH2 -DPAT and 5 -F-8 -CONH2 -DPAT. The amide group is both electron 
withdrawing and reasonably polar and hence the metabolism of 8 -CONH2 -DPAT was 
not rapid and there was no evidence for aromatic hydroxylation. The metabolism of 
5 -F-8 -CONH2 -DPAT appeared to be slightly faster which was probably a function of the 
increased lipophilicity. Some MS/MS evidence for both propyl side-chain hydroxylation 
and saturated ring hydroxylation was obtained for 8 -CONH2 -DPAT whereas with
5 -F-8 -CONH2 -DPAT only the product of the former pathway was detected. It is 
possible that the presence of the 5-fluoro and 8 -amide functions have deactivated the 
benzylic carbons of 5-F-8-C0NH2-DPAT with respect to electrophilic attack.
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The trifluoromethylsulphonyl (triflate) substituent is an electron-withdrawing group 
which confers markedly increased lipophilicity. Neither 5-OTf- nor 8 -OTf-DPAT 
underwent aromatic hydroxylation and this may have been due to the deactivating 
effect of the triflate group. Despite the increased lipophilicity, neither compound 
appeared to be particularly rapidly metabolised and one explanation could be that the 
relatively bulky triflate substituent could limit access of the compounds to the active 
site of the enzyme responsible for their metabolism.
The carbon fluorine bond is one of the strongest in organic compounds; 112 kcal mol'^  
compared to 98 kcal moM for C-A/. However, in certain circumstances, the stability 
of the fluoride ion favours defluorination. The action of phenylalanine hydroxylase on 
4 -fluoro-L-phenylalanine results in the production L-tyrosine and fluoride (Kaufman 
1961). The defluorination of 2-fluoro-17-o-ethynyloestradiol to produce 
2 -hydroxyethynyloestradiol is proposed to occur via facile loss of a fluoride ion from 
an epoxide intermediate as the strength of the C-F bond would not favour direct 
oxygen insertion (Morgan ef a/. 1992). There was no evidence of metabolic 
defluorination occurring for any of the compounds in the current study.
The mass spectroscopic analysis of the metabolites of 8 -Br-DPAT was aided by the 
existence of bromine as both ’®Br and ®^ Br in an approximate 1:1 ratio. 8 -Br-DPAT 
underwent reasonably rapid metabolism and, in addition to /V-dealkylation, 
hydroxylation in both rings was observed. The relative amount of aromatic 
hydroxylation appeared to be less than that observed for 5-F-DPAT. The greater 
electronegativity of fluorine would predict that fluorobenzene would undergo 
electrophilic substitution less readily than other halobenzenes. However, the overlap 
of the 2p orbital of fluorine with the 2p orbital of carbon means that the fluorine
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electrons can resonance-stabilise the intermediate in electrophilic substitution reactions. 
The overlap of different sized orbitals that occurs with the other halobenzenes is much 
less efficient and hence, from a purely chemical standpoint, fluorobenzene is the most 
susceptible to electrophilic attack (Fessenden and Fessenden 1982).
The metabolism of bromobenzene has been extensively studied {e.g. Lertratanangkoon 
and Horning 1987, Zheng and Hanzlik 1992) and metabolites have been identified 
resulting from hydroxylation, epoxidation, glutathione conjugation and debromination. 
There were no debrominated metabolites of 8 -Br-DPAT detected in the current study.
/V-Acétylation is a well established route of biotransformation for aromatic and aliphatic 
amines, hydrazines, hydrazides and sulphonamides (Weber 1973). In the intact animal 
at least, the metabolism of foreign compounds via this route appears to be mainly 
limited to aromatic amines and hydrazines (Weber and Glowinski 1980). One example 
of this reaction occurring in vivo with a sulphonamide is found in the metabolism of 
Zonisamide in the rat (Stiff and Zemaitis 1990). The possibility of this 
biotransformation occurring with 8 -SO2NH2-DPAT was investigated. Interestingly, in 
the case of the dipropylaminotetralins, /V-acetylation would result in a gain of 42 amu 
which is the same mass that would be lost by A -^dealkylation. For example, an 
A/-acetylated di-A^-dealkylated metabolite would have the same molecular ion as the 
mono-A/-dealkylated metabolite. However, in the case of 8 -SO2NH2-DPAT there were 
no peaks in the corresponding single ion trace other than that which was identical by 
retention time and MS/MS spectrum to a synthetic standard of the A/-dealkylated 
metabolite.
Nitriles can undergo hydrolysis in either acidic or basic conditions to yield amides or
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more commonly {since amides are themselves hydrolysed) carboxylic acids {March 
1985). No evidence for such a biotransformation was found in two studies of the 
metabolism of benzonitrile-containing compounds (Bakke et aL 1988, Hesk et a!. 
1988). Indeed, the metabolites of 2 ,6 -dichlorothiobenzamide in rat urine were found 
to have undergone conversion to the nitrile (Bakke et aL 1988). The products of such 
reactions were not detected in the incubates of either 8 -CONH2-DPAT or 8 -CN-DPAT.
8-(Pyrrole-2-carbonyl)-DPAT was the only compound studied containing a cyclic 
substituent. Whilst there appears to be little published information on the metabolism 
of pyrrole, it is electron-rich and the C2 and C5 positions in the ring, having a higher 
electron density than C3 and C4, are susceptible to electrophilic attack (Damani and 
Crooks 1982). Consistent with this, RO 5-3335 (a 2-pyrrole substituted 
benzodiazepine) was reported to undergo hydroxylation at the C5 position in the rat 
(Town et aL 1992). However the pyrrole-2-carbonyl moiety of 8-(pyrrole-2- 
carbonyD-DPAT did not appear to undergo metabolism and this may be due to the 
electron-withdrawing effect of the carbonyl group.
The oxidative deamination of alicyclic primary amines, including 2 -aminotetralin, to 
yield the corresponding ketone has been studied in liver microsomes from rat and rabbit 
(Kurebayashi et a!. 1988). This reaction was thought to occur either by a-carbon 
hydroxylation with subsequent loss of ammonia or by an /V-hydroxylation pathway via 
an oxime intermediate. The deamination rate of 2 -aminotetralin was some 5- to 6 -fold 
lower in rat compared to rabbit. In addition, the deamination of 1 -aminotetralin was
6 -fold faster than that of 2 -aminotetralin in rat and this was thought to be due to the 
lower pKa of 1 -aminotetralin arising from the negative inductive effect of the phenyl 
ring. Thus it appears that even following the production of significant amounts of the
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various substituted 2-aminotetralins (by /V-dealkylation of their A/,/V-dipropyl parents), 
deamination would not be a major pathway in the rat hepatocyte system. The ketone 
products of oxidative deamination, i.e. substituted ;9-tetralones, would not be well 
detected by positive-ion LC/MS due to the lack of a protonatable group and it was 
therefore impossible to assess the potential contribution of this pathway using the 
current methodology.
There was mass spectroscopic evidence for hydroxylation in the saturated ring for four 
of the compounds studied; 8 -OTf-, 8 -CF3 -, 8 -Br- and S-CONHg-DPAT. Hydroxylation 
at an aliphatic carbon is believed to proceed via hydrogen atom abstraction (Amodeo 
et ai. 1990). The energy required to break a carbon-hydrogen bond is approximately 
420 kJ mol'  ^ for a primary alkyl carbon compared to 340-360 kJ moM for an allylic or 
benzylic carbon. Therefore, energetics clearly favours hydroxylation of an aminotetralin 
at a benzylic (1- or 4-) position compared to the primary alkyl (2- or 3-) positions.
In summary, it has been demonstrated that /V-dealkylation is the major metabolic route 
for the /V,/V-dipropyl-2-aminotetralins in rat isolated hepatocytes. There was no 
evidence for /V-oxide formation. Substitution on the aromatic ring appeared to have an 
effect on the extent of aromatic hydroxylation. Whilst these experiments were 
intended to provide qualitative metabolism information, it was nevertheless evident that 
the overall rates of metabolism were affected by the substituents on the aromatic ring. 
The affects of the various aromatic substitutions on the quantitative metabolism of the 
aminotetralins are dealt with in the next chapter.
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CHAPTER 4
THE METABOLISM OF THE AMINOTETRALIN SERIES BY 
SUSPENSIONS OF FRESHLY ISOLATED RAT HEPATOCYTES:
QUANTITATIVE STUDIES
94
4.1 Introduction
In chapter 3, the effects of various substituents on the routes of aminotetralin 
metabolism were discussed. In this chapter, the effects of these substituents on the 
rates of metabolism are dealt with. The measurement of the initial rate of metabolism 
at three drug concentrations yielded values for CL^ by means of Michaelis-Menten 
analysis using the direct linear plot (see 2.6.3). As each aminotetralin required three 
incubations, it was not technically possible to use the same hepatocyte preparation for 
the whole series. This was compounded by the need for repeat incubations due, in the 
main, to instrument failure during HPLC analysis. Clearly, some way of standardising 
with respect to the metabolic capability of the various preparations of hepatocytes was 
needed. When performing studies with microsomes, their ease of storage means that 
full characterisation can be carried out at a convenient time. With the need to use 
hepatocytes as soon as possible after isolation, even a crude estimation of total P450, 
which may not be very informative, requires the assistance of another operator. It was 
decided that the best method of 'characterising" the hepatocytes was to incubate a 
reference compound with each preparation. The template dipropylaminotetralin DPAT 
was deemed most suitable for this purpose as it would reflect the metabolic capability 
of each preparation with relevance to the whole aminotetralin series. Thus, the CL;  ^
value obtained for each aminotetralin was normalised to the CLj  ^ for DPAT in the 
relevant hepatocyte preparation to give a value of 'relative metabolic stability' (DPAT 
= 1). The methods used to study the quantitative metabolism of the aminotetralins 
are detailed in 2 .6 .
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4.2  Results
The values of 01;^ and relative metabolic stability {vs. DPAT) obtained for the 
aminotetralin series are presented in Table 4.1. The most rapidly metabolised 
compound was 5-F-8-OH-DPAT whereas no measurable metabolism was observed for 
8 -CO2H-DPAT. 8 -CONH2-DPAT was approximately 10-fold more metabolically stable 
than 5-F-8-OH-DPAT.
The effect on the assay of not shaking the incubation flasks is illustrated in Figure 4.1. 
An example of the variation in the number of cells sampled is shown in Figure 4.2.
4.3 Discussion
The wide range of relative metabolic stabilities in Table 4.1 illustrates the 
effects of the substituents on the rates of metabolism. The data presented in 
chapter 3 demonstrated that, although the substituents appeared to have some bearing 
on the sites of oxidation, A/-dealkylation was the major metabolic route for all the 
compounds studied. Altering, or indeed blocking, potential sites of oxidation by 
substitution would therefore not be expected to have a significant quantitative effect 
on metabolism (unless the substituents themselves were metabolised). The 
substituents (at the 5- and 8 - positions) are far removed from the amine nitrogen and 
this might preclude any direct effects of substitution on /V-dealkylation. It would seem 
then, that the substituents are affecting the rates of metabolism of the aminotetralins 
by one, or a combination, of the following means: 1. Modulation of lipophilicity, 
thereby influencing cell penetration and therefore the extent of access to the drug 
metabolising enzymes; 2. Alteration of the extent and strength of binding to the drug
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Table 4.1 values obtained following incubation of aminotetralins with rat
isolated hepatocytes, analysis of incubates by HPLC and data analysis 
using the direct linear plot. All values were obtained from singlet 
incubations with singlet HPLC assays.
Compound Run
no.
Vm« 
(nmoles min*’ 
1 0® cells '')
Km
(nmoles mM)
CL.m 
(ml min*^  
1 0 ® cells")
Relative 
Metabolic 
Stability 
vs. DPAT*
DPAT 1 1.70 54.0 0.0315 1
2 2.95 73.0 0.0404
3 0.53 38.5 0,0136
4 2.15 81.0 0.0265
5 2.50 83.0 0.0301
8 -Br-DPAT 1 1.85 45.0 0.0411 0.766
8-(pyrrole-2-carbonyl)-DPAT 1 0.45 17.5 0.0257 1.226
8 -CN-DPAT 1 5.59 240.0 0.0233 1.352
8 -OH-DPAT 1 1.48 84.0 0.0176 1.790
5-F-DPAT 2 0.81 25.5 0.0318 1.272
8 -CF3-DPAT 3 2.25 97.5 0.0231 0.589
5-OTf-DPAT 3 0.59 18.0 0.0328 0.415
8 -CONH2-DPAT 4 0.18 2 2 .0 0.0080" 3.313
8 -OTf-DPAT 4 1.46 47.5 0.0307 0.863
5-F-8-OH-DPAT 4 4.10 51.5 0.0796 0.333
5 -F-8 -CONH2-DPAT 5 0.72 54.0 0.0133 2.263
8 -SONH2-DPAT 5 2.19 159.0 0.0138 2.181
8 -CO2H-DPAT 5 - - 0 .0 0 0 * 00
CLjrt for S-CONHg-DPAT was derived from the intersect of only the 60 //M and 
20 //M incubations as the rate of metabolism at 10 //M was too low to measure.
There was no measurable metabolism of 8-C0,H-DPAT.
Relative m etabolic s tab ility  of compound vs 
CL|„t (DPAT)/CLj„t(compound).
DPAT =
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Figure 4.1 Disappearance of DPAT during incubation at 10, 20 and 60 fjM with rat 
isolated hepatocytes. Top panel is incubation with continuous shaking, 
bottom panel is static incubation.
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Figure 4.2 Viable cell content of samples (0.5 ml) taken from an incubation of rat 
isolated hepatocytes at 5 x 10® viable cells ml.'  ^(mean of 3 incubations).
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metabolising enzymes; 3. Change in the enzyme (or isoform of the enzyme) responsible 
for the metabolism. In addition to these factors, the hydroxy substituents of 
8 -OH-DPAT and 5-F-8-OH-DPAT were vulnerable to conjugation whereas none of the 
substituents on the other compounds appeared to be metabolised. The metabolic 
stability data will also be discussed in subsequent chapters where the effects of 
substitution on lipophilicity and metabolism by various enzymes will also be dealt with.
Probably the most commonly used methods of obtaining the kinetic parameters 
and Km are the straight line plots of the Michaelis-Menten equation. The most popular 
of these is the double reciprocal or Lineweaver-Burk plot of 1/v against 1/s (where v 
is the reaction velocity and s is the substrate concentration). This method is probably 
the least satisfactory since similar errors in the measurement of v result in widely 
differing errors in 1 1v such that it is difficult to judge the amount of weight to be given 
to each data point. The two other commonly used plots {s/v against s and v against 
v/s) are not free from this sort of distortion but suffer much less than the double 
reciprocal plot. The direct linear plot (Eisenthal and Cornish-Bowden 1974) is 
conceptually different in that V^ ax and are treated as variables and v and s as the 
constants. Straight lines are drawn linking -s on the Km axis and v on the V^ax axis 
(see example in Figure 4.3). For a set of observations of vat different concentrations, 
the lines should yield a common intersect (in the absence of experimental error) whose 
coordinates represent the values of V a^x and that satisfy all the observations. 
However, in reality in it is more common to obtain a family of intersects numbering 
%/7(/7-1 ) where n is the number of observations. Values of V a^x and are obtained 
from the median intercept of the family. The median intercept is used in preference to 
the mean as no calculation is required to find the median. Additionally, where some 
pairs of lines are nearly parallel, their intercept may be far removed from the true value
100
VmQx (nmoles/min/10® cells) 0.7 -
0.5 -
70 - 6 0  - 5 0  - 4 0  - 3 0  - 2 0  - 1 0  0 10 20 30
Km (nmoles/ml, i.e. uM)
Figure 4.3 Direct linear plot obtained for 5-OTf-DPAT. Extrapolation from intercept 
gives = 0.59 nmoles min'^  10® cells and = 18.0 //M.
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which would distort a calculation of the mean but would have little effect on the 
median. Thus, the direct linear plot is less susceptible to individual erroneous 
observations and kinetic parameters can be estimated without calculation and without 
the need for weighted regression analysis of data.
The values of and given in Table 4.1 are a means of obtaining CL.-^  rather than 
true kinetic parameters (CL;^ t = see chapter 2). Far from being a simple
enzyme/substrate situation, there are many processes occurring in this system. An 
aminotetralin added to a suspension of hepatocytes will partition between the cells and 
medium according to (!) the proportions of ionised and unionised compound (dependent 
on the pH and the pKa) and (ii) the partition coefficient of the unionised form. Having 
penetrated the cell and the smooth endoplasmic reticulum (in which the majority of the 
drug metabolising enzymes are located) the compound may be acted upon by more 
than one enzyme. In the case of 8 -OH-DPAT, the /V-dealkylation and conjugation 
reactions are catalysed by different enzyme systems as will be discussed in more detail 
in later chapters. A further complication is that a metabolite may compete with the 
parent drug for further metabolism by the same enzyme thereby acting as a 
competitive inhibitor. There is also the possibility that the drug may bind to proteins, 
both intracellular and extracellular. All of these factors combine to determine the 
concentration of drug at the site of metabolism and hence the kinetic parameters 
obtained in this assay are a reflection of all of these processes.
Houston (1994) demonstrated a strategy for the prediction of in vivo metabolic 
clearance based on in vitro CL,  ^determinations. For 17 drugs metabolised by P450 in 
the rat, a good relationship between CL;  ^determined in rat isolated hepatocytes and 
in vivo CL,rt was demonstrated. There was no apparent difference between in vitro
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data derived from metabolite appearance and that derived from substrate loss. The 
studies reported here have utilised disappearance of parent drug with the assumption 
that the protein precipitation step would release any bound drug. It was felt that to 
attempt to assay the formation of the primary metabolites would be technically very 
difficult and may be complicated by their further metabolism. Nonetheless, for some 
compounds the appearance of the major metabolite could be simultaneously monitored 
with the disappearance of the unchanged drug. An example of this is given in 
Figure 4.4 for 8 -Br-DPAT. Although it is recognised that the rate of metabolism will 
depend on substrate concentration {i.e. first-order kinetics) a straight line has been 
fitted to the data to illustrate the overall rate of metabolism in the 1 0  min assay period. 
The standard of the /V-dealkylated metabolite was found to have a virtually identical 
extinction coefficient in the HPLC UV detector as the parent drug (as was the case for 
other aminotetralins for which an /V-dealkylated standard was available). The slope of 
the fitted line for the appearance of the /V-dealkylated metabolite was 85% of that for 
the disappearance of parent drug. It is therefore reasonable to suggest that 8 -Br-DPAT 
was metabolised almost exclusively by /V-dealkylation over the 10 min assay period.
When plotting the data for disappearance of parent drug, a phenomenon was 
sometimes observed which is illustrated in Figure 4.5. The concentration of parent 
drug appeared to increase for the first minute or so, after which the expected decline 
in parent drug levels was observed. The phenomenon did not appear to be specific for 
any particular aminotetralin and could not be consistently demonstrated with DPAT, 
the most frequently analysed compound. Potential problems with insolubility of the 
compounds following addition to the incubate were ruled out on the grounds that the 
phenomenon was not consistently observed for any of the compounds.
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Figure 4 .4  Disappearance of 8 -Br-DPAT and appearance of its A/-dealkylated 
metabolite during incubation at 60 //M with rat isolated hepatocytes 
(fitted with first order regression line) (n = 1 ).
104
4000
10 uM
3500 -
3000 -
2500 -
o 2000 -
^  1500 -
1000  -
500 -
0 2 4 6 8 10
Time (min)
5000 -1
'— 10 uM 
20 uM 
—^ 60 uM
4500 -
4000 -
3500 -  
Î  3000 -  
S 2500 -
S 2000 -
1500 -
1000 -
500 -
0 2 4 6 8 10
Time (min)
Figure 4.5 Disappearance of DPAT during incubation at 10, 20 and 60 //M with rat 
isolated hepatocytes. Top panel: typical data; bottom panel: illustration 
of phenomenon sometimes observed for some of the compounds. 
Straight lines indicate the initial reaction rate estimated by inspection. 
CLirt values calculated from direct linear plots of the reaction rates: 
0.0286 (top) and 0.0275 (bottom) ml min*’ 10® cells.*^
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The data presented in Figure 4.1 demonstrate that the incubation which was not 
continuously shaken produced erratic results. Errors in sample volume are unlikely to 
account for the data given the accuracy and precision of modern pipettes. It is 
probable that the lack of shaking of the incubation would result in unrepresentative 
samples, i.e. samples of equal volume containing different proportions of 
hepatocytes:incubation medium. If the drug favoured distribution in the medium, then 
the number of hepatocytes taken in the sample would not greatly affect the assay as 
the combined volume of the cells in the incubate is considerably smaller than that of 
the medium. Conversely, if the drug favoured distribution into the hepatocytes, then 
the number of hepatocytes in the sample would have a large bearing on the assay. 
This latter case seems the more likely based on the reported partition coefficient (at 
pH 7.4) for 7-OH-DPAT of 43 (Asselin et at. 1986; the partition coefficients of the 
aminotetralins are discussed in chapter 5).
It is clear that even the data from the continuously shaken incubate show some 
resemblance to the data presented in Figure 4.5 (bottom panel) and may be indicative 
of non-representative sampling. Figure 4.2 demonstrates that, even in a well mixed 
incubate, it may be possible to incur sampling errors of 1 0 % or more in terms of the 
number of hepatocytes sampled. It should be noted that this conclusion includes the 
assumption that there are no errors in the cell counting. Nonetheless, it is worth 
investigating the effect of this sampling error on the data. Figure 4.6 shows a model 
for the hepatocyte incubation. Drug is added to the medium and distribution into the 
hepatocytes takes place according to the rate constant k^ ; it is assumed that there is 
no return of compound from the hepatocytes to the medium. The compound is cleared 
by metabolism at a rate described by kg. The partition coefficient of 7-OH-DPAT (P = 
43 at pH 7.4; Asselin et aL 1986) suggests that distribution into the hepatocyte
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Amount = S 
at t = 0 __ OhQm
Medium Hepatocytes
M
Metabolites
Rgure 4.6 Model for distribution and metabolism of a substrate in a suspension of 
isolated hepatocytes. Qm and Oh represent the amount of substrate in 
the medium and hepatocyte compartments respectively at a given time.
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would be favoured. Therefore, although no experiments were performed to investigate
whether metabolism was limited by the rate of entry of the compound into
the hepatocytes, it was assumed that is larger than kg. If the total
amount of substrate at t= 0  is S, then the decline in the amount of substrate in the
medium (Qm) as it distributes into the hepatocytes may be described as:
Qm = S.e
The amount of compound in the hepatocyte compartment (Qh) will depend upon its 
entry by the distribution process as well as its removal by metabolism. This is very 
similar to the changes in plasma levels of a compound following a single oral dose 
which will depend upon both the absorption and clearance processes. The amount of 
compound in the hepatocyte compartment is therefore:
0 /7  =
These two equations have been used to predict values for Qm and Qh using an initial 
amount of drug of S = 1 (arbitrary units), k, = 2.31 min'^  (t% = 0.3 min) and kg = 
0.0693 min'^  (t% = 10 min). Figure 4.7 shows plots of these values. It is important 
to note that the calculations are based on the fraction of the original amount of drug 
(S =  1 ) present as Qm or Qh and it is therefore not necessary to take into account the 
respective volumes of cells and medium. A 'true' sample is represented by Qm +  Qh. 
If the sample contains a 10% excess of hepatocytes then the relative contribution to 
this 'biased' sample will be (0.9 x Qm) +  (1.1 x Qh). The plot of the biased samples 
in Figure 4.7 is not unlike those occasionally seen for the aminotetralins (Figure 4.5) 
and it is therefore possible that such biased sampling may explain this phenomenon. 
The estimated rate of metabolism does not seem to be greatly affected by this as
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Figure 4.7 Plot of theoretical data predicted by the model shown in Figure 4.6. The 
amount of drug at t = 0  was taken as 1 . 0  and the biased samples were 
calculated from a 1 0 % excess of hepatocytes.
* The biased samples were calculated from a 10% excess of 
hepatocytes; the relative contribution to the biased sample is 
(0.9 X Qm) + (1.1 X Qh).
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evidenced by the good agreement between the CL,  ^values calculated for the data in 
Figure 4.5 (see caption).
To summarise, the addition of various substituents to the aromatic ring of DPAT, whilst 
not appearing to alter the major route of metabolism (/V-dealkylation), has certainly 
affected the rate of metabolism. The reasons for this may be related to compound 
lipophilicity (and hence access to the site of metabolism) or possibly some effect on 
the enzymology of aminotetralin metabolism with the variation in substituent. These 
possible explanations are investigated in subsequent chapters.
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CHAPTER 5
THE INFLUENCE OF LIPOPHILICITY 
ON THE METABOLISM OF AMINOTETRALINS 
BY RAT ISOLATED HEPATOCYTES
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5.1 Introduction
It has long been known that hydrophobic character is a key factor in the 
microsomal metabolism of xenobiotics (Brodie eta/. 1958, Hansch 1972, Seydel and 
Schaper 1982). The cytochrome P450 family of enzymes is located primarily in the 
lipid-rich endoplasmic reticulum and, in general, the more lipophilic a compound, the 
more susceptible to metabolism it is. The importance of lipophilicity is further 
emphasised when using intact cell systems as a compound must first cross the cell 
membrane before gaining access to the endoplasmic reticulum. Drug lipophilicity can 
be described in terms of its octanol/water partition coefficient P (generally expressed 
as log P) which is defined as the ratio of the concentrations of drug in the organic and 
aqueous phases at equilibrium. Where a compound is partly ionised in the aqueous 
phase, an additional equilibrium exists:
[Ionised [Unionised [Unionised
where it is assumed that only the unionised form of the drug is present in the organic 
phase. Thus the distribution coefficient D (generally expressed as log D) is defined as 
the ratio of the concentration of the drug in the organic phase to the concentration of 
both ionised and unionised drug in the aqueous phase at a given pH (Scherrer and 
Howard 1977). The aim of this part of the study was to determine the distribution 
coefficients for the aminotetralins and to investigate possible correlations between 
log D and the values of metabolic stability discussed in chapter 4. The classical 
approach in attempting to correlate biological activity with physicochemical parameters 
involves the hydrophobic substituent parameter *if (Leo et a/. 1971, Hansch and Leo 
1979).
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For a given substituent X:
substituent X  ~ ^ R -X  ~ ^^ 9 ^ R -H
This enables calculation of partition coefficients for compounds for which there are no
experimental data. Log P values may now be calculated using a computer program
developed by Leo (Leo, A. Pomona College Medicinal Chemistry Project, Pomona
College, Claremont, CA 91711, USA). The fundamental basis of the Hansch approach
is that the partitioning between organic and aqueous phases provides some measure
of a compounds ability to penetrate biological membranes. The octanol/water standard
introduced by Hansch and coworkers some 30 years ago has become the accepted
system for partition coefficients and there appears to be a linear relationship between
(Hansch and Leo 1979) 
log P and penetration of a compound through biological membrane^ However, the
relationship has a finite range and compounds of high log P values may partition into
and be held by the first lipophilic compartment they come into contact with.
Conversely, compounds may be so hydrophilic as to be unable to cross lipophilic
barriers.
Log P is clearly not the only determinant of whether a compound can interact with 
receptor proteins (in this case the metabolising enzymes) and other factors such as 
molecular volume, shape and hydrogen bonding capability may play a role. However 
since Brodie and coworkers first recognised the importance of the hydrophobic 
character of drugs to their oxidation by microsomes (Brodie et a!. 1958) there have 
been many successful attempts to correlate lipophilicity with aspects of drug 
metabolism with particular emphasis on P450. Thus there are .examples of correlations 
between P450 binding and log P(Cornell eta/. 1987), P450 induction and t t  (Dénommé 
eta/. 1985, Cornell eta/. 1987) and rate of oxidation by P450 and log P(Martin and
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Hansch 1971).
cLog P values were calculated using the program developed by Leo. Log D 
determinations for the aminotetralins were made using an octanol/buffer system with 
HPLC analysis of the two phases (details given in 2.8).
5.2 Results
The values of clog Pand log D obtained for the aminotetralins are given in Table 
5.1 together with the relative metabolic stabilities from chapter 4 for correlation 
purposes. The wide range of lipophilicity encompassed by the aminotetralin series is 
indicated by the 4 log unit span of the log D values. Values of clog P were plotted 
against log D (Figure 5.1) and yielded a first-order correlation with r^  = 0.893  
(8 -CO2H-DPAT omitted). Values of clog P were plotted against relative metabolic 
stability (Figure 5.2) and yielded first-order correlations with r^  = 0.685 (8 -CO2H-DPAT 
omitted) and r^  = 0.805 (8 -CO2H-DPAT and 5-F-80H-DPAT omitted). Values of log D 
were plotted against relative metabolic stability (Figure 5.3) and yielded first-order 
correlations with r^  = 0.711 (8 -CO2H-DPAT omitted) and r^  = 0.878 (8 -CO2H-DPAT 
and 5-F-8-OH-DPAT omitted).
5.3 Discussion
Figure 5.1 illustrates a good correlation between clog P and log D. This is as would 
be expected from a series of compounds where the structural alterations are unlikely 
to significantly affect the pKa of the basic nitrogen. The deviations from the line of 
best fit could have arisen from errors in log P calculation or small variations in pKa but
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Table 5.1 Values of clog P and log D values for aminotetralins together with 
metabolic stability data (see chapter 4) and compound identification 
numbers for Figures 5.1 - 5.3.
Compound ID No. clog P log D 
(pH 7.4)'
Relative metabolic 
stability vs. DPAT
5-F-8-OH-DPAT 1 4.308 1.459 0.333
5-OTf-DPAT 2 5.753 3.173 0.415
8 -CF3-DPAT 3 5.418 2.607 0.589
8 -Br-DPAT 4 5.398 3.043 0.766
8 -OTf-DPAT 5 5.753 2.889 0.863
DPAT 6 4.535 1.476 1 . 0 0 0
8-(pyrrole-2-carbonyl)-DPAT 7 4.627 2.359 1.226
5-F-DPAT 8 4.678 1.805 1.272
8 -CN-DPAT 9 3.968 1.748 1.352
8 -OH-DPAT 1 0 3.868 1.147 1.790
8 -SONH2-DPAT 11 2.718 0.485 2.181
5 -F-8 -CONH2-DPAT 1 2 3.393 0.933 2.263
8 -CONH2-DPAT 13 3.048 -0.254 3.313
8 -CO2H-DPAT 14 4.278* -1.031 00
t  Mean of two experiments.
* Calculated as the undissociated acid.
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f  = 91.517, p <  0.00013
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Figure 5.1 Graph illustrating relationship between clog P and log D for the 
aminotetralin series (with the omission of S-COgH-DPAT). Refer to 
Table 5.1 for compound identification numbers.
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Figure 5.2 Graph illustrating relationship between clog P and relative metabolic 
stability for the aminotetralin series. Top panel: 8 -CO2H-DPAT omitted; 
bottom panel: S-COjH-DPAT and 5-F-80H-DPAT omitted. Refer to 
Table 5.1 for compound identification numbers.
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Figure 5.3 Graph illustrating relationship between log D and relative metabolic 
stability for the aminotetralin series. Top panel: S-COgH-DPAT omitted; 
bottom panel: S-COgH-DPAT and 5-F-80H-DPAT omitted. Refer to 
Table 5.1 for compound identification numbers.
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could also have resulted from experimental error in the determination of log D. 
Although the computer program did not permit calculation of log P for ionised 
compounds, this was not thought to be a problem as it was assumed that all the 
dipropylaminotetralins would be ionised to approximately the same extent {/.e. similar 
pKa values for the basic nitrogens). However S-COg-DPAT also contains a carboxylic 
acid function that would almost certainly be dissociated at pH 7.4 when one considers 
the pKa of benzoic acid is 4.2 (Grunwald 1951). Thus, whilst the clog P value of 
8 -COg-DPAT was approximately mid-range for the series, it was found to have the 
lowest log D value of the series. Although experimental pKa values were not 
determined, the clog Pand log D values may be used to obtain estimates of pKa from 
the equation (Manners et al. 1988):
pKa = pH + log 1
The mean value obtained (excluding 8 -COg-DPAT) was 9.99 ±  0.41 with a range from 
9.24 (DPAT) to 10.70 (8 -CONHg-DPAT). This could explain the deviations in the 
correlation between clog Pand log D although errors in the values of clog Pand log D 
cannot be ruled out. Another estimate of pKa may be obtained by using the correlation 
equation in Figure 5.1. If the slope of the correlation equation is assumed to be 1.0 
then the relationship, log D = clog P - 2.575 can be substituted into a rearrangement 
of equation 1 to give:
log +1] = 2.575 2
which for a pH of 7.4 yields an estimated pKa of 9.98.
The pKa estimates are in good agreement with published values for /V-methyl-
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/V-propylaminotetralin and A/-methyl-/V-butylaminotetralin which are 9.83 and 9.71 
respectively (Perrin 1965). If the pKa for the amine function of 8 -CO2H-DPAT is 
assumed to be 9.99, then the log P calculated from equation 2 is 1.56 which is, as 
expected, much lower than the clog Pof the undissociated acid (4.278; see Table 5.1).
The correlation between log P and metabolic stability (Figure 5.2) suggested that 
lipophilicity was a major determinant of aminotetralin metabolism by rat isolated 
hepatocytes. A slightly better correlation with metabolic stability was obtained by 
using log D (Figure 5.3). This may again reflect possible small variations in pKa which 
are accounted for in log D but not clog P. Where no experimental data exists, 
calculated log P values can be very useful, especially for compounds with no ionisable 
group or for series of compounds where the structural changes have little or no effect 
on the dissociation constant. In the latter case, however, clog P cannot be used to 
predict partitioning in a biological system without a reasonable estimate of the 
dissociation constant. In this study, the use of experimentally determined log D 
circumvents the need for pKa data. This would be further emphasised if a series of 
aminotetralins with amine-substituent modifications were studied, as the pka values 
might show more substantial variation.
Whilst penetration of the hepatocyte and endoplasmic reticulum membranes is a 
prerequisite for metabolism, the process of /V-dealkylation itself is known to favour 
more lipophilic compounds. In an in vivo study in humans, the A/-dealkylation rate of 
a series of A/-substituted amphetamines (structurally very similar to the aminotetralins) 
increased with Increasing lipophilicity (Testa and Salveson 1980) and the authors 
postulated that this was due to increased enzyme affinity. Martin and Hansch studied 
the metabolism of a set of miscellaneous compounds, containing a subset of
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dimethylanilines, by PB-induced rat liver microsomes (Martin and Hansch 1971). They 
found that was fairly constant and that log (l/K^,) correlated well with log P; i.e. 
formation of the enzyme-substrate complex was the most important event with higher 
log P equating to higher enzyme affinity. In their correlation, log P accounted for 85%  
of the variation in log (1 /K,^ ) which again demonstrates the importance of lipophilicity 
in metabolism. From a slightly different perspective, the effect of pH on 
/V-demethylation has been studied in microsomes; Cho and Miwa (1973) concluded 
that the rate of déméthylation of a series of dimethylamines was dependent on both 
the degree of ionisation and the partitioning between microsomes and aqueous media. 
For those compounds that were ionised at the pH range studied (6.9-8.1 ), there was 
an increase in the rate of déméthylation with increasing pH due to greater amounts of 
the unionised being available for metabolism. A similar conclusion was reached by 
Delaforge et ai. (1992) who studied the effect of pH on the A/-demethylation of 
erythromycin derivatives. Thus for the aminotetralins, in common with many other 
compound classes, the rate of /V-dealkylation is dependent on the proportion of 
unionised compound existing at pH 7.4, and the tendency of that unionised species to 
cross membranes.
There was no measurable rate of metabolism for 8 -COgH-DPAT; it is reasonable to 
suggest that this compound, possessing two charged groups at physiological pH, is too 
hydrophilic to extensively penetrate into the hepatocyte over the time course of the 
assay. The rate of metabolism of the rest of the series correlated well with log D with 
the exception of 5-F-8-OH-DPAT which was the most rapidly metabolised of all the 
compounds. A possible explanation for 5-F-8-OH-DPAT being an outlier in the 
correlation could be a large error in the measurement of log D. However, this would 
seem to be unlikely if the log D values of DPAT (1.476), 8 -OH-DPAT (1.147) and
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5-F-DPAT (1.805) are considered. The n values for the 8 -hydroxy and 5-fiuoro 
substituents can be calculated from the log D data to be -0.329 and +0.329  
respectively (assuming the pKa values are the same). The log D value of 
5-F-8-OH-DPAT would therefore be predicted to be similar to that of DPAT as the net 
contribution from the 5-F and 8 -OH substituents would be zero. The experimentally 
determined value for 5-F-8-OH-DPAT (1.459) is in fact only 0.017 log units different 
from that of DPAT. In addition, the clog P value for 5-F-8-OH-DPAT is similar to that 
of DPAT and fits the correlation with log D well (see Figure 5.1). In chapter 3 it was 
found that 8 -OH-DPAT and 5-F-8-OH-DPAT were metabolised by both A/-dealkylation 
and 0-glucuronidation. The more lipophilic character of 5-F-8-OH-DPAT would allow 
greater penetration of the smooth endoplasmic reticulum membrane which contains 
both the P450 (Mannering 1971) and glucuronyl transferase (Dutton 1980) enzyme 
families. The high rate of metabolism of 5-F-8-OH-DPAT may therefore have been due 
to an increase in the rate of both /V-dealkylation and O-glucuronidation pathways. For 
5-F-8-OH-DPAT at least, it appears that enzymological factors, in addition to 
lipophilicity, may have a significant contribution to the overall rate of metabolism. 
Investigations into the enzymology of aminotetralin metabolism is detailed in 
subsequent chapters.
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CHAPTER 6
THE METABOLISM OF THE AMINOTETRALIN SERIES 
BY RAT HEPATIC MICROSOMES
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6.1 Introduction
Hepatic microsomal preparations from rats pretreated with known 
enzyme-inducing agents are a frequently used tool in studies to determine the 
isoform of P450 responsible for the metabolism of a given compound. Although 
there are very few absolutely specific inducers for the various P450 isoforms, a 
microsome preparation may be characterised by using a range of probe substrates. 
Most inducing agents are at best specific for a subfamily of P450 rather than for 
a single isoform and some agents induce across a range of families (Waxman and 
Azaroff 1992). For these reasons, experiments with induced microsomes are 
usually combined with studies using known P450 inhibitors. In this way, data from 
individual experiments, rarely conclusive in isolation, can be combined to implicate 
a particular P450 isoform in the metabolism of a compound.
Thus far, the metabolism of the aminotetralins has been studied in rat isolated 
hepatocytes. Nonetheless, it was felt that microsomes were technically much 
better suited to the study of the effects of enzyme inducers due to their relative 
ease of preparation and storage. In addition, the characterisation methodology is 
better established for microsomes than hepatocytes, the latter also being 
constrained by the need to use the cells within a few hours after preparation.
In this study, rats were treated with various enzyme-inducing agents prior to 
preparation of hepatic microsomes. The microsomes were characterised with 
respect to several P450-dependent reactions and the effects of the various 
pretreatments on aminotetralin metabolism was studied. Details of the methods 
employed are given in 2.9 - 2.13.
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6.2 Results
The results from the probe substrate assays for the various microsomal 
preparations are presented graphically in Figures, 6.1, 6.2 and 6.3. Ethoxyresorufin 
0-deethylase activity was induced 25-fold in the BN F group compared to control 
{p<0.001 ); a milder induction was also observed in the PB group although this was 
also statistically significant (p<0.001). Pentoxyresorufin 0-depentylase activity 
was elevated in all treatment groups compared to control (p < 0 .0 0 1  for all groups), 
the level of induction being between 2- and 4-fold for BNF, INH and PCN but 
approximately 45-fold in the PB group. The activity of p-nitrophenol hydroxylase 
was elevated 1.7-fold in the INH group (p<0.05) but was decreased by nearly
2-fold in the PCN group (p<0.05). Aniline hydroxylase was induced by 
approximately 2-fold in the BNF, PB and INH groups (p<0.001 ) but was unchanged 
in the PCN group. Induction of erythromycin /V-demethylase was seen after 
treatment with either PB (1.7-fold, p<0 .01) or PCN (2.4-fold, p<0 .001).
For both S-COgH-DPAT and 8 -CONHg-DPAT, there was very little disappearance of 
parent drug observed over the 2 0  min incubation and there was no difference 
between any of the treatment groups and control (data not shown). For 
5-F-8-C0NHg-DPAT there was some suggestion of an increase in metabolism in the 
PB group (Figure 6.4). This was more clear-cut with 8 -SONHg-DPAT (Figure 6.5) 
and 5-F-8-OH-DPAT (Figure 6 .6 ) where there was also some evidence for an 
increased rate of metabolism in the PCN group. For the remaining compounds, 
where the appearance of the A/-dealkylated metabolite was monitored, it was a 
general observation that the rate of appearance was markedly increased in the PB 
group {e.g. DPAT, Figure 6.7). For some compounds there was also an
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Figure 6.1 Ethoxyresorufin 0-deethylase {EROD; top panel) and pentoxyresorufin 
0-depentylase (PROD; bottom panel) activities of rat hepatic microsomal 
preparations following pretreatment of animals with various inducing agents (see 
horizontal axis); CON = control, BNF = ^-naphthoflavone, PB = phénobarbital, INH 
= isoniazid, PCN = pregnenolone 16a-carbonitrile. Error bars represent standard 
deviation; statistical difference from the control group, * p < 0 .05 , * *  p < 0 .01 , * * *  
p<0.001 (n = 3).
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Figure 6.2 p-NItrophenol hydroxylase (PNPOH; top panel) and aniline hydroxylase 
(ANOH; bottom panel) activities of rat hepatic microsomal preparations following 
pretreatment of animals with various inducing agents (see horizontal axis); CON = 
control, BNF = )ff-naphthoflavone, PB =  phénobarbital, INH = isoniazid, PCN = 
pregnenolone 16a-carbonitrile. Error bars represent standard deviation; statistical 
difference from the control group, * p<0 .05 , * *  p < 0 .01 , * * *  p<0.001 (n = 3).
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Figure 6.3 Erythromycin /V-demethylase (EMND) activity of rat hepatic microsomal 
preparations following pretreatment of animals with various inducing agents (see 
horizontal axis); CON = control, BNF = yff-naphthoflavone, PB = phénobarbital, INH 
= isoniazid, PCN = pregnenolone 1 Go-carbonitrile. Error bars represent standard 
deviation; statistical difference from the control group, *p < 0 .0 5 , * * p < 0 .0 1 , * * *  
p<0.001 (n = 3).
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Figure 6.4 Metabolism of S-F-B-CONHg-DPAT in rat hepatic microsomes.
Disappearance of parent drug monitored by HPLC. Animal pretreatment: 
BNF =  /ff-naphthoflavone, PB = phénobarbital, INH = isoniazid, PCN =  
pregnenolone 16a-carbonitrile (n = 1 ).
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Figure 6.5 Metabolism of S-SONHg-DPAT in rat hepatic microsomes.
Disappearance of parent drug monitored by HPLC. Animal pretreatment: 
BNF = /ff-naphthoflavone, PB = phénobarbital, INH = isoniazid, PCN = 
pregnenolone 16a-carbonitrile (n = 1 ).
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Figure 6 .6  Metabolism of 5-F-8-OH-DPAT in rat hepatic microsomes.
Disappearance of parent drug monitored by HPLC. Animal pretreatment: 
BNF =  ^-naphthoflavone, PB =  phénobarbital, INH = isoniazid, PCN = 
pregnenolone 1 Go-carbonitrile, (n = 1 ).
500
— Control
— BNF§
^  400 -
Ec
'— PCN
o
2 300 -o
"oO)o_
200 -O)
■i
E  1 0 0 -
•X Dd)
o
0 5 10 15 20 25
Time (min)
Figure 6.7 Metabolism of DPAT in rat hepatic microsomes. Appearance of 
/V-dealkylated metabolite monitored by HPLC. Animal pretreatment: BNF 
= )ff-naphthoflavone, PB =  phénobarbital, INH = isoniazid, PCN = 
pregnenolone 16a-carbonitrile (n = 1 ).
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increase in /V-dealkylation observed in the PCN group {e.g. 5-OTf-DPAT, Figure 6 .8 ). 
This was also observed for DPAT, 8-0H-, 8 -CF3- and 8 -Br-DPAT but the effect was 
masked when the rates of metabolism were normalised to total P450 content (see 
Figures 6.7, 6.9, 6.10 and 6.11 respectively).
Many of the compounds displayed a decrease in the rate of /V-dealkylation in the BNF 
group compared to control, for example DPAT (Figure 6.7) and 5-F-DPAT (Figure 6.12). 
In the case of 5-F-DPAT (Figure 6.12) and 8 -OTf-DPAT (Figure 6.13), /V-dealkylation 
appeared to be induced in the INH group to a similar extent as the PCN group and there 
was also evidence for this with the hydroxylation of 8-(pyrrole-2-carbonyl)-DPAT 
(Figure 6.14).
6.3 Discussion
The 25-fold induction of ethoxyresorufin 0-deethylase (expressed per nmol total 
P450) by yff-naphthoflavone was consistent with data obtained by other workers 
(24-fold, Fentem and Fry 1991) although these workers expressed activity per mg of 
microsomal protein. The dééthylation of ethoxyresorufin is not a selective probe for 
P450 1 A l in microsomes from untreated or PB-treated rats where it is catalysed mainly 
by 2C6 and 2B1 respectively (Burke at al. 1994). The 3-fold induction of 
ethoxyresorufin 0-deethylase activity observed in the PB-treated group (Figure 6 .1 , top 
panel) is therefore probably a consequence of elevated 2B1 levels. Treatment with PB 
produced the expected elevation in pentoxyresorufin 0 -depentylase activity ( « 4 5 -fold; 
Figure 6.1, bottom panel). Again, Burke at ai. (1994) reported some non-specificity 
for pentoxyresorufin, its metabolism being catalysed by the P450 1A subfamily in 
microsomes from rats treated with 3-methylcholanthrene, a 1A inducer. The
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Figure 6 . 8  Metabolism of 5-OTf-DPAT in rat hepatic microsomes. Disappearance 
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Figure 6.9 Metabolism of 8 -OH-DPAT In rat hepatic microsomes. Disappearance of 
parent drug (top) and appearance of /V-dealkylated metabolite (bottom) 
monitored by HPLC. Animal pretreatment: BNF =  /ff-naphthoflavone, PB 
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Figure 6.10 Metabolism of 8 -CF3-DPAT in rat hepatic microsomes. Disappearance 
of parent drug (top) and appearance of A/ dealkylated metabolite 
(bottom) monitored by HPLC. Animal pretreatment: BNF =  
^-naphthoflavone, PB = phénobarbital, INH = isoniazid, PCN =  
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Figure 6.12 Metabolism of 5-F-DPAT in rat hepatic microsomes. Appearance of 
A/-dealkylated metabolite monitored by HPLC. Animal pretreatment: BNF 
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Figure 6.13 Metabolism of 8 -OTf-DPAT in rat hepatic microsomes. Appearance of 
/V-dealkylated metabolite monitored by HPLC. Animal pretreatment: BNF 
= /ff-naphthoflavone, PB =  phénobarbital, INH = isoniazid, PCN = 
pregnenolone 16a-carbonitrile (n = 1 ).
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Figure 6 .14 Metabolism of 8-(pyrrole-2-carbonyl)-DPAT in rat hepatic microsomes.
Appearance of A/-dealkyiated metabolite (top) and side-chain 
hydroxylated metabolite (bottom) monitored by HPLC. Animal 
pretreatment: BNF = jg-naphthoflavone, PB = phénobarbital, INH = 
isoniazid, PCN = pregnenolone 16a-carbonitrile (n = 1).
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3 .7 -fold elevation of pentoxyresorufin 0 -depentylase activity seen in microsomes from 
BNF-treated rats in the current study agrees with these findings. The 1.7-fold 
induction of p-nitrophenol hydroxylase activity by INH (Figure 6.2, top panel) was 
lower than was observed by Fentem and Fry (1991) but was nonetheless significant 
at the p<0.05  level. A similar induction (1.8-fold) was seen with the aniline 
hydroxylase assay (Figure 6.2, bottom panel) but this was significant at the p< 0.001 
level. Both activities were also elevated in the BNF and PB groups, consistent with 
previous reports by Chrastril and Wilson (1975) and Reinke and Moyer (1985). In a 
review of the function of rat P450s (Soucek and Gut 1992) it was reported that aniline 
is a substrate for P450 1A and 2B1 as well as 2E1 and aniline hydroxylase activity 
would therefore be expected to show induction following pretreatment of animals with 
BNF or PB. P450 3A activity, as measured by the erythromycin /V-demethylase assay, 
was elevated 2.4-fold in the PCN group (Figure 6.3) compared to the 3.8-fold found 
by Fentem and Fry (1991). In addition, a 1.7-fold elevation of erythromycin 
/V-demethylase activity was observed in the PB group which was consistent with the 
known induction of P450 3A by PB (Gonzalez et al. 1986).
The relative rates of metabolism of the various compounds in microsomes from 
untreated rats appeared to be consistent with the findings in hepatocytes with the 
exception of 5 -F-8 -OH-DPAT. This compound was the most rapidly metabolised of the 
series in hepatocytes with a relative metabolic stability (vs. DPAT) of 0 .333  
(Table 4.1). Compared to other compounds where the disappearance of parent drug 
was monitored, 5-F-8-OH-DPAT (Figure 6 .6 ) did not appear to be metabolised any 
faster in control microsomes than 8 -CF3-DPAT (Figure 6.10) or 8 -Br-DPAT (Figure 6.11 ) 
despite the fact that these two compounds were more slowly metabolised in 
hepatocytes than 5 -F-8 -OH-DPAT with relative metabolic stabilities of 0 .766 and 0.589
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respectively. Furthermore, in microsomes from the PB group, metabolism of 
8 -Br-DPAT and 8 -CF3-DPAT appeared to proceed faster than 5-F-8-OH-DPAT. As 
discussed in chapter 3, 5-F-8-0H-DPAT is thought to be a substrate for both 
A/-dealkylation and 0-glucuronidation, hence its rapid metabolism in hepatocytes. 
However microsomes are generally not capable of carrying out glucuronidation 
reactions unless they are supplemented with UDP-glucuronic acid. This may explain 
why the rate of metabolism of 5-F-8-OH-DPAT appears to be slower in microsomes 
than would be predicted by the hepatocyte data.
In general, the initial rate of appearance of the yv-dealkylated metabolite (where 
measured) was faster in the PB group than in the control group but this was followed 
by a decline in levels in the later part of the assay period. A typical example of this is 
8 -Br-DPAT (Figure 6.11). In the PB group, the rate of disappearance of 8 -Br-DPAT was 
initially very fast but decreased as the levels of parent drug were depleted. This was 
mirrored by the appearance of the /V-dealkylated (secondary amine) metabolite, but as 
the levels of this metabolite increased, so its own metabolism by further /V-dealkylation 
and hydroxylation (see Figure 3.11) would be expected to increase. For 8 -Br-DPAT, 
it appeared that after about 5 min, the rate of removal of the secondary amine 
metabolite in the PB group was greater than its rate of production resulting in a net 
decrease in its levels. This pattern would be expected to occur in the other groups if 
the microsome incubation could be continued for a longer period. The fact that it 
occurred relatively quickly in the PB group suggests that the isoenzymes responsible 
for the further metabolism of the secondary amine metabolite are also PB-inducible, and 
may indeed be the same isoenzymes that catalyse its formation.
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The increased rate of metabolism of many of the aminotetralins in the PB group 
suggests that the /V-dealkylation pathway is catalysed predominantly by P450 2B1/2, 
the major PB-inducible isoforms in rat liver (Waxman and Azaroff 1992). However, PB 
is also known to induce members of the P450 2A, 2C and 3A subfamilies (Waxman 
and Azaroff 1992) and it is therefore possible that one of these isoforms may also be 
contributing to the metabolism.
The increased rate of metabolism in the PCN group for many compounds was often not 
apparent following normalisation of the data to total P450 content. However, for some 
of the compounds (e.g. 5-OTf-DPAT, Figure 6 .8 ) the difference between the PCN group 
and control was still discernible after normalisation. Thus it appears that 3A1/2 (the 
rat isoforms of 3A; Soucek and Gut 1992) may be partly responsible for the 
/V-dealkylation pathway. The proportion of total /V-dealkylation catalysed by 3A may 
however be relatively small as the increase in /V-dealkylation rate observed in the PCN 
group was usually somewhat less than the 2.4-fold elevation in 3A activity. It has 
previously been shown that the rate of /V-dealkylation of U-93385E (a 
'dipropylaminotetralin' with one of the propyl chains attached to C-1 to form a 
pyrrolidine ring) was induced in vitro and in vivo by pretreatment of rats with PCN 
(Martin et ai. 1993a).
P450 2B and 3A are known to carry out many /V-dealkylation reactions in the rat and 
examples include the /V-demethylation of diazepam (2B1, Jauregui et ai. 1991), 
/V,/V-dimethylaniline (2B1, Pandey et ai. 1989) and tamoxifen (3A, Mani et ai. 1993) 
and the /V-deethylation of lidocaine (3A, Imaoka et ai. 1990). Coutts et ai. (1994) 
reviewed the involvement of various P450 isoforms in /V-dealkylation reactions and 
concluded that the most commonly identified isoforms responsible for /V-dealkylation
140
in animal species were P450 1A1, 2B1, 2B4, 2C11 and 3A2. In a review of species 
differences in P450 isoforms (Smith 1991 ) it was concluded that many of the reactions 
catalysed by P450 3A involve electron abstraction from nitrogen (e.g. /V-dealkylation). 
in addition, 3A substrates tended to be lipophilic with log D values ranging from 0.4  
(codeine) to 8  or greater (dihydroergotamine). This range encompasses all of the 
aminotetralins studied in this thesis except 8 -CONH2- and 8 -CO2H-DPAT (see 5.2).
In the current study, the appearance of hydroxylated metabolites was not followed, 
with the exception of 8-(pyrrole-2-carbonyl)-DPAT. However there was mass 
spectroscopic evidence from hepatocyte incubations (see 3.2) for hydroxylation in the 
saturated ring of four of the compounds studied; 8 -OTf-, 8 -CF3-, 8 -Br- and 
8 -CONH2-DPAT. Aliphatic carbon hydroxylation proceeds via hydrogen atom 
abstraction (Amodeo et ai. 1990) and to break the carbon-hydrogen bond requires 
approximately 420 kJ mol'^  for a simple primary alkyl carbon compared to 
340-360 kJ mol*’ for an equivalent allylic or benzylic carbon. Thus the energetics 
associated with the initial hydrogen abstraction clearly favour hydroxylation at a 
benzylic position. P450 3A has been shown to favour oxidation at allylic position in 
a number of structurally diverse compounds including cyclosporin (Kronbach et ai.
1988), quinidine (Guengerich et ai. 1986a), -tetrahydrocannabinol (Bornheim et ai. 
1992) and lovastatin (Wang et ai. 1991). It therefore seems likely that the 
hydroxylation in the saturated ring observed for four of the aminotetralins has occurred 
at a benzylic position and was catalysed by P450 3A. Evidence against this conclusion 
is the relative polarity of 8 -CONH2-DPAT (log D -0.254; see 5.2) which is outside the 
range for P450 3A substrates previously suggested (Smith 1991).
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The apparent induction of the A/dealkylation of 5 -F-DPAT (Figure 6.12) and 
8 -O T f-D P A T (Figure 6 .1 3 ) and the side-chain hydroxylation of 
8-(pyrrole-2-carbonyl)-DPAT (Figure 6.14) in the INH group may suggest P450 2E1 
involvement. This isoform of P450 is known to be responsible for the metabolism of 
a diverse range of xenobiotics such as alcohols, nitrosamines and halogenated alkanes 
(Koop et a!. 1989) as well as the metabolic activation of small-molecule toxins and 
carcinogens such as benzene and vinyl chloride (Guengerich et at. 1991). It would 
therefore not be surprising if, in addition to this wide substrate specificity, 2E1 were 
able to catalyse metabolism at different sites (A/-dealkylation and aliphatic 
hydroxylation) of compounds which share a large degree of structural similarity at the 
sites of metabolism.
The reason for the decrease in /V-dealkylation rate seen for some of the aminotetralins 
(e.g. DPAT, Figure 6.7) in the BNF group is not clear. Down-regulation of the enzymes 
responsible for aminotetralin /V-dealkylation by BNF may be responsible although there 
was no decrease in pentoxyresorufin 0 -depentylase (for reasons discussed earlier) or 
erythromycin /V-demethylase activity observed in the BNF group. In a study of 
antipyrine metabolism in isolated rat hepatocytes (Loft and Poulsen 1989), the
3-methyl hydroxylation pathway was decreased relative to control by pretreatment of 
animals with 3-methylcholanthrene. However, the authors did not deem this to be 
significant and no explanation was offered. The 3-methyl hydroxylation of antipyrine 
by rat liver microsomes was shown to be increased by pretreatment of animals with 
PB (Kahn etaL 1982). Pretreatment with 3-methylcholanthrene resulted in a decrease 
in this pathway to 32% of control, as assessed by V^/K ^ ratio, for which a > 2-fold 
increase in was largely responsible. Thus, the decrease in the rate of metabolism 
seen for the aminotetralins is consistent with other studies.
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Evidence for the involvement of P450 2B111 and 3A1/2 (and possibly also 2E1 ) in the 
metabolism of the aminotetralins has been obtained. The overlapping substrate 
specificity of the different P450 isoforms is well established (Ryan and Levin 1990); 
an example is the oxidation of testosterone in rat liver microsomes by five different 
isoforms of P450 to produce ten chromatographically distinct metabolites (Sonderfan 
etal. 1987).
The data from the current study do not give any insight into how the relative 
contribution of the different P450 isoforms to aminotetralin metabolism varies with 
drug concentration. P450 2B1/2 appeared to be the major isoform responsible at an 
aminotetralin concentration of 60 //M. If the Km for 2B1/2 in this process is much 
lower than the other enzymes, then it may be possible that 2B1/2 is saturated at 
60 //M, giving the aminotetralin access to the other enzymes. However, 3A1/2 and 
2E1 may have lower Km values than 2B1 /2 and contribute proportionally more to the 
metabolism at lower concentrations. An example of this latter case has been reported 
for the hydroxylation of chlorzoxazone (Jayyosi et aL 1995) which is often used as a 
marker activity for P450 2E1. It was found that in rat liver microsomes, at high 
substrate concentrations, 2E1 was the major enzyme responsible for chlorzoxazone 
hydroxylation with a minor contribution from 3A whereas the roles were reversed at 
low substrate concentrations.
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CHAPTER 7
THE IN  VITRO METABOLISM OF AMINOTETRALINS: 
INFLUENCE OF INHIBITORS OF DRUG METABOLISM
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7.1 Introduction
Evidence has been obtained, in the previous chapter, for the involvement of 
P450 2B1 /2 and 3A1 /2 (and possibly also 2E1 ) in the metabolism of the aminotetralins 
in rat hepatic microsomes. In order to provide further evidence for their involvement, 
the effects of various inhibitors of drug metabolism were investigated. It was felt 
important to gain at least some of the evidence for the enzymology of aminotetralin 
metabolism using the isolated hepatocyte system. Accordingly, in contrast to the 
studies in chapter 6 , which were carried out in microsomes, these experiments with 
inhibitors were performed, for the most part, in hepatocytes.
Orphenadrine and erythromycin have been shown to inhibit P450 2B1 (Reidy et aL
1989) and 3A (Murray 1987, Murray and Reidy 1990) respectively. Such inhibition 
by alkylamine compounds is thought to occur via several P450 catalysed steps leading 
to a reactive nitroso intermediate which can bind irreversibly to P450 (Murray 1992).
The metabolism of 8 -OH- and 5-F-8-OH-DPAT is thought to proceed via 
0-glucuronidation as well as /V-dealkylation (see 3.3). This was investigated using 
galactosamine as an inhibitor of glucuronidation (Schwarz 1980). Galactosamine acts 
by both trapping uridine nucleotides (Keppler et ai. 1970) and by inhibiting UDP-glucose 
dehydrogenase (Bauer and Reutter 1973) thereby lowering the concentration of 
UDP-glucuronic acid.
The amphetamine derivatives methoxyphenamine, amiflamine and deprenyl bear 
structural similarity to DPAT and are metabolised by the polymorphically expressed 
P450 2D6 (Alvén et ai. 1984, Hawes et ai. 1987, Grace et ai. 1994). As the P450
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2D subfamily is not inducible (Smith 1991), it was not possible to study the 
metabolism of the aminotetralins in microsomes with elevated levels of 2 D 1 (the rat 
orthologue). Therefore quinine, a potent inhibitor of 2D1 (Kobayashi etal. 1989), was 
used to assess the potential role of P450 2D in the metabolism of DPAT. This study 
was performed in microsomes with a view to repeating it in hepatocytes should the 
microsomal data show evidence for inhibition by quinine.
The effects of the various inhibitors on aminotetralin metabolism was monitored by 
HPLC analysis of samples taken from the incubates at various times. In order to 
validate the data, the influence of the inhibitors on the metabolism of certain probe 
substrates was assessed. In addition, the effects of the inhibitors on hepatocyte 
viability was investigated. Experimental details are given in 2.14 - 2.19.
7.2 Results
The present study was intended to provide confirmatory data for the findings 
in chapter 6 . Due to the consistent results obtained with the first few compounds and 
because of the time and compound-consuming nature of the experiments, it was 
decided not to proceed with the remaining compounds. The data for 8-(pyrrole-2- 
carbonyD-DPAT presented here are representative of the data obtained with DPAT, 
5-F-DPAT and 8 -CF3-DPAT.
Galactosamine markedly inhibited the metabolism of resorufin in hepatocytes 
(Figure 7.1 ). This suggested that the pentoxyresorufin 0-depentylase assay for P450 
2B1 activity in microsomes, which measures the appearance of resorufin 
fluorimetrically (Burke and Mayer 1974), would not be suitable for use in hepatocytes
146
2000
Galactosamine (mM)
1500
c
Z 3
1000<uo
o
500
20 40 60
Time (min)
80 100
Figure 7.1 The influence of galactosamine on the metabolism of resorufin by rat 
isolated hepatocytes (disappearance of resorufin monitored 
fluorimetrically; Excitation 522 nm. Emission 588 nm) (n = 1).
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due to the removal of resorufin by glucuronidation. Whilst resorufin at concentrations 
up to 500 nM was found to be mainly sulphated in rat hepatocytes (Burke and Orrenius 
1978) it was suggested that at higher concentrations (the present study used 50 //M), 
glucuronidation would predominate. A modified assay was therefore required to 
demonstrate that orphenadrine was indeed inhibiting P450 281 in hepatocytes. The 
approach used here was to follow the disappearance of pentoxyresorufin 
colorimetrically. By monitoring pentoxyresorufin levels at 466 nm, the inhibitory effect 
of orphenadrine on pentoxyresorufin 0-depentylase could be demonstrated (Figure 7.2). 
it was also shown that erythromycin had no inhibitory effect on this activity. 
Galactosamine was shown to inhibit the metabolism of p-nitrophenol (Figure 7.3), a 
substrate commonly used to assess glucuronyltranferase activity (Bock ef a/. 1983). 
None of the inhibitors used with hepatocytes significantly affected cell viability during 
incubation (Figures 7.4 and 7.5).
The effects of orphenadrine and erythromycin on the metabolism of 8-(pyrrole-2-
carbonyD-DPAT, the appearance of its /V-dealkylated metabolite and the appearance of
its side-chain hydroxylated metabolite during incubation with rat isolated hepatocytes
are shown in Figures 7.6 , 7.7 and 7.8 respectively. Both the dealkylation and
hydroxylation pathways were inhibited to a greater degree by orphenadrine and, for
clarity, only the 0 and 1000 pM erythromycin plots are shown. Similar results were
obtained for 8 -Br-DPAT (both inhibitors) and for DPAT, 5-F-DPAT and 8 -CF3-DPAT 
data not shown
(orphenadrine onl\|. The /V-dealkylation of DPAT by rat hepatic microsomes was not 
inhibited by quinine at concentrations up to 100 pM (Figure 7.9), although some 
inhibition was observed at 1000 pM quinine.
The influence of orphenadrine and galactosamine on the metabolism of 8 -OH-DPAT and 
5-F-8-OH-DPAT is illustrated in Figures 7.10 and 7.11 respectively.
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Figure 7.2 The effects of orphenadrine and erythromycin on the metabolism of 
pentoxyresorufin in rat isolated hepatocytes (disappearance of 
pentoxyresorufin monitored colorimetrically at 466 nm) (n = 1).
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Figure 7.3 Effect of galactosamine on the metabolism of p-nitrophenol in rat 
isolated hepatocytes (monitored by decline in absorbance at 400 nm)
(n = 1 ).
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Effects of orphenadrine and erythromycin on cell viability during 
incubation with rat isolated hepatocytes (n = 1 ).
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Effect of galactosamine on cell viability during incubation with rat 
isolated hepatocytes (n = 1 ).
150
9000 -
8000 -
7000 -
§ 5000 -O
i 4000 -
Orphenadrine3000 -
2000 -
 A t— 100
- T -  500 
— 1000
1000 -
302515 205 100
Time (min)
10000 -
9000 -
Erythromycin
8000 -
7000 -
6000 -SO
5000 -
4000 -
3000 -
2000 -
1000 -
302515 205 100
Time (min)
Figure 7.6 Effects of orphenadrine (top) and erythromycin (bottom) on the 
metabolism of 8-(pyrrole-2-carbonyi)-DPAT by rat isolated hepatocytes 
(monitored by HPLC peak area of parent drug)(n = 1).
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Figure 7.7 Effects of orphenadrine (top) and erythromycin (bottom) on the 
appearance of the /V-dealkylated metabolite of 8-(pyrrole-2- 
carbonyD-DPAT during incubation of the latter with rat isolated 
hepatocytes (monitored by HPLC peak area of metabolite)(n = 1 ).
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Figure 7.8 Effects of orphenadrine (top) and erythromycin (bottom) on the 
appearance of the side-chain hydroxylated metabolite of 8-(pyrrole-2- 
carbonyD-DPAT during incubation of the latter with rat isolated 
hepatocytes (monitored by HPLC peak area of metabolite) (n = 1 ).
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Figure 7.9 HPLC peak area of DPAT and its /V-dealkylated metabolite following 
incubation with rat isolated hepatocytes for 20 min in the presence of 
quinine (n = 1).
154
3500
Orphenadrine (uM)
3000 -
I -  1000
2000 -
I
1500 -
1000 -
500 -
25 305 10 15 200
Time (min)
Galactosamine (mM)
1250 -
3
1000 -
S 750 -O
S
Q -
500 -
250 -
302515 205 100
Time (min)
Figure 7.10 Effects of orphenadrine (top) and galactosamine (bottom) on the 
metabolism of 8-OH-DPAT by rat isolated hepatocytes (monitored by 
HPLC peak area of parent drug) (n = 1 ).
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Figure 7.11 Effects of orphenadrine (top) and galactosamine (bottom) on the 
metabolism of 5-F-8-OH-DPAT by rat isolated hepatocytes (monitored by 
HPLC peak area of parent drug) (n = 1 ).
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The inhibitory effect of orphenadrine was not as marked (especially in the case of 
5-F-8-OH-DPAT) as with 8-(pyrrole-2-carbonyl)-DPAT (see Figure 7.6) or indeed any of 
the other compounds incubated with orphenadrine. The metabolism of both 
8-OH-DPAT and 5-F-8-OH-DPAT was inhibited by galactosamine.
7.3 Discussion
Using 8-(pyrrole-2-carbonyl)-DPAT as the example, it was found that both 
A/-dealkylation and side-chain hydroxylation were inhibited by orphenadrine (Figure 7.7 
and 7.8) suggesting that both pathways are catalysed by P450 2B1. In support of 
this, orphenadrine was shown to inhibit the 2B1-dependent pentoxyresorufin 
0-depentylase activity in hepatocytes. Erythromycin was also shown to have an 
inhibitory effect on 8-(pyrrole-2-carbonyl)-DPAT metabolism indicating that P450 3A 
may also be involved. The degree of inhibition seen at 1000 //M erythromycin was less 
than that seen at 50 //M orphenadrine for both the dealkylation and hydroxylation 
pathways. This indicates that either these pathways are predominantly catalysed by 
2B1 (with a much smaller 3A component) or that the inhibition constant of 
erythromycin under these conditions is much higher than that of orphenadrine. A 
further possibility is that the aminotetralin substrate has a high affinity for the 3A 
enzyme but a low V ^ .
Orphenadrine is a potent inhibitor (K, = 30 / j W \) of P450 2B1 -mediated androstenedione 
16^-hydroxylase activity (K  ^ = 200 //M) in microsomes from PB-pretreated rats (Reidy 
etal. 1989, Murray and Reidy 1990). The data presented in Figure 7.2 suggest that 
in the control rat isolated hepatocyte system, orphenadrine is not a potent inhibitor of 
PROD, requiring somewhere between 500 and 1000 //M to obtain 50% inhibition. The
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clog /’ value for orphenadrine is 3.851 (See 2.8) and the pKa has been determined to 
be 8.40 (Newton and Kluza 1978), therefore the log D value (pH 7.4) can be estimated 
at 2.81 (see equation 1 in 5.3). Thus orphenadrine would be expected to extensively 
penetrate the cell membrane and the relatively weak inhibition of pentoxyresorufin 
0-depentylase is therefore not due to limited access to the 2B1 enzyme. In contrast, 
orphenadrine was a much more potent inhibitor of aminotetralin metabolism; inspection 
of Figures 7.6 - 7.8 suggests that approximately 100 //M orphenadrine was required 
for 50% inhibition of 8-(pyrrole-2-carbonyl)-DPAT metabolism. This discrepancy 
suggests that aminotetralin metabolism is carried out by another P450 isoform that is 
also inhibited by orphenadrine. Orphenadrine has been shown to inhibit 2C6 by the 
same mechanism as 2B1 (Reidy and Murray 1990), although it is more potent towards 
2B1 as evidenced by the Kj values of 3 0 //M  versus 151 //M for 2C6. Whilst in 
PB-induced microsomes the metabolism of aminotetralins was catalysed predominantly 
by P450 2B1, it seems that in hepatocytes from untreated rats 2C6 may have a 
significant role. Whilst P450 2B1 is the major isoform in livers from PB-induced rats, 
it is expressed at very low levels in untreated rats (Waxman and Azaroff 1992). Using 
immunoblotting techniques, 2C6 was found to represent approximately 6% of the total 
P450 in untreated rat liver whereas 2B1/2 constituted less than 1 % (Imaoka and Funae 
1991).
One of the characteristics of the rat 2C subfamily is their overlap in substrate 
specificity with 3A (Smith 1991). For example, nifedipine oxidation is carried out by 
members of both the 2C and 3A subfamilies in rat whereas this activity appears to be 
primarily catalysed by 3A in man (Guengerich et aL 1986b). With regard to 
/V-dealkylation reactions, substrates such as Lidocaine (Bargetzi et ai. 1989) and 
benzphetamine (Guengerich et ai. 1986b) are metabolised predominantly by 3A in man.
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In the rat, however, these A/-dealkylations are inhibited by sulphaphenazole {Smith 
1991) thereby indicating the involvement of 2C isoforms.
The inhibition of 3A by erythromycin appears to be of similar potency as orphenadrine 
inhibition of 2C6 {e.g. K; for 3A-catalysed 1 '-hydroxymidazolam formation in human 
microsomes = 194//M; Wrighton and Ring 1994). Whilst penetration of the cell 
membrane would not be as extensive as with orphenadrine (log D of erythromycin at 
pH 7.4 = 0.66; Wildfeur and Lemme 1985), only mild inhibition of aminotetralin 
metabolism was seen at 1000/yM erythromycin. These data, allied with the 
microsomal data presented in 6.2, suggest that 3A is a relatively minor contributor to 
aminotetralin metabolism.
In the uninhibited incubations, after an initial increase, the levels of both the 
/V-dealkylated and side-chain hydroxylated metabolites of 8-(pyrrole-2-carbonyl)-DPAT 
were seen to decline (Figures 7.7 and 7.8). This situation appears analogous to that 
observed in microsomes for many of the aminotetralins (see 6.2) and may be explained 
thus. As the levels of parent drug are depleted (Figure 7.6), there is a concomitant 
decrease in the rate of production of the primary metabolites (a primary metabolite 
being the result of a single biotransformation). As the levels of the primary metabolites 
rise, so the rate of their further metabolism increases, eventually overtaking their rate 
of production and a net decrease in the levels of the primary metabolites is observed 
(Figures 7.7 and 7.8). At first glance, this explanation appears to be contradicted by 
the data from 50 and 100 //M orphenadrine incubations. Although levels of both the 
/V-dealkylated and hydroxylated metabolites, at 20 and 10 min respectively, are similar 
to those in the uninhibited incubation, their rate of further metabolism is much slower. 
However, this may be accounted for if the same P450 isoforms are also responsible
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for this further metabolism such that orphenadrine inhibits both production and further 
metabolism of the primary metabolites. This is consistent with the findings obtained 
with microsomes from pretreated rats (see 6.2) where PB appeared to induce both the 
production and subsequent metabolism of the primary metabolite.
Consideration of the structure of DPAT and of known substrates of P450 2D (Islam et 
aL 1991) suggests that DPAT may be a substrate for this polymorphically expressed 
enzyme. The 5-hydroxylation of methoxyphenamine (Hawes et aL 1987) and 
A/-demethylation of deprenyl (Grace etal. 1994) have been shown to be catalysed by 
P450 2D6 (the human orthologue). The structural similarities between these two 
compounds and DPAT is illustrated in Figure 7.12. The metabolism of DPAT in 
microsomes was not significantly affected by quinine up to 100 //M (Figure 7.9). Both 
the amount of DPAT remaining after 20 min incubation and the amount of 
/V-dealkylated metabolite produced were reasonably constant up to 100 //M quinine but 
there was some inhibition of metabolism at 1000 //M. Quinine is a very potent inhibitor 
of P450 2D-cataIysed debrisoquine 4-hydroxylase in rat (IC50 = 2.4 //M, Kobayashi et 
ai. 1989) and it is therefore unlikely that this enzyme contributes significantly to the 
metabolism of DPAT. It is not clear whether the apparent inhibition seen at 1000 //M 
quinine may be the result of non-specific inhibition of P450 due to very high inhibitor 
concentrations. As aromatic hydroxylation has been shown to be a minor metabolic 
route of DPAT, compared to /V-dealkylation (see 3.2.3 and appendix), it is not clear 
whether analysis of parent drug levels during incubation with or without quinine would 
have shown up any inhibition of this pathway. However, due to the low levels of 
metabolites generated by this pathway, the simple UV/HPLC assay did not provide 
sufficient sensitivity to assay the phenolic metabolites.
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Figure 7.12 Illustration of the structural similarity between DPAT, 
methoxyphenamine and deprenyl. The asterisks indicate the 5-position 
which, in the case of methoxyphenamine, have been shown to be 
hydroxylated by P450 2D6 (Hawes etal. 1987)
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The effect of orphenadrine on the metabolism of 8-OH-DPAT (Figure 7.10) and
5-F-8-OH-DPAT (Figure 7.11) was not as great as for the other compounds studied, 
such as 8-(pyrrole-2-carbonyl)-DPAT (Figure 7.6). The data from the incubations with 
galactosamine suggest that this is due to glucuronidation having a significant role in 
the metabolism of these compounds. Comparison of the relative effects of 
orphenadrine and galactosamine on the rate of metabolism suggests that 
glucuronidation is a more important pathway for 5-F-8-OH-DPAT than for 8-OH-DPAT. 
The relative contributions of the /V-dealkylation and glucuronidation pathways under 
control conditions has not been established and inhibition of one pathway may 
lead to a greater flux through the other. Nonetheless these data may help to explain 
why 5-F-8-OH-DPAT does not fit the correlation between log D and relative metabolic 
stability (5.3).
The data from studies with inhibitors have provided further evidence for the P450 
isoform involvement proposed in chapter 6. Whilst 2B1 was the major isoform 
responsible for aminotetralin metabolism in PB-induced microsomes, it is likely that 
206 has a role in control rat hepatocytes. In both systems there was also a 
contribution from 3A1/2 but 2D1 did not appear to be involved in the metabolism of 
DPAT. The possibility of a minor role for P450 2E1 was not investigated. The two 
compounds containing hydroxy functions, 8-OH- and 5-F-8-OH-DPAT, were shown to 
be metabolised by glucuronidation in addition to /V-dealkylation. Glucuronidation 
appeared to be particularly important for 5-F-8-OH-DPAT and this provides a possible 
explanation for why 5-F-8-OH-DPAT is metabolised at a faster rate than would be 
predicted by its log D value (see 5.3).
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CHAPTER 8
THE IN  VIVO METABOLISM OF AMINOTETRALINS
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8.1 Introduction
The aim of this in vivo study was to investigate the metabolism of some of the 
aminotetraiin compounds and assess the utility of the hepatocyte model in predicting 
the in vivo metabolites. The compounds chosen for this study were DPAT, 
8 -CO2-DPAT, 8-{pyrrole-2-carbonyl)-DPAT, 8 -CF3-DPAT and 5-F-8-OH-DPAT. These 
compounds were felt to be representative of the various metabolic pathways seen in 
hepatocytes, those being A/-dealkylation, aromatic hydroxylation, aliphatic 
hydroxylation (at both primary alkyl and benzylic positions) and glucuronidation (see 
3.2.3). With respect to metabolic rates, the chosen compounds included examples of 
slow, medium and fast metabolism in vitro (see 4.2). The compounds were 
administered to rats via oral gavage at a dose level of 25 //mol kg ’. Urine was 
collected up to 48 h postdose and analysed, without further treatment, by ESI/LC/MS. 
Details of the methods employed may be found in 2.21.
8.2 Results
This was not intended as a precise quantitative study and the absolute amounts 
of drug and metabolites in urine were not determined. However, by comparison of the 
peak height for a given metabolite between different urine samples (0-6, 6-24 and 
24-48 h) and taking into account the volume of each sample, an assessment of the 
relative amounts excreted could be made. In this regard, the volumes of urine 
collected are given in Table 8.1. Comparisons of the relative amounts of different 
metabolites assumes equal instrument response. All of the metabolite ions discussed 
below were absent from the respective predose urine samples. Due to instrument 
availability it was not possible to confirm the identities of all of the urinary
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Table 8.1 Urine volumes collected from male Sprague Dawley rats following single 
oral administration of various aminotetralins.
Aminotetraiin
administered
Urine collected (ml)
0 - 6  h 6-24 h 24-48 h
DPAT 0.4 3.3 4.7
8 -CO2-DPAT 0.9 6.9 7.0
8-(pyrrole-2-carbonyl)-DPAT 2.5 8 . 6 7.9
8 -CF3-DPAT 2.5 1 1 . 0 1 1 . 1
5-F-8-0H-DPAT 1.4 6.7 8 . 2
* Urine samples were weighed and expressed as volumes assuming a density of 1 g ml*’.
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metabolites by MS/MS as had been done for the majority of the hepatocyte metabolites 
(see appendix). However, by comparison of retention times and molecular ions it 
appeared that many of the metabolites identified by MS/MS from hepatocyte 
incubates, were also present in urine. MS/MS analysis was performed for selected 
metabolites whose identities could not be inferred in this way. Whilst glucuronide 
conjugates were a feature of the urinary metabolite profiles (with the exception of 
8 -CF3-DPAT), no sulphate conjugates were detected.
8.2.1 DPAT
The structures and [IVI4-H]+ ions of the metabolites of DPAT are shown in 
Figure 8.2. Examples of MS/MS spectra interpretation are given in 3.2.
LC/MS
Ions were detected in the 0-6 h urine sample corresponding to [IVI-HHj+ for 
parent drug (m/z 232) and its A/-dealkylated metabolite (m/z 190, see Figure 8.1). Four 
ions were detected at m/z 248 consistent with oxidation of the parent drug as well as 
a peak (possibly two) corresponding to oxidation of the /V-dealkylated metabolite 
(m/z 206). The major metabolite appeared to be the product of di-oxidation (m/z 264), 
possibly a catechol. Two peaks were detected in the m/z 278 ion chromatogram 
corresponding to putative methylated catechols. Ions at m/z 424 and 440 were 
indicative of the intact glucuronides of the m/z 248 and m/z 264 metabolites 
respectively, representing a gain of 176 amu.
(data not shown)
All of the above ions were detected in the 6-24 h sampl^. Taking into account the 
respective urine volumes, all of the drug-related species were excreted in larger
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Figure 8.1 Mass chromatogram of urine collected 0-6 h following single oral 
administration of DPAT (25 //mol kg ’) to a male Sprague Dawley rat. Horizontal axis 
is time (min); right-hand vertical axis indicates intensity of ion current (exponential 
notation). IM + H]"^  for DPAT: 232 amu.
167
m/z 278
CH,0,
OH
HO'
m/z 232
OH
m/z 264
HO,
m/z 190 HO,
OH
{6, 24]HO'
HO.NHg m/z 206
m/z 148
GLUCURONIDATION
OH
m/z 206
Compound
(m/z)
MS/MS spectra (relative intensity of m/z Ions)
440 345 278 264 248 230 206 188 177 163 148 147 145 132 131 129 119 102 100 43
D (248) 100 27 49 6 16 12
E l * (248) 14 100 7
E2* (248) 14 5 100 1 3 14
E31 (248) 22 100 4 2 3 19
G1 (278) 26 100 17 2
G2 (278) 29 100 22 1
HI (264) 40 100 26 15
H2 (264) 45 100 15 9
J (206) 12 36 100 26
K1 (440) 100 16 5 36
K2 (440) 100 6 47 2
Î  - corresponding to Rt of 6-OH-DPAT, t - corresponding to Rt of 7-OH-DPAT 
5 - corresponding to Rt of 7-OH-DPAT
Figure 8.2 Proposed pathway and tabulated MS/MS spectra of urinary metabolites 
following single oral administration of DPAT (25 //mol kg'^ ) to a male Sprague Dawley 
rat. Solid box: metabolite found in urine but not in hepatocyte incubate. Dashed box: 
metabolite found in hepatocyte incubate but not in urine. Numbers in square brackets 
indicate the major drug-related component in the 0-6 h [6], 6-24 h [24] and 24-48 h 
[48] urine samples. Letters denote metabolites whose MS/MS spectra are tabulated.
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amounts over the 6-24 h collection period compared to 0-6 h. The exception to this 
was the m/z 440 metabolite which was present in much lower concentrations than in 
the 0-6 h sample but was very clearly two distinct metabolites in the 6-24 h sample. 
The major metabolite was still the m/z 264 ion which was approximately 11 -fold more 
abundant in the 6-24 h sample compared to the 0-6 h sample. No m/z 424 or m/z 440 
(proposed glucuronides) responses were seen in the 24-48 h urine and most of the 
other metabolites were present only at very low levels. The exceptions were the 
m/z 206 and m/z 248 metabolites of which similar amounts were excreted in the 
24-48 h urine compared to the 0-6 h sample.
LC/MS/MS
The m/z 190 peak for the proposed /V-dealkylated metabolite had the same 
retention time as the m/z 190 peak previously confirmed by MS/MS as the 
/V-dealkylated metabolite from the hepatocyte incubate. The earliest eluting m/z 248 
metabolite was shown by MS/MS to be the product of hydroxylation in the side chain 
(Figure 8.2). The remaining m/z 248 metabolites were shown by MS/MS and retention 
time comparison (with authentic standards) to be 6-, 7- and 5-OH-DPAT (in order of 
increasing retention time).
Both m/z 264 metabolites gave very similar CID spectra to an authentic standard of the 
catechol, 6,7-dihydroxy-DPAT. The spectrum of this standard was obtained by loop 
injection using the TSP interface during the investigations with hepatocytes. No 
retention time was measured as no evidence of catechol formation was obtained from 
hepatocyte incubations of DPAT. Similarly, both m/z 278 metabolites gave almost 
identical CID spectra to an authentic standard of 7-hydroxy-8-methoxy-DPAT. As no 
8-OH-DPAT was observed in the urine sample, it is likely that the two catechol
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metabolites were the 5,6-dihydroxy-DPAT and 6,7-dihydroxy-DPAT isomers. 
Subsequent méthylation of these catechols yielded the m/z 278 metabolites.
Both m/z 440 metabolites showed losses of 176 amu by MS/MS, characteristic of 
glucuronide conjugates; no MS/MS analysis was performed on the m/z 424  
metabolites. Based on these data, the proposed metabolic pathway for DPAT is shown 
in Figure 8.2.
8.2.2 8 -CO2H-DPAT
The structures and IM +H]^ ions of the metabolites of 8 -CO2H-DPAT are shown 
in Figure 8.4. Examples of MS/MS spectra interpretation are given in 3.2.
LC/MS
The 0-6 h urine sample mass chromatogram was dominated by a saturating ion 
at m/z 276 corresponding to the [M + H]+ for parent drug (Figure 8.3). Strong ions 
were observed corresponding to the products of /V-dealkylation to the secondary amine 
(m/z 234) and the primary amine (m/z 192), oxidation (at least four metabolites at 
m/z 292) and direct glucuronidation of the parent drug (m/z 452). Weaker responses 
were observed indicative of a combination of oxidation and /V-dealkylation (m/z 250) 
as well as oxidation and glucuronidation (m/z 468). All of these proposed metabolites 
were present at much lower levels than parent drug.
Unchanged drug was also the major drug-related species in the 6-24 h urine sample
and the total amount of 8 -CO2-DPAT excreted in this sample appeared to be similar to 
(data not shown)
the 0-6 h sampl^ This was also the case for the m/z 292 ions. The only other
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Figure 8.3 Mass chromatogram of urine collected 0-6 h following single oral 
administration of S-COgH-DPAT (25 //mol kg' )^ to a male Sprague Dawley rat. 
Horizontal axis is time (min); right-hand vertical axis indicates intensity of ion current 
(exponential notation). [M4-H]^ for S-COg-DPAT: 276 amu.
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Figure 8.4 Proposed pathway of urinary metabolites following single oral administration 
of S-COg-DPAT (25 //mol kg*^ ) to a male Sprague Dawley rat. Metabolites in solid boxes 
were found in urine but not in hepatocyte incubate. Numbers in square brackets indicate 
the major drug-related component in the 0-6 h [6], 6-24 h [24] and 24-48 h [48] urine 
samples. Letters denote metabolites whose MS/MS spectra are tabulated.
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metabolite ions detected in this sample (m/z 234 and m/z 452) were present in smaller
quantities than observed in the 0-6 h sample. The 24-48 h urine sample contained
essentially only parent drug, the total amount being approximately half that present in the 
(data not shown)
6-24 h sampl^
LC/MS/MS
MS/MS analysis provided good evidence for several of the proposed metabolites 
(Figure 8.4). Spectral proof for the /V-dealkylated metabolite (secondary amine, m/z 234) 
was obtained by comparison to the parent drug. Three of the four most abundant m/z 292 
metabolites were shown to be the products of hydroxylation in the propyl side-chain; the 
remaining metabolite gave fragment ions characteristic of hydroxylation in the tetralin 
nucleus. The proposed glucuronide of the parent drug gave the expected loss of 176 amu, 
characteristic of a glucuronide conjugate. The proposed metabolic pathway is shown in 
Figure 8.4.
8.2.3 8-(pyrroie-2-carbonyl)-DPAT
The structures and [M-FHj^ ions of the metabolites of 8-(pyrrole-2-carbonyl)-DPAT 
are shown in Figure 8.6. Examples of MS/MS spectra interpretation are given in 3.2.
LC/MS
In the 0-6 h urine, ions corresponding to parent drug (m/z 325), its /V-dealkylated 
metabolite (m/z 283) and an oxidised metabolite (m/z 341 ) were present in approximately 
equal amounts (Figure 8.5). Two smaller m/z 341 peaks were also observed as well as 
2 peaks at m/z 517 which were consistent with oxidation followed by glucuronidation. 
At least 2 peaks were detected at m/z 299 which could have resulted from a combination
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Figure 8.5 Mass chromatogram of urine collected 0-6 h following single oral administration 
of 8-(pyrrole-2-carbonyl)-DPAT (25 //mol kg*^ ) to a male Sprague Dawley rat. Horizontal 
axis is time (min); right-hand vertical axis indicates intensity of ion current (exponential 
notation). [M + H]"^  for 8-(pyrrole-2-carbonyl)-DPAT: 325 amu.
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Compound
(m/z)
MS/MS spectra (relative intensity of m/z ions)
357 341 325 299 240 224 223 212 207 196 168 157 129 118 102 100 94 76
D1 (341) 100 61 6 4 12 2
D2 (341) 100 51 5 4
D3 (341) 100 54 8 4
El (299) 100 34 4 15 3 3
E2 (299) 100 93 29 8 4 7
FI (357) 100 29 8 5 17
F2 (357) 100 19 13 37 7
Figure 8.6 Proposed pathway of urinary metabolites following single oral administration 
of 8-(pyrrole-2-carbonyl)-DPAT (25 //mol kg*’) to a male Sprague Dawley rat. The solid box 
indicates a metabolite found in urine but not in hepatocyte incubate. Numbers in square 
brackets indicate the major drug-related component in the 0-6 h [6], 6-24 h [24] and 
24-48 h [48] urine samples. Letters denote metabolites whose MS/MS spectra are 
tabulated.
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of A/-dealkylation and oxidation. Further metabolite ions were m/z 241, consistent w ith 
/V-dealkylation through to the primary amine and m/z 357, the result of di-oxidation of the 
parent drug.
Of the above ions, only m/z 325, 283 and 341 were observed in the 6-24 h urine sample
and smaller amounts were excreted compared to the 0-6 h sample. These three ions were
(data not shown) 
just detectable in the 24-48 h u r in ^
LC/MS/MS
MS/MS experiments were focused on confirming sites of oxidation. All of the 
proposed mono-oxidised metabolites (m/z 299 and m/z 341) gave spectra consistent 
w ith hydroxylation in the propyl side-chain (Figure 8 .6 ). Both m/z 357 metabolites 
(proposed di-oxidised compounds) gave weak spectra but w ith  ions suggestive of 
hydroxylation both in the propyl side-chain and in the tetralin nucleus. A  metabolite 
pathway was proposed from these data and is shown in Figure 8 .6 .
8.2.4 8 -CF3 -DPAT
The structures and [M-hHj^ ions of the metabolites of 8 -CF3 -DPAT are shown 
in Figure 8 .8 . Examples of MS/MS spectra interpretation are given in 3.2.
LC/MS
The major metabolites of 8 -CF3 -DPAT observed in the 0-6 h urine appeared to 
be the products of /V-dealkylation (m/z 258) and a combination of /V-dealkylation and 
oxidation (m/z 274, Figure 8.7). Two peaks at m/z 216, corresponding to the primary 
amine metabolite, were detected although the later-eluting peak appeared to  be a
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Figure 8.7 Mass chromatogram of urine collected 0-6 h following single oral 
administration of 8 -CF3 -DPAT (25 //mol kg ’) to a male Sprague Dawley rat. Horizontal 
axis is time (min); right-hand vertical axis indicates intensity of ion current (exponential 
notation). [M-HH]^ for 8 -CF3 -DPAT: 300 amu.
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Compound MS/MS spectra (relative intensity of m/z ions)
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E (274) 38 100 3
F (332) 100 100 9 15 36
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Figure 8 . 8  Proposed pathway of urinary metabolites following single oral 
administration of 8 -CF3-DPAT {25 //mol kg' )^ to a male Sprague Dawley rat. The solid 
boxes indicate metabolites found in urine but not in hepatocyte incubate. Numbers in 
square brackets indicate the major drug-related component in the 0-6 h [6 ], 6-24 h [24] 
and 24-48 h [48] urine samples. Letters denote metabolites whose MS/MS spectra are 
tabulated.
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breakdown product of the m/z 274 metabolite. A possible oxidised metabolite was 
detected at m/z 316 and several peaks were observed in the m/z 332 ion trace which 
may have been the products of di-oxidation of the parent drug. The parent drug 
(m/z 300) was present at relatively low levels. There was no evidence for any 
glucuronide conjugates.
Similar amounts of the above metabolites were excreted in urine over the 6-24 h period
with the exception of the m/z 316 and m/z 332 metabolites of which approximately
twice as much was excreted compared to the 0-6 h period. In the 24-48 h sample, the
(data not shown)
only drug-related ions observed were weak responses at m/z 258, 274 and 31 ^  
LC/MS/MS
The proposed /V-dealkylated metabolite was confirmed by MS/MS (Figure 8 .8 ). 
Good evidence was obtained for both mono-oxidised metabolites (m/z 274 and 316) 
being the products of hydroxylation in the tetralin nucleus. Only two of the proposed 
di-oxidised metabolites were sufficiently abundant to provide MS/MS spectra. 
Hydroxylation in the tetralin nucleus appeared to be common to both metabolites with 
further hydroxylation either in the propyl side-chain or again in the tetralin nucleus.
The proposed metabolic pathway is given in Figure 8 . 8
8.2.5 5-F-8-0H-DPAT
The structures and [M + H]"^  ions of the metabolites of 5-F-8-OH-DPAT are 
shown in Figure 8.10. Examples of MS/MS spectra interpretation are given in 3.2.
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Figure 8 .9  Mass chromatogram of urine collected 0-6 h following single oral 
administration of 5 -F-8 -OH-DPAT (25 //mol kg' )^ to a male Sprague Dawley rat. 
Horizontal axis is time (min); right-hand vertical axis indicates intensity of ion current 
(exponential notation). [M-FH]^ for 5-F-B-OH-DPAT: 266 amu.
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Figure 8 .10 Proposed pathway of urinary metabolites following single oral 
administration of 5-F-8-0H-DPAT (25 //mol kg ’ ) to a male Sprague Dawley rat. Solid 
box: metabolite found in urine but not in hepatocyte incubate. Dashed box: metabolite 
found in hepatocyte incubate but not in urine. Numbers in square brackets indicate the 
major drug-related component in the 0-6 h [6], 6-24 h [24] and 24-48 h [48] urine 
samples. Letters denote metabolites whose MS/MS spectra are tabulated.
* - metabolite inferred from fragmentation of its glucuronide conjugate.
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LC/MS
The 0-6 h urine mass chromatogram was dominated by ions corresponding to 
glucuronide conjugates, the major metabolite appearing to be a glucuronide of the 
parent drug (m/z 442, Figure 8.9). Peaks corresponding to a glucuronide of oxidised 
5 -F-8 -OH-DPAT (m/z 458; at least 3 metabolites) and parent drug itself (m/z 266) were 
the next largest responses. Ions for oxidised 5 -F-8 -OH-DPAT (m/z 282) and the 
glucuronide of the /V-dealkylated metabolite (m/z 400) were also detected although 
these were relatively minor.
The putative glucuronide of oxidised 5 -F-8 -OH-DPAT (m/z 458) was the major 
metabolite in the 6-24 h sample with some 6 -fold more being excreted in the urine over 
this time period compared to 0-6 h. The parent drug and its glucuronide were also 
present in the 6-24 h urine but at lower levels; a similar profile was observed in the 
24-48 h sample (data not shown).
LC/MS/MS
Good evidence for the major metabolite (m/z 442) being the glucuronide of the 
parent drug was provided by the characteristic loss of 176 amu in the MS/MS 
spectrum (Figure 8.10). All three metabolites at m/z 458 were also shown to be 
glucuronides and the site of oxidation in the most abundant metabolite appeared to be 
the tetralin nucleus. The CID spectrum of the m/z 400 metabolite was consistent with 
it being the glucuronide of /V-dealkylated 5 -F-8 -OH-DPAT. The position of oxidation in 
the m/z 282 metabolite was shown to be in the propyl side-chain. The metabolite 
pathway suggested by these data is given in Figure 8.10.
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8.3 Discussion
For the aminotetralins, the mass spectrometer was approximately 100-fold more
sensitive in ESI mode compared to the TSP mode used in the analysis of the
samples
hepatocyte incubates. In addition, the urine/ (especially the 0-6 h samples) may well 
have contained different amounts of drug-related material than the hepatocyte 
incubates. These factors may be responsible for some of the differences observed 
between the in vitro and in vivo metabolite pathways, especially for minor metabolites.
A further issue in the interpretation of the urinary data is the role of biliary excretion 
of the metabolites. In the rat, compounds with molecular weight less than 300 tend 
to be poorly excreted in the bile (Smith 1973). Biliary excretion tends to be favoured 
for compounds with molecular weight greater than 400 and this may be enhanced by 
the presence of a polar functional group. Conjugation of a compound with glucuronic 
acid confers both extra weight and a polar group and such conjugates are, in general, 
readily excreted in the bile. For the aminotetralins studied in vivo, the maximum 
molecular weight of the unchanged drugs and their phase I metabolites was well below 
400 and these would therefore be expected to appear predominantly in the urine. 
However, with the exception of 8 -CF3-DPAT, all of the compounds formed glucuronide 
conjugates, with molecular weights ranging from 400 to 517. Whilst these conjugates 
were detected in urine, it is possible that they were present in greater quantities in the 
bile. Contrary to this suggestion, greater than 60% of an oral dose of 8 -OH-DPAT to 
rats, was excreted in the urine as the glucuronides of 8 -OH-DPAT (mw 423) and its 
/V-dealkylated metabolite (mw 381; Mason ef a/. 1995a). It was subsequently reported 
that following intravenous administration of 8 -OH-DPAT, only 10% of the dose was 
excreted in the bile as these glucuronides (Mason et ai. 1995b). This was similar to
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the amount recovered in the faeces follorwing intravenous dosing from which the 
authors concluded that little or no enterohepatic circulation had occurred.
For 8 -(pyrrole-2 -carbonyl)-DPAT and 8 -CF3-DPAT, the urinary metabolite profiles 
(Figures 8 . 6  and 8 .8 ) were very similar to those obtained in hepatocytes. The only 
differences were the presence of minor di-oxidised metabolites in urine, but this may 
well have been a function of the greater sensitivity of the mass spectrometer in ESI 
mode. The positions of oxidation in the mono-oxidised metabolites were also predicted 
by the hepatocyte data. The added sensitivity of the ESI interface allowed positive 
identification of all 3 mono-oxidised metabolites of 8 -(pyrrole-2 -carbonyl)-DPAT as the 
products of hydroxylation in the propyl side-chain. This has stereochemical 
implications as the introduction of a hydroxy function on the propyl group in either the 
a o r p  positions creates a new chiral centre. This topic will be discussed in more detail
in chapter 9.
In hepatocytes, S-CO^H-DPAT was very slowly metabolised, with only the 
/V-dealkylated metabolite detected after 120 min incubation. In 5.3 it was proposed 
that this compound was too hydrophilic to penetrate the hepatocyte and endoplasmic 
reticulum membranes to gain access to the drug metabolising enzymes. At first 
glance, it seems that this compound was extensively metabolised in vivo judging by 
the urinary metabolite pathway (Figure 8.4). However, the mass chromatogram 
(Figure 8.3) was dominated by the saturating parent drug peak which, by peak area, 
was probably at least an order of magnitude more abundant than any of the 
metabolites (instrument sensitivity may also have had a bearing as well). The 
hepatocyte data were therefore quite predictive in that 8 -CO3H-DPAT was excreted (in 
urine at least) predominantly unchanged. Whilst it is possible that the bile was a
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quantitatively more important elimination route for the glucuronide, the data suggest 
that 8 -CO2H-DPAT itself was cleared predominantly via the kidneys.
Consistent with the in vitro data, DPAT was metabolised by /V-dealkylation, aromatic 
hydroxylation and propyl side-chain hydroxylation in vivo (Figure 8.2). However, the 
major urinary metabolites were catechols and their 0 -methylated products, non of 
which were detected in vitro. In contrast, hydroxylated metabolites in the urine 
accounted for less than 1 % of the dose following single oral, intraperitoneal or 
intravenous administration of 8 -OH-DPAT to rats (Mason et ai. 1995a). The fact that 
8 -OH-DPAT appeared to be a good substrate for glucuronidation is a possible 
explanation for this, the majority of the metabolism probably occurring presystemically, 
perhaps during absorption. Following oral administration of phenol to rats, only 3% of 
the dose appeared in the systemic circulation, conjugation during absorption through 
the intestine being primarily responsible and the lung also contributing (Cassidy and 
Houston 1980).
The discrepancy between the urine and hepatocyte data for DPAT may have arisen 
from differences in the duration of exposure to the drug metabolising enzymes. Whilst 
the hepatocyte incubations were carried out for 2 hours, DPAT and its metabolites 
were present in the body for longer periods, the majority of the urinary excretion taking 
place over the 6-24 h collection period. Any glucuronides excreted in the bile might 
have been subject to the /9-glucuronidase of the intestinal flora, an enzyme activity 
which is particularly abundant in the rat small intestine (Hawksworth et ai. 1971). 
Liberation of the aglycone and subsequent reabsorption would present an opportunity 
for further metabolism, possibly catechol formation. Alternatively, aromatic 
hydroxylation might occur in the gut wall during absorption of DPAT itself, a reaction
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known to occur with biphenyl in rat (Chhabra et a!. 1974).
The drug concentration may also have had a bearing on the routes of metabolism. The 
hepatocyte incubation was carried out at an initial concentration of 60 //M. No 
pharmacokinetic information was obtained in the in vivo study. By a crude estimate, 
instantaneous complete absorption of a dose of 25 //moles kg ’ and distribution in body 
water (0.7 litres kg ’ ) would have resulted in a peak plasma concentration of 
approximately 36 //M. In reality, drug concentrations in the plasma would probably 
have been much lower than this although during the absorption phase, the levels in the 
hepatic portal vein, and hence liver, would be higher than in the general circulation. 
Differences between the metabolite profiles observed in vitro and in vivo may have 
arisen from the exposure of the drug metabolising enzymes to different drug 
concentrations and the possible variation in the affinities (K )^ and capacities (V,^) of 
the metabolising enzymes with respect to the different pathways.
Metabolite identification data from chapter 3 and inhibition studies with galactosamine 
(7.2) have demonstrated that glucuronidation is an important pathway in the in vitro 
metabolism of 5-F-8-0H-DPAT. This was also the case in vivo with glucuronide 
conjugates being the major drug-related components in the urine (Figures 8.9 and 
8.10). The major metabolite in hepatocytes was identified as the product of 
/V-dealkylation (Figure 3.9) but in urine, this metabolite was only observed as a 
glucuronide conjugate. Comparison of the single ion mass chromatograms for these 
metabolites revealed their retention times to be very similar, it is therefore probable 
that the component previously identified as the /V-dealkylated metabolite in 
hepatocytes, was in fact the glucuronide conjugate which underwent degradation in 
the TSP interface to yield the aglycone (see 3.1, 3.2.2 and 3.3) but remained intact
186
in the ESI interface. If this was the case, then the importance of glucuronidation for 
5-F-8-OH-DPAT has been underestimated, a proportion of the parent drug and all of its 
/V-dealkylated product being metabolised by this route.
The effects of various factors such as detector sensitivity, excretion route and drug 
concentration on the metabolite profiles of the aminotetralins in hepatocytes and urine 
have been discussed. When attempting to use hepatocyte data to predict the in vivo 
situation there are some other important considerations. The hepatocyte incubation 
is a closed system and apart from metabolism, no other routes of clearance are 
available to the compound of interest. Because the metabolites are not removed from 
the incubation, product inhibition can occur. In contrast, the intact animal is a dynamic 
system where, following absorption, a drug may be subject to a number of clearance 
routes such as metabolism, renal clearance and biliary clearance. Metabolites produced 
by a particular organ are removed in the bloodstream. Circulating metabolites may be 
excreted by the kidney, or by the liver into the bile, from which they may be 
reabsorbed in the gastrointestinal tract.
For the majority of drugs, the liver is quantitatively the most important site of 
metabolism. For such compounds, isolated hepatocytes are generally a good model 
system, especially where both phase I and phase II pathways are important. In the 
whole animal however, drugs may be subject to metabolism by other organs such as 
the lung, intestine and kidney which may lead to difference between the in vitro and 
in vivo metabolite profiles. For orally administered compounds, metabolism can take 
place during absorption in the intestine and both phase I and phase II pathways are 
known to occur in the gut wall. Examples relevant to aminotetraiin metabolism include 
aromatic hydroxylation and /V-dealkylation (Chhabra et ai. 1974) and glucuronidation
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of both aromatic carboxylic acids (Hartiala 1973) and phenols (Cassidy and Houston 
1980). As discussed earlier, glucuronide conjugates excreted in the bile may be 
subject to cleavage by the /9-glucuronidase enzymes of the intestinal microflora. The 
deconjugated compound may then be reabsorbed and transported to the liver where 
it may again be glucuronidated and excreted in the bile, so-called enterohepatic 
circulation. Alternatively, the deconjugated compound may be subject to further 
metabolism by phase I processes.
The data presented in this chapter support the utility of isolated hepatocytes in 
predicting the urinary metabolites of the aminotetralins following oral administration. 
Differences between the in vitro and in vivo metabolite profiles in this study may be 
attributable to a number of factors, namely, mass spectrometer sensitivity, drug 
concentration, duration of exposure to the metabolising enzymes, route of metabolite 
excretion and extrahepatic metabolism.
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CHAPTER 9 
GENERAL DISCUSSION
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9.1 Drug Metabolism and Drug Discovery
The last ten years has seen a change in the role of preciinical DMPK in the drug 
development process. Traditionally, a drug candidate was chosen solely on the basis 
of pharmacological and toxicological profiles. Many candidates would later be 
discarded (having consumed valuable resources) due to inappropriate pharmacokinetics 
such as poor oral bioavailability. Today, the DMPK unit is much more involved in 
supporting drug discovery and provides information to assist in candidate selection.
j
For many classes of new chemical entities, hepatic first pass metabolism is the major 
determinant of oral bioavailability and in vitro techniques, such as the hepatocyte assay 
used in this study, can prove very useful in screening large numbers of compounds. 
Those compounds with high CL,  ^values in hepatocytes would be expected to undergo 
extensive hepatic first pass metabolism and therefore have low oral bioavailability. 
Conversely, a low CL;  ^value would predict low first pass metabolism and hence higher 
oral bioavailability. Based on the hepatocyte data, S-COg-DPAT and 5-F-8-OH-DPAT 
would be expected to be at the extremes of the range of bioavailabilities for the 
aminotetralin series although other factors such as absorption and first pass 
metabolism by the gut may well be important. Identification of metabolites is also 
valuable and can help to build up structure-metabolism relationships and identify 
'problem' functional groups. For example, in the aminotetralin series, the presence of 
an aromatic hydroxy function renders the compound vulnerable to glucuronide 
conjugation which can increase its rate of metabolism. This type of information is of 
great assistance to medicinal chemists in directing future synthetic efforts.
A good example of the value of early drug metabolism information is the case of 
8 -OTf-DPAT. Investigations into the pharmacology of trif late-substituted aminotetralins
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demonstrated that 8 -OTf-DPAT was some 5-10 times more potent a 5-HT,a agonist 
following oral administration to rats compared to subcutaneous administration 
(Sonesson et al. 1993) and suggested the possibility of active metabolites. In the 
classical SAR for 2-aminotetralins, A/,/V-dipropyl substitution is required for maximum 
5-HT,a agonist activity (see Table 1.1). It was therefore thought that following oral 
administration of 8 -OTf-DPAT, first pass metabolism yielded the potent B-HTi^ agonist 
8 -OH-DPAT by cleavage of the triflate group. Subsequent investigation of the 
metabolism of 8 -OTf-DPAT in rat isolated hepatocytes (see Figure 3.10) suggested that 
the major metabolite was the result of /V-dealkylation; no evidence was found for the 
production of 8 -OH-DPAT. The monopropyl metabolite was synthesised and was 
found to be a more potent 5-HT,a agonist than 8 -OTf-DPAT both in vitro and more 
especially in vivo (both compounds administered subcutaneously), contrary to the 
previously mentioned SAR. A -^dealkylation was subsequently identified as the major 
metabolic route in vivo (Sonesson et ai. 1995) and this work has lead to interest in re­
evaluating the structure-activity relationship. Oral administration of 8 -OTf-DPAT 
resulted in an almost identical magnitude of B-HTi^ agonist response as subcutaneous 
administration of its monopropyl metabolite. 8 -OTf-DPAT may therefore be useful as 
a prodrug and in this regard it would be of interest to assess the bioavailability of the 
monopropyl metabolite following oral administration of 8 -OTf-DPAT.
9.2 Drug Metabolism and the Site of Action
The ability of any drug to exert its pharmacological effect is largely dependent 
on it attaining sufficient concentration at the site of action; this will be governed by the 
drug's pharmacokinetic properties. Drugs targeted at the brain, such as the 
aminotetralins, must also cross the blood-brain barrier, the cerebral capillary endothelial
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cells of the cerebral vessels being characterised by tight intercellular junctions and a 
lack of pinocytic vesicles. Generally, the most important parameter for penetration of 
the blood-brain barrier is lipophilicity of the compound at physiological pH {i.e. log D) 
with an optimum value of around 2 {Hansch et ai. 1987). The affinity of the 
monopropyl metabolite of 8 -OTf-DPAT for the 5-HT^a receptor in vitro, was some 
2.5-fold greater than that of 8 -OTf-DPAT itself; however the potency difference was 
much more marked in vivo (Sonesson et ai. 1993). Some of this difference may be 
due to the monopropyl metabolite being able to penetrate the blood-brain barrier more 
readily than 8 -OTf-DPAT. The log D of 8 -OTf-DPAT was found to be 2.889 (Table 5.1 ) 
and hence dealkylation may result in a value closer to the optimum for blood-brain 
barrier penetration.
Having penetrated the blood-brain barrier, compounds may be subject to 
biotransformation by drug metabolising enzymes within the brain, which for the 
aminotetralins would probably involve the P450 system. The existence of P450 in rat 
brain is well established but it appears to be present at very low levels, Stromstedt et 
ai. (1990) reporting levels of 0.25% of that found in liver. The isoforms of P450 
implicated in the hepatic metabolism of the aminotetralins are 2C6, 2B1/2 and 3A1/2 
(see 6.3 and 7.3). Much of the published information on expression of specific 
isoforms in the brain is inconsistent. A range of 2C isoforms has been reported to 
exist in rat brain, including 2C6, 2C11, 2C12 and 2C23 (Zaphiropoulos and Wood 
1993). In contrast, rat brain microsomes did not metabolise testosterone to 2a- or 
1 Ga-hydroxytestosterone (Jayyosi et ai. 1992) these being the major products of the 
2C11 isoform. Pentoxyresorufin 0-depentylase activity (catalysed by 2B1/2) has been 
reported in brain tissue but in widely varying amounts. Perrin et ai. (1990) reported 
pentoxyresorufin 0-depentylase activities ranging from 0.16 to 0.46 pmol min*^  mg*’
192
protein in the cortex and olfactory bulb respectively; a value of 1 2  pmol min ’ mg ’ 
protein for whole brain, corresponding to one third the activity of liver, has also been 
reported (Anandatheerthavarada et at. 1993). The presence of P450 3A in the rat 
brain has been detected by immunoblotting studies (Jayyosi et at. 1992). Thus it 
would appear that aminotetralin metabolism could take place in brain tissue and in the 
case of 8 -OTf-DPAT this could result in pharmacological activation.
9.3 Chiral Aspects of Drug Metabolism
Of the fourteen compounds studied here, ten were racemic mixtures whilst the 
remainder (DPAT, 5-F-, 5-F-8-OH- and 5 -F-8 -CONH2-DPAT) were single enantiomers 
(see Figure 1.3). Investigation of the stereochemical aspects of aminotetralin 
metabolism was not an objective of this study. Nevertheless, the fact that the 
aminotetralins possess a chiral centre may potentially give rise to stereoselective 
metabolism and this would be an interesting area for future investigations. Analytical 
methodology capable of distinguishing enantiomers would be required to undertake 
such studies. Chiral HPLC methods for the resolution of 2-aminotetralin enantiomers 
have been reported (Witte et at. 1992, Castelnovo 1993) and these may prove suitable 
for drug metabolism studies.
Drug metabolism may exhibit stereoselectivity at both the substrate and product levels. 
Thus one of a pair of stereoisomers may be preferentially metabolised over the other 
or metabolism may preferentially yield one stereoisomer. Furthermore, both of these 
selectivities may be expressed in the same biotransformation. The various outcomes 
of metabolism involving chiral compounds may be categorised as follows:
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•  Prochiral to chiral - metabolism results in the introduction of a new chiral centre.
•  Chiral to diastereolsomeric - diastereoisomers may be produced by the prochiral 
to chiral metabolism (see above) of drugs already containing a chiral centre. 
Alternatively, reaction of a chiral drug with a chiral conjugating agent may result 
in diastereoisomeric conjugates.
•  Chiral to chiral - the enantiomers of chiral compounds may be metabolised by 
different routes and/or at different rates whilst retaining the original chirality.
•  Chiral to non-chlral - metabolism may result in loss of chirality.
In addition to the above, certain drugs can undergo chemical racémisation or chiral 
inversion such that administration of a single enantiomer may result in production of 
the other enantiomer with associated pharmacological and toxicological implications.
Hydroxylation of 8-(pyrrole-2-carbonyl)-DPAT at either of the a ox p positions on the 
propyl side-chains (see Figure 3.4) would result in the generation of a new chiral centre 
although the a-hydroxy product, a carbinolamine, would probably decompose to yield s 
the /V-dealkylated metabolite and propionaldéhyde. As 8-(pyrrole-2-carbonyl)-DPAT is 
a racemic mixture, the /ff-hydroxy metabolite could exist as two pairs of 
diastereoisomers and it may therefore be possible to resolve them using non-chiral 
chromatography. In both hepatocyte incubates and urine (3.2.1 and 8.2.3) there were 
three metabolite peaks (one major and two minor) with [M+Hj'^ ions corresponding to 
hydroxylated 8-(pyrrole-2-carbonyl)-DPAT; MS/MS analysis showed them to be 
hydroxylated in the propyl side-chain. It is possible that two of these peaks were the
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resolved diastereoisomers of the )9-hydroxy metabolite, each peak containing a pair of 
enantiomers. If the major peak was one of the proposed diastereoisomers then this 
would indicate that the hydroxylation of 8-(pyrrole-2-carbonyl)-DPAT exhibited some 
degree of stereoselectivity.
Formation of a conjugate with D-glucuronic acid also introduces a new chiral centre. 
Therefore, glucuronidation of a chiral compound can result in the formation of 
diastereoisomeric conjugates with the potential for separation using non-chiral 
chromatography; an example of this is the glucuronidation of 2-phenylpropionic acid 
(Fournel and Caldwell 1986). This pathway is thought to occur (following initial 
hydroxylation) for many of the aminotetralins both in vitro and in vivo. The two 
phenolic aminotetralins, 8-OH- and 5-F-8-OH-DPAT, were shown to undergo direct 
glucuronidation both in vitro and in vivo. As 5-F-8-OH-DPAT is a single enantiomer, 
its D-glucuronic acid conjugate would also be a single enantiomer. In the case of the 
racemic 8-OH-DPAT, non-stereoselective glucuronidation would yield a pair of 
diastereoisomers. Figure 3.5 shows that the glucuronide of 8-OH-DPAT formed in 
hepatocytes appeared to be a single peak in the LC/MS mass chromatogram. This 
suggests that either glucuronidation was specific for one enantiomer of 8-OH-DPAT or 
that if both enantiomers were glucuronidated, the HPLC method employed did not 
separate the diastereoisomeric products. In this regard, 2-(/V-propyl-A/- 
2-thienylethylamino)-5-hydroxytetralin was found to form diastereoisomeric 
glucuronides (Gerding et ai. 1990b) and furthermore, these could be separated using 
simple reversed-phase achiral HPLC.
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9.4 Metabolism of Aminotetralins in the Rat: Extrapolation to Human
The studies of aminotetralin metabolism described in this thesis have been 
limited to the rat. As with any drug intended for human use, it is necessary to 
establish the metabolic pathways that occur in humans in order to validate safety 
studies performed in experimental animals. In the early stages of drug development, 
prior to the first administration to volunteers, cross-species comparisons are routinely 
carried out using in v/fro models of metabolism. Any metabolites identified as being 
specific to humans may then be the subject of further toxicological investigations. It 
would obviously be of interest to study the human metabolism of the aminotetralins 
for comparison with the rat data and to establish its relevance to the human case.
A good correlation between rate of metabolism and log D was established in rat 
hepatocytes and the same basic tenet of greater lipophilicity leading to more extensive 
metabolism should hold good in a human model. However, the effect of the different 
profile of drug metabolising enzymes in human liver may result in different metabolic 
pathways predominating with potential impact on the predictive value of log D. The 
rat P450 isoforms responsible for the metabolism of the aminotetralins were 2C6, 
2B1/2 and 3A. The substrate specificity of 2C and 3A in rat are known to overlap 
(Smith 1991) and those reactions carried out by 2C isoforms in rat are likely to be 
catalysed by 3A in human. P450 3A is the major subfamily in human liver with 3A4 
representing anywhere between 10 and 60% of human hepatic P450 (Gonzalez 1992). 
The P450 3A subfamily has also been found to be prevalent in human small intestine 
(Peters and Kremers 1989) with levels in the jejunum comparable to those found in 
liver (Watkins et ai. 1987). Following oral administration to volunteers, it is possible 
that the aminotetralins would be subject to first pass metabolism during absorption
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from the small intestine with implications for oral bioavailability. The human orthologue 
of rat 2B1 is 2B6 (Soucek and Gut 1992) but this isoform is thought to be expressed 
only at very low levels in human liver (Nedelcheva and Gut 1994).
9.5 Conclusions and Implications for Future Studies
The metabolism of the series of A/,/V-dipropylaminotetralins in isolated rat 
hepatocytes proceeds mainly v/a A/-dealkylation with hydroxylation playing a minor role. 
The overall rate of metabolism of the various compounds is largely predicted by their 
log D values. The exception to this is 5-F-8-OH-DPAT which, in addition to 
A/-dealkylation, undergoes extensive glucuronidation resulting in faster overall 
metabolism than would be predicted by its log D. In hepatic microsomes from rats 
pretreated with phénobarbital, 2B is the major P450 subfamily responsible for 
aminotetralin metabolism but in hepatocytes from untreated rats, 206 appears to be 
important. In both models, P450 3A is a minor contributor to aminotetralin 
metabolism. Isolated hepatocytes are a reasonably good predictor of the urinary 
metabolite profile of the aminotetralins.
The findings throw up several interesting questions which could be addressed in future 
studies. Whilst a lot of information has been generated on the in vitro and in vivo 
metabolism of this particular series of aminotetralins, there are many other compounds 
of this class about which nothing is known. Within the series studied here, the in vivo 
picture is incomplete. Collection of bile and analysis for metabolites would be 
complementary to the urine data and an assessment of the effects of dose route on the 
metabolite profiles would help to pinpoint which organs, apart from the liver, are 
contributing to the metabolism.
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Little or nothing is known about these compounds from a pharmacokinetic viewpoint. 
Measurement of parameters such as oral bioavailability and clearance would allow an 
assessment of the predictive nature of the quantitative hepatocyte data and hence the 
utility of using hepatocytes to screen out compounds which are likely to show high 
hepatic clearance and hence low bioavailability in vivo. The correlation between log D 
and relative metabolic stability in hepatocytes could be the foundation of a 
structure-metabolism relationship for this class of compounds. It would be interesting 
to see if computational modelling techniques could be used to refine the correlation and 
whether this type of approach could be applied to other compound classes.
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Tabulated LC/MS/MS Data of Metabolites following Incubation of 
Aminotetralins with Rat isolated Hepatocytes.
8-(pyrrole-2-carbonyl)-DPAT
C O N JU G A TIO N
Compound
(m/z)
m/z of ions observed (data expressed as relative intensity)
341 325 283 241 224 222 207 196 168 157 129 118 102 100 94 72 60 58 43
Std. A 
(325)
13 100 12 16 67 20 4 39 22
Std. B 
(283)
12 100 14 21 80 46 11 30 14
Met. B 
(283)
16 100 10 70 38 6 23 7 5
Met. C 
(241)
2 23 100 50
Met. D. 
(341)
59 13 22 100 4 48 89 9 41 17 7
Met. E. 
(299)
No MS/MS data; assignment based on LC/MS data ( M + H^l ion).
Std - Authentic standard; Met - Metabolite.
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8 -OH-DPAT
HO
A
HO
NH
30, 120
HO
conjugate
HO
(01
Compound
(m/z)
m/z of ions observed (data expressed as relative 
intensity)
248 206 147 132 119 107 102 91 60
Std. A 
(248)
7 100 9 13 19 15 7
Std. B 
(206)
6 100 15 40 42 33 5
Met. B 
(206)
3 100 14 26 40 32 2
Met. C 
(164)
No MS/MS data; assignment based on LC/MS data 
([M + H^l ion and Rt of authentic standard)
Met. D. 
(248')
1 100 5 10 8 5
Met. E. 
(264)
No MS/MS data; assignment based on LC/MS data 
([M + H+1 ion)
Std - Authentic standard; Met - Metabolite.
* This is not the true molecular ion as deconjugation takes place in the TSF interface. 
MS/MS was performed on the deconjugated species (daughters of m/z 248).
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DPAT
OH
OH
HO'
HO,
OH
.NH.
►  CONJUGATIONHO
120
FC
Compound
(m/z)
m/z of ions observed (data expressed as relative intensity)
248 232 230 206 190 148 147 132 131 129 119 118 116 115 107 102 100 91 60 58 56 44 43 41
Std. A 
(232)
6 100 6 8 8 34
Std, B 
(190)
7 100 8 15 4 82 3
Std. C 
(148)
9 50 16 8 100
Std. E *  
(248)
7 100 9 13 19 15 7
Std. F 
(206)
6 100 15 40 42 33 5
Met. B 
(190)
9 100 9 13 4 84 2
Met. C 
(148)
8 25 11 100 8 4
Met. D 
(248)
8 5 4 100 71 4 10 7 4 3
Met. El Î  
(248)
3 100 9 9 10 4 3
Met. E2$ 
(248)
16 100 2 10 19 5
Met. FI 
(206)
6 100 23 23 57 18 2
Met. F2 
(206)
10 100 24 6 16 53 16 4
Std - Authentic standard; Met - Metabolite.
* - Spectra for 5-, 6-, 7- and 8-OH-DPAT were identical 
t  - corresponding to Rt of 6-OH-DPAT 
$ - corresponding to Rt of 7-OH-DPAT 
Two peaks were observed by LC/MS at mz 248 with retention times corresponding to 5* 
and 8-OH-DPAT; however the responses were too weak to obtain MS/MS data.
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5-F-DPAT
F 120 
CONJUGATION ?
►  CONJUGATION
Compound
(m/z)
m/z of ions observed (data expressed as relative intensity)
266 250 224 208 166 165 163 150 149 147 146 145 137 134 129 125 117 109 102 91 74 61 60 45 43
Std. A 
(250)
6 100 6 75 26 3 4
Std. D 
(266)
3 100 2 4 33 4 43 23 4 4
Met. B 
(208)
10 100 4 27 8
Met. 0  
(166)
4 35 18 100 7
Met. D 
(266)
No MS/MS data; assignment based on LC/MS data ([M + H *] ion and Rt of authentic standard)
Met. E 
(266)
100 5 5 6 38
Met FI 
(224)
3 100 9 39 5 43 37 8 4
M etF2
(224)
5 100 18 4 8 35 86 13 49 4 2
Std - Authentic standard; Met - Metabolite.
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5-F-8 OH DPAT
conjugate
OH
A
OH
OH
OH
NH
B
CONJUGATION30. 120
OH
OH
OH NH
NH
c
F
Compound
(m/z)
m/z of Ions observed (data expressed as relative Intensity)
282 266 240 224 165 164 151 145 137 136 125 123 118 117 109 102 100 91 82 77 60 58 43 41
Std. A 
(266)
24 100 43 15 4 43 79 12 8 4
Met. B 
(224)
5 100 42 24 7 57 16 5
Met. C 
(182)
23 16 22 73 63 100 29 14
Met. D 
(266*)
5 100 3 20 8 34 23 5
Met. El 
(282)
25 100 15 16 17 7 11
Met.E2
(282)
5 100 8 5 46 16 9 5
Met. F 
(240)
22 100
Std - Authentic standard; Met - Metabolite.
* This is not the true molecular ion as deconjugation takes place in the TSF interface. 
MS/MS was performed on the deconjugated species (daughters of m/z 266).
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8-OTf-DPAT
-S  *-0
I
0
NH
f 3  
— s  ►O
OH
OH
0 <  S 3*0
I
0
NH,
CONJUGATION
120
Compound
(m/z)
m/z of ions observed (data expressed as relative intensity)
380 354 338 314 296 294 279 247 218 205 176 163 161 146 143 129 127 118 117 102 72 60 43
Std. A 
(380)
32 6 21 100 4 37 9 55 28 4
Std. B 
(338)
94 47 100 97 22 37 4 22 3
Met. 8 
(338)
63 38 100 69 3 29 43 3 22 4
Met. C 
(296)
22 73 2 43 100 3
Met. D 
(396)
No MS/MS data; assignment based on LC/MS data |[M +  H *] ion).
Met. E. 
(354)
14 95 100 25 13 3
Std - Authentic standard; Met - Metabolite.
205
5-OTf-DPAT
— S— > 0
CF
.NH
30.120
0 < — S — ^ 0  
1
CF,
CF
OH
.NH
01
o < — s — 
1
CF
NH,
01
— s —  I
CF,
Compound
(m/z)
m /z  o f ions o b served  (data  expressed  as rela tive  in ten s ity )
396 380 378 364 344 338 296 293 279 263 262 247 234 221 218 206 176 146 146 129 128 118 117 102 100 99 72 60 68
Std. A 
(380)
66 36 83 88 18 63 38 100 10
Met. B 
(338)
21 36 48 47 78 100 6 37
Met. C 
(296)
1 23 60 100
Met. D1 
(398)
100 3 29 62 67 9 4 16 38 36 43
Met. 02  
(396)
2 10 30 17 63 21 100 93 86 23
Met. 03  
(396)
100 68 28 16 67 16 14 60 63 42 92 84 13 39
Met. E 
(364)
61 36 16 32 9 68 100 16
Std - Authentic standard; Met - Metabolite.
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8 -CF,-DPAT
CF
NH
30, 120
CF
►
OH
CF
NH
OH
Compound
(m/z)
m/z of ions observed (data expressed as relative intensity)
300 258 215 199 197 179 177 164 159 146 130 102 60 43
Std. A 
(300)
17 100 11 15 6 42 11 5
Std. B 
(258)
11 100 24 26 12 18 5
Met. B 
(258)
17 100 23 8 14 2
Met. C 
(216)
3 100 23 14 55 14
Met. D 
(316)
No MS/MS data; assignment based on LC/MS data ([M + H *] ion).
Met. El 
(274)
72 100
Met. E2 
(274)
100 5 19 6
Std - Authentic standard; Met - Metabolite.
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8-Br-DPAT
>-
HO
NH NH
CONJUGATION
B HO30.120
NH
NH
OH
Compound
{mlzV
m/z of ions observed (data expressed as relative intensity)
328 312 286 270 227 211 146 145 134 131 130 129 128 120 118 115 102 98 60 43
Std. A 
(312)
13 59 100 16
Met. B 
(270)
1 8 100 14 5 4 2
Met. C 
(228)
5 100 37 13
Met. D 
(328)
1 4 100 5 18 10 11 26 4
Met. El 
(286)
1 12 100 16 10 2
Met. E2 
(286)
35 100 19 4 7 10
Met. E3 
(286)
1 14 100 5 7 2
Std - Authentic standard; Met - Metabolite.
t  - Molecular weights were calculated using the heavier isotope of bromine (®^ Br). All 
standards and metabolites exhibited characteristic bromine isotope distributions in 
their LC/MS spectrum {’®Br:®^ Br = 50.5:49.5).
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S-CONH^-DPAT
OH
0,
OH
.NH
30, 120 NH
OH
► CC lJUGATlON
Compound
(m/z)
m/z of ions observed (data expressed as relative intensity)
291 275 249 233 230 223 216 214 190 174 172 157 155 154 132 131 129 128 118 116 102 91 86 72 60 5S
Std. A 
(275)
6 36 18 100 6 17 6
Std. B 
(233)
8 2 15 12 100 14 3 11 3
Met. B 
(233)
6 2 23 17 100 11 14 3
Met. C 
(291)
3 24 3 100 21
Met. D 
(291)
1 41 5 100 14 18 8 77 7
Met. E 
(249)
18 8 6 96 50 100 39 31 4 4
Std - Authentic standard; Met - Metabolite.
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5-F-8-CONH2-DPAT
OH
NH NH
C=0
A
OHNH NH
C=0
NH NH
B
30, 120
NH
c=o
Compound
(m/z)
m/z of ions observed (data expressed as relative intensity)
293 251 209 205 192 177 175 172 149 147 146 127 118 109 102 100 60 58 44 43
Std. A 
(293)
14 7 80 100 12 45 15 4
Met. B 
(251)
7 44 19 69 100 15 26 10 17
Met. C 
(209)
17 11 91 100 34 91 21 10 20 100
Met. 01 
(309)
100 95 57 59
-
10 19
Met. 02  
(309)
36 53 100 12
Met. E 
(267)
No MS/MS data; assignment based on LC/MS data ([M + H*] ion).
Std - Authentic standard; Met - Metabolite.
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8-S0NH,-DPAT
NH
SO
NH
30, 120
NH
SO
NH
Compound
(m/z)
m/z of ions observed (data expressed as relative intensity)
311 269 210 193 147 129 128 118 102 100 60 43 41
Std. A 
(311)
9 1 18 4 100 38 4 4 1
Std. B 
(269)
8 1 12 100 14 3
Met. B 
(269)
6 1 14 100 7 16 1
Met. C 
(227)
4 3 100 19
Met. D 
(327)
23 100 118 9
Met. E 
(285)
No MS/MS data; assignment based on LC/MS data ([M + H*] ion).
Std - Authentic standard; Met - Metabolite.
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8-CN-DPAT
30, 120
CONJUGATION
Compound
(m/z)
m/z of ions observed (data expressed as relative intensity)
257 231 172 170 168 164 157 156 154 145 141 132 131 129 127 117 116 102 100 89 86 78 60 58 43
Std. A 
(257)
15 100 12 82 57 64 23 28
Met. B 
(215)
26 21 87 100 5
Met. C 
(173)
8 17 46 100 66 20
Met. D 
(273)
25 100 52 50
Met. E 
(273)
100 13 9 40 26 14 26 28
Met. F 
(231)
2 100 4 14 70 10 10 23 3 2
Std - Authentic standard; Met - Metabolite.
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Chemical and Optical Purity of Aminotetralins
(see 2.9, p27)
The aminotetralins studied in this thesis were synthesised in the Medicinal 
Chemistry Research unit of Upjohn Laboratories, Kalamazoo, Ml, USA. Compounds 
were subjected to preparative HPLC with UV detection until apparent 100% purity 
was obtained. Subsequent elemental analyses were satisfactory.
Four compounds (DPAT, 5-F-DPAT, B-F-S-CONHg-DPAT and 5-F-8-OH-DPAT) were 
supplied as single enantiomers and were prepared from optically pure precursors. 
Optical rotations were obtained for three of the compounds:
DPAT: [a]25, D = -62.1 (c = 1.46 methanol).
S-F-B-CONHg-DPAT: [a]25, D = +95 .6  (c = 1.25 methanol).
5-F-8-0H-DPAT: [or]25, D = + 60 .2  (c = 1.34 methanol).
